Anti-vista constructs and uses thereof
Patent Information
- Application Number
- TW111108076
- Authority / Receiving Office
- TW · TW
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2021-03-05
- Filing Date
- 2022-03-04
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2042-03-03
AI Technical Summary
Current therapies for autoimmune diseases and immune-related conditions, such as graft-versus-host disease and systemic lupus, are limited in effectively modulating T-cell responses and immune tolerance, as VISTA's role in regulating these processes is not fully exploited.
Development of anti-VISTA constructs, including antibodies and antigen-binding fragments, that specifically target VISTA to modulate its signaling pathways, either as inhibitors or agonists, to enhance or suppress immune responses as needed.
The anti-VISTA constructs provide targeted modulation of immune responses, offering potential therapeutic benefits in autoimmune diseases and immune disorders by enhancing immune tolerance and reducing disease severity.
Smart Images

Figure TWG2TB001919924_001 
Figure TWG2TB001919924_002 
Figure TWG2TB001919924_003
Abstract
Description
[Technical Field]
[0001] This invention relates to anti-VISTA constructs (such as anti-VISTA antibodies) and their uses. [Previous Technology]
[0002] VISTA (also known as planned cell death 1 homolog PD-1H, VSIR, Dies1, DD1α, Gi24) is a cell surface inhibitory molecule of the B7 / CD28 gene family expressed on T cells and bone marrow cells. VISTA can act as an inhibitory ligand on antigen-presenting cells (APCs) and regulate T cell responses via an unknown receptor. In addition, VISTA can also act as an inhibitory receptor on T cells. For example, activating VISTA monoclonal antibodies (mAbs) significantly regulate antigen-specific CD4+ T cell responses and protect mice from graft-versus-host disease (GVHD) and experimental hepatitis. VISTA-deficient mice with a C57BL / 6 background (B6 PD-1H KO) are more susceptible to autoimmune induction, such as experimental autoimmune encephalomyelitis and systemic lupus erythematosus, upon backcrossing with lupus-prone cell lines. VISTA has been shown to participate in peripheral immune tolerance and negatively regulate T cell activation. See, for example, Sci Transl Med. 11 Dec 2019; 11(522).
[0003] All disclosures, patents, patent applications and published patent applications mentioned herein are hereby incorporated herein by reference in their entirety. [Summary of the Invention]
[0004] In one embodiment, this application provides an anti-VISTA construct comprising an antibody portion comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the antibody portion competes with an antibody or antibody fragment comprising a second heavy chain variable region (VH-2) and a second light chain variable region (VL-2) for the binding antigenic determinant of VISTA, wherein: a) the VH-2 comprises: HC-CDR1 comprising amino acid sequence SEQ ID NO: 1, HC-CDR2 comprising amino acid sequence SEQ ID NO: 2, and HC-CDR3 comprising amino acid sequence SEQ ID NO: 3, and the VL-2 comprises: LC-CDR1 comprising amino acid sequence SEQ ID NO: 4, LC-CDR2 comprising amino acid sequence SEQ ID NO: 5, and LC-CDR3 comprising amino acid sequence SEQ ID NO: 6; b) the VH-2 comprises: comprising amino acid sequence SEQ ID NO: c) The VH-2 comprises: HC-CDR1 containing the amino acid sequence SEQ ID NO: 10, HC-CDR2 containing the amino acid sequence SEQ ID NO: 10, and HC-CDR3 containing the amino acid sequence SEQ ID NO: 11, and the VL-2 comprises: LC-CDR1 containing the amino acid sequence SEQ ID NO: 12, LC-CDR2 containing the amino acid sequence SEQ ID NO: 13, and LC-CDR3 containing the amino acid sequence SEQ ID NO: 14; d) The VH-2 comprises: HC-CDR1 containing the amino acid sequence SEQ ID NO: 25, HC-CDR2 containing the amino acid sequence SEQ ID NO: 26, and HC-CDR3 containing the amino acid sequence SEQ ID NO: 27, and the VL-2 comprises: LC-CDR1 containing the amino acid sequence SEQ ID NO: 28, LC-CDR2 containing the amino acid sequence SEQ ID NO: 29, and LC-CDR3 containing the amino acid sequence SEQ ID NO: 30;Or e) The VH-2 comprises: HC-CDR1 containing the amino acid sequence SEQ ID NO: 33, HC-CDR2 containing the amino acid sequence SEQ ID NO: 34, and HC-CDR3 containing the amino acid sequence SEQ ID NO: 35, and the VL-2 comprises: LC-CDR1 containing the amino acid sequence SEQ ID NO: 36, LC-CDR2 containing the amino acid sequence SEQ ID NO: 37, and LC-CDR3 containing the amino acid sequence SEQ ID NO: 38.
[0005] In some embodiments, the VH comprises: i) HC-CDR1 containing the amino acid sequence SEQ ID NO: 1, ii) HC-CDR2 containing the amino acid sequence SEQ ID NO: 2, and iii) HC-CDR3 containing the amino acid sequence SEQ ID NO: 3, or variants thereof containing 5, 4, 3, 2, or 1 amino acid substitution in the HC-CDRs; and the VL comprises: i) LC-CDR1 containing the amino acid sequence SEQ ID NO: 4, ii) LC-CDR2 containing the amino acid sequence SEQ ID NO: 5, and iii) LC-CDR3 containing the amino acid sequence SEQ ID NO: 6, or variants thereof containing 5, 4, 3, 2, or 1 amino acid substitution in the LC-CDRs. In some embodiments, the VH comprises: i) HC-CDR1 containing the amino acid sequence SEQ ID NO: 9, ii) HC-CDR2 containing the amino acid sequence SEQ ID NO: 10, and iii) HC-CDR3 containing the amino acid sequence SEQ ID NO: 11, or variants thereof containing 5, 4, 3, 2, or 1 amino acid substitution in the HC-CDRs; and the VL comprises: i) LC-CDR1 containing the amino acid sequence SEQ ID NO: 12, ii) LC-CDR2 containing the amino acid sequence SEQ ID NO: 13, and iii) LC-CDR3 containing the amino acid sequence SEQ ID NO: 14, or variants thereof containing 5, 4, 3, 2, or 1 amino acid substitution in the LC-CDRs. In some embodiments, the VH comprises: i) HC-CDR1 containing the amino acid sequence SEQ ID NO: 17, ii) HC-CDR2 containing the amino acid sequence SEQ ID NO: 18, and iii) HC-CDR3 containing the amino acid sequence SEQ ID NO: 19, or variants thereof containing 5, 4, 3, 2, or 1 amino acid substitution in the HC-CDRs; and the VL comprises: i) LC-CDR1 containing the amino acid sequence SEQ ID NO: 20, ii) LC-CDR2 containing the amino acid sequence SEQ ID NO: 21, and iii) LC-CDR3 containing the amino acid sequence SEQ ID NO: 22, or variants thereof containing 5, 4, 3, 2, or 1 amino acid substitution in the LC-CDRs.In some embodiments, the VH comprises: i) HC-CDR1 containing the amino acid sequence SEQ ID NO: 25, ii) HC-CDR2 containing the amino acid sequence SEQ ID NO: 26, and iii) HC-CDR3 containing the amino acid sequence SEQ ID NO: 27, or variants thereof containing 5, 4, 3, 2, or 1 amino acid substitution in the HC-CDRs; and the VL comprises: i) LC-CDR1 containing the amino acid sequence SEQ ID NO: 28, ii) LC-CDR2 containing the amino acid sequence SEQ ID NO: 29, and iii) LC-CDR3 containing the amino acid sequence SEQ ID NO: 30, or variants thereof containing 5, 4, 3, 2, or 1 amino acid substitution in the LC-CDRs. In some embodiments, the VH comprises: i) HC-CDR1 containing the amino acid sequence SEQ ID NO: 33, ii) HC-CDR2 containing the amino acid sequence SEQ ID NO: 34, and iii) HC-CDR3 containing the amino acid sequence SEQ ID NO: 35, or variants thereof containing 5, 4, 3, 2, or 1 amino acid substitution in the HC-CDRs; and the VL comprises: i) LC-CDR1 containing the amino acid sequence SEQ ID NO: 36, ii) LC-CDR2 containing the amino acid sequence SEQ ID NO: 37, and iii) LC-CDR3 containing the amino acid sequence SEQ ID NO: 38, or variants thereof containing 5, 4, 3, 2, or 1 amino acid substitution in the LC-CDRs. In some embodiments, the VH comprises: i) HC-CDR1 containing the amino acid sequence SEQ ID NO: 41, ii) HC-CDR2 containing the amino acid sequence SEQ ID NO: 42 or 51, and iii) HC-CDR3 containing the amino acid sequence SEQ ID NO: 11; and the VL comprises: i) LC-CDR1 containing the amino acid sequence SEQ ID NO: 46, ii) LC-CDR2 containing the amino acid sequence SEQ ID NO: 13, and iii) LC-CDR3 containing the amino acid sequence SEQ ID NO: 47. In some embodiments, the VH comprises: i) HC-CDR1 containing the amino acid sequence SEQ ID NO: 43, ii) HC-CDR2 containing the amino acid sequence SEQ ID NO: 44 or 52, and iii) HC-CDR3 containing the amino acid sequence SEQ ID NO: 45; and the VL comprises: i) LC-CDR1 containing the amino acid sequence SEQ ID NO: 54, ii) LC-CDR2 containing the amino acid sequence SEQ ID NO: 55, and iii) LC-CDR3 containing the amino acid sequence SEQ ID NO: 56 or 57.In some embodiments, the VH comprises: i) HC-CDR1 containing the amino acid sequence SEQ ID NO: 41 or 43, ii) HC-CDR2 containing any of the amino acid sequences SEQ ID NO: 58, and iii) HC-CDR3 containing the amino acid sequence SEQ ID NO: 11 or 45; and the VL comprises: i) LC-CDR1 containing the amino acid sequence SEQ ID NO: 48, ii) LC-CDR2 containing the amino acid sequence SEQ ID NO: 49, and iii) LC-CDR3 containing the amino acid sequence SEQ ID NO: 50 or 53.
[0006] In another embodiment, this application provides an anti-VISTA construct comprising an antibody portion specifically binding to VISTA. The anti-VISTA construct comprises: a) HC-CDR1, HC-CDR2, and HC-CDR3, each comprising an amino acid sequence of CDR1, CDR2, and CDR3 within a VH chain region having the sequence described in SEQ ID NO: 7; and LC-CDR1, LC-CDR2, and LC-CDR3, each comprising an amino acid sequence of CDR1, CDR2, and CDR3 within a VL chain region having the sequence described in SEQ ID NO: 8; b) HC-CDR1, HC-CDR2, and HC-CDR3, each comprising an amino acid sequence of CDR1, CDR2, and CDR3 within a VH chain region having the sequence described in SEQ ID NO: 15; and LC-CDR1, LC-CDR2, and LC-CDR3, each comprising an amino acid sequence of CDR1, CDR2, and CDR3 within a VH chain region having the sequence described in SEQ ID NO: 15. c) The amino acid sequences of CDR1, CDR2, and CDR3 within the VL region of the sequence described in SEQ ID NO: 23; and LC-CDR1, LC-CDR2, and LC-CDR3, each containing the amino acid sequences of CDR1, CDR2, and CDR3 within the VH region of the sequence described in SEQ ID NO: 24; d) The amino acid sequences of CDR1, CDR2, and CDR3 within the VH region of the sequence described in SEQ ID NO: 31; and LC-CDR1, LC-CDR2, and LC-CDR3, each containing the amino acid sequences of CDR1, CDR2, and CDR3 within the VL region of the sequence described in SEQ ID NO: 24. The amino acid sequences of CDR1, CDR2 and CDR3 within the VL chain region of the sequence described in SEQ ID NO: 32; or e) HC-CDR1, HC-CDR2 and HC-CDR3, each containing the amino acid sequences of CDR1, CDR2 and CDR3 within the VH chain region of the sequence described in SEQ ID NO: 39; and LC-CDR1, LC-CDR2 and LC-CDR3, each containing the amino acid sequences of CDR1, CDR2 and CDR3 within the VL chain region of the sequence described in SEQ ID NO: 40.
[0007] In some embodiments of any of the anti-VISTA constructs described above, the VH comprises any of the amino acid sequences SEQ ID NO: 7, 15, 23, 31 and 39, or contains a variant of an amino acid sequence having at least about 80% sequence identity; and / or wherein the VL comprises any of the amino acid sequences SEQ ID NO: 8, 16, 24, 32 and 40, or contains a variant of an amino acid sequence having at least about 80% sequence identity. In some embodiments, the VH comprises the amino acid sequence SEQ ID NO: 7, or contains a variant of an amino acid sequence having at least about 80% sequence identity; and the VL comprises the amino acid sequence SEQ ID NO: 8, or contains a variant of an amino acid sequence having at least about 80% sequence identity. In some embodiments, the VH comprises the amino acid sequence SEQ ID NO: 15, or a variant of the amino acid sequence having at least about 80% sequence identity; and the VL comprises the amino acid sequence SEQ ID NO: 16, or a variant of the amino acid sequence having at least about 80% sequence identity. In some embodiments, the VH comprises the amino acid sequence SEQ ID NO: 23, or a variant of the amino acid sequence having at least about 80% sequence identity; and the VL comprises the amino acid sequence SEQ ID NO: 24, or a variant of the amino acid sequence having at least about 80% sequence identity. In some embodiments, the VH comprises the amino acid sequence SEQ ID NO: 31, or a variant of the amino acid sequence having at least about 80% sequence identity; and the VL comprises the amino acid sequence SEQ ID NO: 32, or a variant of the amino acid sequence having at least about 80% sequence identity. In some embodiments, the VH contains an amino acid sequence SEQ ID NO: 39, or a variant of an amino acid sequence having at least about 80% sequence identity; and the VL contains an amino acid sequence SEQ ID NO: 40, or a variant of an amino acid sequence having at least about 80% sequence identity.
[0008] In some embodiments of any of the anti-VISTA constructs described above, the antibody portion is an antibody or antigen-binding fragment thereof selected from the group consisting of: full-length antibody, bispecific antibody, single-chain Fv (scFv) fragment, Fab fragment, Fab' fragment, F(ab')2, Fv fragment, disulfide-stabilized Fv fragment (dsFv), (dsFv)2, Fv-Fc fusion, scFv-Fc fusion, scFv-Fv fusion, bifunctional antibody (diabody), trifunctional antibody (tribody), and tetrafunctional antibody (tetrabody). In some embodiments, the antibody portion is a full-length antibody.
[0009] In some embodiments of any of the anti-VISTA constructs described above, the antibody portion has an Fc fragment selected from the group consisting of Fc fragments derived from IgG, IgA, IgD, IgE, IgM, and combinations thereof and hybrids thereof. In some embodiments, the Fc fragment is selected from the group consisting of Fc fragments derived from IgG1, IgG2, IgG3, IgG4, and combinations thereof and hybrids thereof. In some embodiments, the effector function of the Fc fragment is weakened compared to the corresponding wild-type Fc fragment. In some embodiments, the half-life of the Fc fragment is prolonged compared to the corresponding wild-type Fc fragment.
[0010] In some embodiments of any of the anti-VISTA constructs described above, the antibody of the anti-VISTA construct partially activates the downstream signaling pathway of VISTA.
[0011] In some embodiments of any of the anti-VISTA constructs described above, the anti-VISTA construct is a VISTA-enhancing antibody. In some embodiments, the antibody portion of the anti-VISTA construct activates or enhances the downstream signaling pathways of VISTA by at least about 20%.
[0012] In some embodiments of any of the anti-VISTA structures described above, the VISTA is a human VISTA.
[0013] In another embodiment, this application provides a pharmaceutical composition comprising the anti-VISTA construct described above and a pharmaceutically acceptable carrier.
[0014] In another embodiment, this application provides an isolated nucleic acid that encodes the anti-VISTA construct described above.
[0015] In another embodiment, this application provides a vector comprising the isolated nucleic acid sequence described above.
[0016] In another embodiment, this application provides an isolated host cell containing an isolated nucleic acid sequence or a vector described above.
[0017] In another embodiment, this application provides an immune conjugate comprising the anti-VISTA construct described above, the anti-VISTA construct being linked to a therapeutic agent or a marker.
[0018] In another embodiment, this application provides a method for generating an anti-VISTA construct, comprising: a) culturing the isolated host cells described above under conditions that effectively express the anti-VISTA construct; and b) obtaining the expressed anti-VISTA construct from the host cells.
[0019] In another embodiment, this application provides a method for treating a disease or condition in an individual, comprising administering to the individual an effective amount of the anti-VISTA construct or pharmaceutical composition described above. In some embodiments, the disease or condition is related to an immune system disorder. In some embodiments, the disease or condition is an autoimmune disease, inflammation, infection, graft-versus-host disease (GvHD), or a transplant-related condition. In some embodiments, the autoimmune disease is selected from cutaneous lupus, rheumatoid arthritis, psoriasis, autoimmune intestinal disease, systemic lupus erythematosus (SLE), and discoid lupus erythematosus (DLE). In some embodiments, the anti-VISTA construct is administered intravenously or subcutaneously to the individual. In some embodiments, the anti-VISTA construct is administered at a dose of about 0.001 mg / kg to about 100 mg / kg. In some embodiments, the individual is a human.
[0020] In another embodiment, this application provides a kit that includes the VISTA-resistant structure described above.
Implementation Method
[0051] Cross-reference to related applications
[0052] This application claims priority to U.S. Provisional Patent Application No. 63 / 157,182, filed March 5, 2021, which is incorporated herein by reference in its entirety for all purposes.
[0053] This application provides novel anti-VISTA constructs that specifically bind to VISTA, methods for preparing anti-VISTA constructs, and methods for using the constructs (e.g., methods for treating diseases or conditions). Exemplary anti-VISTA constructs include activating antibodies capable of binding to and activating VISTA. I. Definitions
[0054] The term "antibody" is used in its broadest sense and covers a wide range of antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), full-length antibodies, and their antigen-binding fragments, as long as they exhibit the desired antigen-binding activity. The term "antibody fraction" refers to a full-length antibody or its antigen-binding fragment.
[0055] Full-length antibodies consist of two heavy chains and two light chains. The variable regions of the light and heavy chains are responsible for antigen binding. The variable domains of the heavy and light chains can be referred to as "VH" and "VL," respectively. The variable regions of both chains generally contain three highly variable loops called complementarity-determining regions (CDRs) (light chain (LC) CDRs, including LC-CDR1, LC-CDR2, and LC-CDR3; heavy chain (HC) CDRs, including HC-CDR1, HC-CDR2, and HC-CDR3). The CDR boundaries of the antibody and antigen-binding fragments disclosed herein can be defined or identified by the Kabat, Chothia, or Al-Lazikani conventions (Al-Lazikani 1997; Chothia 1985; Chothia 1987; Chothia 1989; Kabat 1987; Kabat 1991). Three CDRs of either the heavy or light chain are inserted between side extensions called framework regions (FRs), which are more conserved than the CDRs and form a backbone supporting the hypervariable ring. The constant regions of the heavy and light chains do not participate in antigen binding but exhibit various effector functions. Antibody systems are designated based on the amino acid sequence of the constant region of their heavy chains. The five major classes or isotypes of antibodies are IgA, IgD, IgE, IgG, and IgM, characterized by the presence of α, δ, ε, γ, and μ heavy chains, respectively. Several major antibody classes are subdivided into subclasses such as IgG1 (γ1 heavy chain), IgG2 (γ2 heavy chain), IgG3 (γ3 heavy chain), IgG4 (γ4 heavy chain), IgGA1 (α1 heavy chain), or IgGA2 (α2 heavy chain). Chimeric Fc regions (such as IgG2 / 4 mixtures) are also considered herein.
[0056] As used herein, the term "antigen-binding fragment" refers to an antibody fragment, including, for example, bifunctional antibodies, Fab, Fab', F(ab')2, Fv fragments, disulfide-stabilized Fv fragments (dsFv), (dsFv)2, bispecific dsFv (dsFv-dsFv'), disulfide-stabilized bifunctional antibodies (ds bifunctional antibodies), single-chain Fv (scFv), scFv dimers (bivalent bifunctional antibodies), multispecific antibodies formed from a portion of an antibody containing one or more CDRs, camel single-domain antibodies, nanoantibodies, domain antibodies, bivalent domain antibodies, or any other antibody fragment bound to an antigen but not containing the complete antibody structure. An antigen-binding fragment can bind to the same antigen as the parent antibody or a parent antibody fragment (e.g., a parental scFv). In some embodiments, the antigen-binding fragment may comprise one or more CDRs from a specific human antibody grafted to a framework region from one or more different human antibodies.
[0057] "Fv" is the smallest antibody fragment containing a complete antigen recognition and binding site. This fragment consists of a dimer of a tightly, non-covalently bound heavy chain variable region and a light chain variable region. Folding of these two domains produces six hypervariable rings (three from the heavy chain and three from the light chain), which promote antigen binding to amino acid residues and confer antigen binding specificity to the antibody. However, even a single variable domain (or half of an Fv containing only the three CDRs specific to the antigen) can recognize and bind to the antigen, but usually with lower affinity than the entire binding site.
[0058] A "single-chain Fv" (also abbreviated as "sFv" or "scFv") is an antibody fragment comprising VH and VL antibody domains linked to a single polypeptide chain. In some embodiments, the scFv polypeptide further comprises a polypeptide linker between the VH and VL domains, which enables the scFv to form the desired structure for antigen binding. For a review of scFv, see Plückthun, THE PHARMACOLOGY OF MONOCLONAL ANTIBODIES, Vol. 113, eds. Rosenburg and Moore, Springer-Verlag, New York, pp. 269-315 (1994).
[0059] As used herein, the term “CDR” or “complementary determination region” is intended to refer to a non-adjacent antigen combination site found in the variable region of both the heavy chain and light chain polypeptides. These specific regions have been documented in Kabat et al., J. Biol. Chem. 252:6609-6616 (1977); Kabat et al., US Dept. of Health and Human Services, "Sequences of proteins of immunological interest" (1991); Chothia et al., J. Mol. Biol. 196:901-917 (1987); Al-Lazikani B. et al., J. Mol. Biol., 273: 927-948 (1997); MacCallum et al., J. Mol. Biol. 262:732-745 (1996); Abhinandan and Martin, Mol. Immunol., 45: 3832-3839 (2008); Lefranc MP et al., Dev. Comp. Immunol., 27: 55-77 (2003); and Honegger and Plückthun, J. Mol. Biol., 309:657-670 (2001), where the definition includes overlap or subset of amino acid residues when compared with each other. Nevertheless, the use of any definition or variant thereof of an antibody or grafted antibody CDR is intended to fall within the scope of the terminology as defined and used herein. The amino acid residues covering the CDRs defined in each of the above-cited references are set forth in Table 1 below for comparison. CDR prediction algorithms and interfaces are known in this art, including, for example, Abhinandan and Martin, Mol. Immunol., 45: 3832-3839 (2008); Ehrenmann F. et al., Nucleic Acids Res., 38: D301-D307 (2010); and Adolf-Bryfogle J. et al., Nucleic Acids Res., 43: D432-D438 (2015). The contents of the references cited in this paragraph are incorporated herein by reference in their entirety for use in this application and may be included in one or more of the technical solutions herein. In some embodiments, the CDR sequence provided herein is based on the IMGT definition.For example, CDR sequences can be determined using the VBASE2 tool (http: / / www.vbase2.org / vbase2.php, see also Retter I, Althaus HH, Münch R, Müller W: VBASE2, an integrative V gene database. Nucleic Acids Res. 1 Jan 2005; 33 (database release): D671-4, which is incorporated herein by reference in its entirety). Table 1: CDR definition. Kabat 1 Chothia 2 MacCallum 3 IMGT 4 AHo 5 V H CDR1 31-35 26-32 30-35 27-38 25-40 V H CDR2 50-65 53-55 47-58 56-65 58-77 V H CDR3 95-102 96-101 93-101 105-117 109-137 V L CDR1 24-34 26-32 30-36 27-38 25-40 V L CDR2 50-56 50-52 46-55 56-65 58-77 V L CDR3 89-97 91-96 89-96 105-117 109-137 1. Residue numbering follows the nomenclature of Kabat et al. (see above). 2. Residue numbering follows the nomenclature of Chothia et al. (see above). 3. Residue numbering follows the nomenclature of MacCallum et al. (see above). 4. Residue numbering follows the nomenclature of Lefranc et al. (see above). 5. Residue numbering follows the nomenclature of Honegger and Plückthun (see above).
[0060] The terms "as in Kabat variable domain residue number" or "as in Kabat amino acid position number" and their variations refer to the heavy chain variable domain or light chain variable domain numbering system used by Kabat et al. (see above) for antibody compilation. Using this numbering system, the actual linear amino acid sequence may contain a shortening or insertion of fewer or additional amino acids corresponding to the FR or hypervariable region (HVR) of the variable domain. For example, the heavy chain variable domain may include a single amino acid insertion after residue 52 of H2 (according to residue 52a in Kabat) and an inserted residue after residue 82 of the heavy chain FR (e.g., according to residues 82a, 82b, and 82c in Kabat). The residue Kabat number of a given antibody can be determined by comparing the homologous region of the antibody sequence with the "standard" Kabat numbered sequence.
[0061] Unless otherwise indicated herein, the residue numbers in the immunoglobulin heavy chain are as per the EU index of Kabat et al. (see above). "EU index as per Kabat" refers to the residue numbers of human IgG1 EU antibodies.
[0062] “Framework” or “FR” residues are other variable domain residues other than CDR residues as defined herein.
[0063] The “humanized” form of a non-human (e.g., rodent) antibody is a chimeric antibody containing a minimal sequence derived from a non-human antibody. To a large extent, a humanized antibody is a human immunoglobulin (receptor antibody) in which residues from the hypervariable region (HVR) of the receptor are replaced by residues from the hypervariable region of a non-human species (donor antibody) such as mice, rats, rabbits, or non-human primates possessing the desired antibody specificity, affinity, and ability. In some cases, the framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, the humanized antibody may contain residues not found in the receptor or donor antibody. These modifications are made to further improve antibody efficacy. Generally, a humanized antibody will contain at least one and usually two variable domains, substantially all of which correspond to the hypervariable loops of the non-human immunoglobulin and all or substantially all of the FRs are FRs of the human immunoglobulin sequence. Humanized antibodies may also include at least a portion of the immunoglobulin constant region (Fc), typically at least a portion of the constant region of human immunoglobulins. For more details, see Jones et al., Nature 321:522-525 (1986); Riechmann et al., Nature 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992).
[0064] "Human antibody" is an antibody having an amino acid sequence corresponding to an antibody produced by humans and / or prepared using any of the human antibody preparation techniques disclosed herein. This definition of human antibody specifically excludes humanized antibodies containing non-human antigen-binding residues. Human antibodies can be produced using various techniques known in this field, including phage presentation libraries. The methods described in Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol. Biol., 222:581 (1991). The methods described in Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985); Boerner et al., J. Immunol., 147(1):86-95 (1991) can also be used to prepare human monoclonal antibodies. See also van Dijk and van de Winkel, Curr. Opin. Pharmacol., 5: 368-74 (2001). Human antibodies can be prepared by administering an antigen to a transgenic animal that is modified to produce such antibodies in response to antigen challenge, but whose endogenous loci are disabled, for example, in xenomouse mice (see, for example, U.S. Patent Nos. 6,075,181 and 6,150,584 relating to XENOMOUSE™ technology). See also, for example, Li et al., Proc. Natl. Acad. Sci. USA, 103:3557-3562 (2006), relating to human antibodies produced via human B-cell fusion tumor technology.
[0065] The "percentage of amino acid sequence identity (%)" or "homology" of the peptide and antibody sequences identified herein is defined as the percentage of amino acid residues in the candidate sequence that are identical to amino acid residues in the compared peptide, after sequence alignment, taking any conserved substitutions as part of sequence identity. Alignment for the purpose of determining the percentage of amino acid sequence identity can be achieved in various ways within the skill of this art, such as using publicly available computer software, such as BLAST, BLAST-2, ALIGN, Megalign (DNASTAR), or MUSCLE software. Those skilled in this art can determine the appropriate parameters used to measure alignment, including any algorithms required to achieve maximum alignment across the full length of the compared sequences. However, for the purposes of this paper, the amino acid sequence identity percentage was generated using the sequence comparison computer program MUSCLE (Edgar, RC, Nucleic Acids Research 32(5):1792-1797, 2004; Edgar, RC, BMC Bioinformatics 5(1):113, 2004).
[0066] "Homology" refers to the sequence similarity or sequence identity between two polypeptides or two nucleic acid molecules. When a position in two compared sequences is occupied by the same base or amino acid monomer subunit, for example, if one position in each of two DNA molecules is occupied by adenine, then the molecules are homologous at that position. The percentage of homology between two sequences is a function of the number of matching or homologous positions shared by the two sequences divided by the number of positions being compared multiplied by 100. For example, if 6 / 10 of the positions in two sequences match or are homologous, then the two sequences are 60% homologous. For example, the amino acid sequences TKLEIK and TALGIE share 50% homology. Generally, two sequences are compared when aligned to produce the greatest homology.
[0067] The term "constant domain" refers to another part of an immunoglobulin molecule that has a more conserved amino acid sequence than the part of the immunoglobulin containing the antigen-binding site (i.e., the variable domain). The constant domain contains the CH1, CH2, and CH3 domains of the heavy chain (collectively referred to as CH) and the CHL (or CL) domain of the light chain.
[0068] The "light chain" of an antibody (immunoglobulin) from any mammalian species can be designated as one of two distinct types called kappa ("κ") and lambda ("λ") based on the amino acid sequence of its constant domain.
[0069] The "CH1 domain" (also known as "C1" of the "H1 domain") usually extends from amino acid 118 to amino acid 215 (EU numbering system).
[0070] The "hinge region" is generally defined as the region corresponding to Glu216 to Pro230 of human IgG1 (Burton, Molec. Immunol. 22:161-206 (1985)). Hinge regions of other IgG isotypes can be compared with the IgG1 sequence by placing the first and last cysteine residues that form the SS bond between heavy chains in the same position.
[0071] The "CH2 domain" (also known as the "C2" domain) of the human IgG Fc region typically extends from about amino acid 231 to about amino acid 340. The unique feature of the CH2 domain is that it does not pair tightly with another domain. In fact, two N-linked branched carbohydrate chains are inserted between the two CH2 domains of the intact native IgG molecule. It has been hypothesized that carbohydrates can provide alternatives for domain-domain pairing and contribute to the stabilization of the CH2 domain. Burton, Molec Immunol. 22:161-206 (1985).
[0072] The "CH3 domain" (also known as the "C2 domain") contains the C-terminal residue elongation of the CH2 domain in the Fc region (i.e., amino acid residue 341 to the C-terminus of the antibody sequence, typically amino acid residue 446 or 447 of IgG).
[0073] The terms "Fc region" or "fragment crystallizable region" are used herein to define the C-terminal region of the immunoglobulin heavy chain, including the native Fc region and variant Fc regions. Although the boundaries of the Fc region of the immunoglobulin heavy chain can vary, the Fc region of the human IgG heavy chain is generally defined as extending from the amino acid residue at position Cys226 or from Pro230 to its carboxyl terminus. The C-terminal lysine (residue 447 according to the EU numbering system) of the Fc region may be removed, for example, during antibody preparation or purification, or by recombinantly engineering the nucleic acid encoding the antibody heavy chain. In some cases, the subsequent C-terminal glycine (residue 446 according to the EU numbering system) of the Fc region may also be removed. Thus, a composition of a complete antibody may comprise an antibody population with all K447 residues removed, an antibody population with K447 residues not removed, and an antibody population containing a mixture of antibodies with and without K447 residues. Suitable native Fc regions for the antibodies described herein include human IgG1, IgG2 (IgG2A, IgG2B), IgG3, and IgG4.
[0074] “Fc receptor” or “FcR” describes a receptor that binds to the Fc region of an antibody. Preferred FcRs are native human FcR sequences. Additionally, preferred FcRs are receptors (γ receptors) that bind IgG antibodies and include receptors of the FcγRI, FcγRII, and FcγRIII subclasses, including allelic variants and alternative splicing forms of these receptors. FcγRII receptors include FcγRIIA (“activating receptor”) and FcγRIIB (“inhibitory receptor”), which have similar amino acid sequences that differ primarily in their cytoplasmic domains. The activating receptor FcγRIIA contains an activating motif (ITAM) based on the immunoreceptor tyrosine in its cytoplasmic domain. The inhibitory receptor FcγRIIB contains an inhibitory motif (ITIM) based on the immunoreceptor tyrosine in its cytoplasmic domain. See M. Daëron, Annu. Rev. Immunol. 15:203-234 (1997). FcRs are reviewed in Ravetch and Kinet, Annu. Rev. Immunol 9: 457-92 (1991); Capel et al., Immunomethods 4: 25-34 (1994); and de Haas et al., J. Lab. Clin. Med. 126: 330-41 (1995). This article covers neonatal Fc receptors (FcRNs). The term "FcR" as used in this article also includes other FcRs, including those to be identified in the future.
[0075] As used herein, "antigenic determinant" refers to a specific atom or group of amino acids on an antigen to which an antibody or antibody portion binds. If two antibodies or antibody portions exhibit competitive binding to an antigen, they may bind to the same antigenic determinant within the antigen.
[0076] As used herein, when a first antibody or fragment thereof is present at an equal molar concentration, and the first antibody or fragment thereof inhibits the binding of a second antibody or fragment thereof to the target antigen by at least about 50% (such as at least about 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%), the first antibody or fragment thereof "competitively" binds to the target antigen with the second antibody or fragment thereof, or vice versa. A high-throughput method for "grouping" antibodies based on cross-competition is described in PCT Publication No. WO 03 / 48731.
[0077] As used herein, the terms "specific binding," "specific recognition," or "specific to" refer to measurable and reproducible interactions, such as the binding between a target and an antibody or antibody moiety, which determines the presence of the target in the presence of a population of heterogeneous molecules (including biomolecules). For example, an antibody or antibody moiety that specifically recognizes a target (which may be an antigenic determinant) is an antibody or antibody moiety that has a greater affinity, affinity, ease, and / or duration of binding to this target than it binds to other targets. In some embodiments, the degree to which an antibody binds to an unrelated target is less than about 10% of the antibody binding to the target, as measured, for example, by radioimmunoassay (RIA). In some embodiments, the dissociation constant (KD) of the antibody that specifically binds to the target is ≤10⁻⁵ M, ≤10⁻⁶ M, ≤10⁻⁷ M, ≤10⁻⁸ M, ≤10⁻⁹ M, ≤10⁻¹⁰ M, ≤10⁻¹¹ M, or ≤10⁻¹² M. In some embodiments, the antibody specifically binds to an antigenic determinant on a conserved protein from different species. In some embodiments, specific binding may include exclusive binding, but is not required. The binding specificity of the antibody or antigen-binding domain can be determined experimentally by methods known in this art. Such methods include, but are not limited to, Western ink dot assay, ELISA, RIA, ECL, IRMA, EIA, BIACORE™ assay, and peptide scanning.
[0078] An "isolated" antibody (or construct) is an antibody (or construct) (e.g., natural or recombinant) that has been identified, isolated, and / or recovered from its environment of origin. Preferably, the isolated polypeptide is unrelated to all other components from its environment of origin.
[0079] The “isolated” nucleic acid molecule encoding the constructs, antibodies, or antigen-binding fragments described herein is a nucleic acid molecule that has been identified and isolated from at least one impurity nucleic acid molecule normally associated with it in its production environment. Preferably, the isolated nucleic acid is unrelated to any components associated with the production environment. The isolated nucleic acid molecules encoding the polypeptides and antibodies described herein are in forms other than those found or defined in nature. Therefore, the isolated nucleic acid molecules are different from the nucleic acids encoding polypeptides and antibodies naturally present in cells as described herein. The isolated nucleic acid molecules include nucleic acid molecules normally contained in cells, but which are located extrachromosomally or at chromosomal locations different from their natural chromosomal locations.
[0080] The term "control sequence" refers to the DNA sequence required to express an operable linking coding sequence in a particular host organism. Control sequences suitable for prokaryotes include, for example, promoters, operator sequences where applicable, and ribosome binding sites. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.
[0081] Nucleic acids are "operably linked" when they are in a functional relationship with another nucleic acid sequence. For example, if the DNA of a presequence or secretory leader sequence is a protein that participates in the secretion of a polypeptide, it is operably linked to the DNA of that polypeptide; if a promoter or enhancer affects the transcription of a coding sequence, it is operably linked to that sequence; or if a ribosome binding site is positioned to facilitate translation, it is operably linked to the coding sequence. Generally, "operably linked" means that the linked DNA sequences are adjacent, and in the case of a secretory leader sequence, adjacent and within the reading frame. However, enhancers do not need to be adjacent. Linkage is achieved by joining at a suitable restriction site. If such a site is not present, synthetic oligonucleotide transposons or linkers are used according to conventional practice.
[0082] As used herein, the term "vector" refers to a nucleic acid molecule capable of propagating to another nucleic acid to which it is attached. This term includes vectors that exhibit a self-replicating nucleic acid structure as well as vectors incorporated into the genome of a host cell to which they have been introduced. Some vectors are capable of directing the expression of the nucleic acid to which they are operatively attached. Such vectors are referred to herein as "expression vectors".
[0083] As used herein, the terms “transfection” or “transformation” or “transduction” refer to the process of transferring or introducing exogenous nucleic acids into or into host cells. “Transfected” or “transformed” or “transduced” cells are cells that have been transfected, transformed, or transduced with exogenous nucleic acids. These cells include primary individual cells and their progeny.
[0084] The terms "host cell," "host cell line," and "host cell culture" are used interchangeably and refer to cells in which exogenous nucleic acids have been introduced, including progeny cells of this type. Host cells include "transformers" and "transformed cells," which include primary transformed cells and their derived progeny (regardless of passage number). The nucleic acid content of progeny cells may not be exactly the same as that of parent cells, and they may contain mutations. This document includes mutant progeny cells with the same function or biological activity screened or selected from the original transformed cells.
[0085] The term "immunoconjugate" includes references to the covalent binding of a therapeutic agent or detectable label to an antibody (such as the antibody portion described herein). The binding may be direct or indirect via a linker (such as a peptide linker).
[0086] As used herein, "treatment" refers to a method for obtaining a beneficial or desired outcome (including clinical outcomes). For the purposes of this application, a beneficial or desired clinical outcome includes, but is not limited to, one or more of the following: relief of one or more symptoms caused by the disease, reduction of the severity of the disease, stabilization of the disease (e.g., prevention or delay of disease progression), prevention or delay of disease spread (e.g., metastasis), prevention or delay of disease recurrence, delay or slowing of disease progression, improvement of disease symptoms, provision of disease remission (partial or complete), reduction of the dosage of one or more other medications required to treat the disease, delay of disease progression, improvement or enhancement of quality of life, increased weight gain, and / or prolonged survival. The methods of this application consider any one or more of these treatment approaches.
[0087] The term "inhibition" or "inhibit" means any reduction or cessation of a phenotypic trait, or a decrease or cessation of the occurrence, degree, or likelihood of that trait. "Reduction" or "inhibit" means a reduction, decrease, or cessation of activity, function, and / or quantity relative to a reference. In some embodiments, "reduction" or "inhibit" means an overall reduction of 20% or more of the ability. In another embodiment, "reduction" or "inhibit" means an overall reduction of 50% or more of the ability. In yet another embodiment, "reduction" or "inhibit" means an overall reduction of 75%, 85%, 90%, 95%, or more of the ability.
[0088] As used herein, "reference" refers to any sample, standard, or level used for comparative purposes. References may be obtained from healthy and / or non-pathological samples. In some instances, references may be obtained from untreated samples. In some instances, references are obtained from non-pathological or untreated samples of individuals. In some embodiments, references are obtained from one or more healthy individuals who are not individuals or patients.
[0089] As used herein, "delayed disease progression" means to postpone, hinder, slow, delay, stabilize, inhibit, and / or postpone the progression of a disease. Depending on the disease history and / or the individual being treated, this delay can vary in length. As will be apparent to those skilled in this technique, sufficient or significant delay can effectively encompass prevention, preventing the individual from developing the disease.
[0090] As used herein, “prevention” includes providing preventive measures against the onset or recurrence of an individual’s disease, in which the individual may be susceptible but has not yet been diagnosed with the disease.
[0091] The terms "subject" and "patient" are used interchangeably herein to refer to mammals, including but not limited to humans, cattle, horses, cats, dogs, rodents, or primates. In some embodiments, the subject is a human.
[0092] The “effective amount” of a drug means the amount that effectively achieves the desired therapeutic or preventive result at the required dose and within the required time period. The specific dose will vary depending on one or more of the following: the specific drug selected, the dosing regimen followed, whether it is administered in combination with other compounds, the timing of administration, the tissue to be imaged, and the physical delivery system that carries it.
[0093] The terms "pharmaceutical formulation" and "pharmaceutical composition" refer to preparations in which the biological activity of the active ingredient is permitted and which do not contain other components that would have unacceptable toxicity to the individual to whom the formulation will be administered. Such formulations may be sterile.
[0094] "Pharmaceutically acceptable carrier" refers to non-toxic solid, semi-solid, or liquid fillers, diluents, encapsulating materials, formulation aids, or carriers known in this art for use with therapeutic agents, collectively comprising the administration of a "pharmaceutical composition" to an individual. A pharmaceutically acceptable carrier is non-toxic to the recipient at the dosage and concentration used and is compatible with other components of the formulation. A pharmaceutically acceptable carrier is suitable for the formulation used.
[0095] "Sterile" preparations are sterile or substantially free of live microorganisms and their spores.
[0096] Administering in combination with one or more other therapeutic agents includes simultaneous (parallel) administration and administration in any order, either sequentially or in sequence.
[0097] The term "parallel" is used herein to refer to the administration of two or more therapeutic agents, wherein at least a portion of the administration overlaps in time or the administration of one therapeutic agent occurs within a shorter time period relative to the administration of another therapeutic agent. For example, the administration of two or more therapeutic agents is spaced no more than about 60 minutes apart, such as no more than any of the following: about 30, 15, 10, 5, or 1 minute.
[0098] The term "sequentially" is used herein to refer to the administration of two or more therapeutic agents in a manner in which the administration of one or more agents continues after the administration of one or more other agents has been interrupted. For example, the administration of two or more therapeutic agents is spaced more than about 15 minutes apart, such as any of the following: about 20, 30, 40, 50 or 60 minutes, 1 day, 2 days, 3 days, 1 week, 2 weeks or 1 month, or longer.
[0099] As used herein, “combination” means administering one treatment modality in addition to another. Therefore, “combination” means administering one treatment modality before, during, or after administering one treatment modality to an individual.
[0100] The term "instructions for use of a drug" refers to the instructions for use that are customarily included in the commercial packaging of a therapeutic product, which contain information about indications, usage, dosage, administration, combination therapy, contraindications and / or warnings related to the use of such therapeutic product.
[0101] "Article" means any manufactured article (e.g., package or container) or kit that contains at least one reagent, such as a medicine for treating a disease or condition, or a probe for specifically detecting a biomarker described herein. In some embodiments, the manufactured article or kit is marketed, distributed, or sold in the form of a unit for performing the methods described herein.
[0102] It should be understood that the embodiments of this application described herein include "consisting of embodiments" and / or "substantially consisting of embodiments".
[0103] In this document, references to “about” a value or parameter include (and descriptions) changes in that value or parameter itself. For example, a description of “about X” includes a description of “X”.
[0104] As used herein, the reference to "not being" a value or parameter generally means and describes "other than a value or parameter". For example, "the method is not used to treat type X disease" means that the method is used to treat types of diseases other than type X.
[0105] The term “about X to Y” as used herein has the same meaning as “about X to about Y”.
[0106] Unless the context clearly indicates otherwise, as used herein and in the claims of the appended patent application, the singular forms "a / an" and "the" include the plural references. II. Anti-VISTA Structure
[0107] This application provides an anti-VISTA construct comprising an anti-VISTA antibody portion that specifically binds to VISTA as described herein. VISTA
[0108] V-domain Ig inhibitor of T cell activation (VISTA) (also known as PD-1H, Gi24, Dies-1, or DD1α) is a recently identified cell surface co-inhibitory molecule of the CD28 / B7 gene family. VISTA has been reported to act as an inhibitory ligand on antigen-presenting cells and regulate T cell responses. Ablation of VISTA with gene knockout or antagonist antibodies enhances T cell immune responses against tumors in mouse models. VISTA also plays an important role in the regulation of inflammation and autoimmune diseases, as demonstrated in mouse models of graft-versus-host disease (GVHD), acute hepatitis, encephalitis, lupus, asthma, and psoriasis. VISTA also acts as a co-inhibitory receptor on T cells. VISTA-enhancing mAbs significantly regulate antigen-specific CD4 T cell responses and protect mice from GVHD, acute hepatitis, and asthma. See Files et al., J. Immunol. 187, 1537-1541 (2011); Files et al., J. Clin. Invest. 124, 1966-1975 (2014); and Liu et al., Cell. Mol. Immunol. 15, 838-845 (2018). Upregulated VISTA in prostate cancer patients has also been shown to be associated with ipilimumab (CTLA-4 mAb) resistance. Furthermore, targeting VISTA has been shown to synergize with other non-redundant pathways such as PD-1 blockade to achieve optimal tumor clearance in experimental mouse models. See Liu et al., Proc. Natl. Acad. Sci. USA 112, 6682-6687 (2015). Therefore, VISTA may be an important molecule for regulating immune responses and a potential target for immunotherapy.
[0109] The VISTA gene is located at 10q22.1. It is retained in chimpanzees, cows, mice, rats, chickens, zebrafish, and frogs. The human VISTA sequence can be found in NCBI reference number NM_022153. The human VISTA protein has 311 amino acids (NCBI reference number: NP_071436.1, SEQ ID NO: 59). Anti-VISTA antibody portion
[0110] In some embodiments, the anti-VISTA construct includes an antibody portion comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the antibody portion competes with an antibody or antibody fragment comprising a second heavy chain variable region (VH-2) and a second light chain variable region (VL-2) for the binding antigenic determinant of VISTA, wherein VH-2 comprises: HC-CDR1 comprising the amino acid sequence SEQ ID NO: 1, HC-CDR2 comprising the amino acid sequence SEQ ID NO: 2, and HC-CDR3 comprising the amino acid sequence SEQ ID NO: 3, and VL-2 comprises: LC-CDR1 comprising the amino acid sequence SEQ ID NO: 4, LC-CDR2 comprising the amino acid sequence SEQ ID NO: 5, and LC-CDR3 comprising the amino acid sequence SEQ ID NO: 6.
[0111] In some embodiments, VH comprises: i) HC-CDR1 containing the amino acid sequence SEQ ID NO: 1, ii) HC-CDR2 containing the amino acid sequence SEQ ID NO: 2, and iii) HC-CDR3 containing the amino acid sequence SEQ ID NO: 3, or variants thereof containing up to 5, 4, 3, 2, or 1 amino acid substitution in the HC-CDRs; and VL comprises: i) LC-CDR1 containing the amino acid sequence SEQ ID NO: 4, ii) LC-CDR2 containing the amino acid sequence SEQ ID NO: 5, and iii) LC-CDR3 containing the amino acid sequence SEQ ID NO: 6, or variants thereof containing up to 5, 4, 3, 2, or 1 amino acid substitution in the LC-CDRs. In some embodiments, the amino acid substitutions described above are limited to the "exemplary substitutions" shown in Table 2 of this application. In some embodiments, the amino acid substitutions are limited to the "preferred substitutions" shown in Table 2 of this application.
[0112] In some embodiments, the anti-VISTA antibody portion is a humanized antibody derived from an anti-VISTA antibody containing a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH contains: i) HC-CDR1 containing the amino acid sequence SEQ ID NO: 1, ii) HC-CDR2 containing the amino acid sequence SEQ ID NO: 2 and iii) HC-CDR3 containing the amino acid sequence SEQ ID NO: 3, and the VL contains: i) LC-CDR1 containing the amino acid sequence SEQ ID NO: 4, ii) LC-CDR2 containing the amino acid sequence SEQ ID NO: 5 and iii) LC-CDR3 containing the amino acid sequence SEQ ID NO: 6.
[0113] In some embodiments, the antibody portion comprises: HC-CDR1, HC-CDR2 and HC-CDR3, each comprising the amino acid sequences of CDR1, CDR2 and CDR3 within the VH chain region having the sequence described in SEQ ID NO: 7; and LC-CDR1, LC-CDR2 and LC-CDR3, each comprising the amino acid sequences of CDR1, CDR2 and CDR3 within the VL chain region having the sequence described in SEQ ID NO: 8.
[0114] In some embodiments, VH comprises the amino acid sequence SEQ ID NO: 7, or a variant of the amino acid sequence having at least about 80% (such as at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity; and VL comprises the amino acid sequence SEQ ID NO: 8, or a variant of the amino acid sequence having at least about 80% (such as at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity.
[0115] In some embodiments, the anti-VISTA construct includes an antibody portion comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the antibody portion competes with an antibody or antibody fragment comprising a second heavy chain variable region (VH-2) and a second light chain variable region (VL-2) for the binding antigenic determinant of VISTA, wherein VH-2 comprises: HC-CDR1 comprising the amino acid sequence SEQ ID NO: 9, HC-CDR2 comprising the amino acid sequence SEQ ID NO: 10, and HC-CDR3 comprising the amino acid sequence SEQ ID NO: 11, and VL-2 comprises: LC-CDR1 comprising the amino acid sequence SEQ ID NO: 12, LC-CDR2 comprising the amino acid sequence SEQ ID NO: 13, and LC-CDR3 comprising the amino acid sequence SEQ ID NO: 14.
[0116] In some embodiments, VH comprises: i) HC-CDR1 containing the amino acid sequence SEQ ID NO: 9, ii) HC-CDR2 containing the amino acid sequence SEQ ID NO: 10, and iii) HC-CDR3 containing the amino acid sequence SEQ ID NO: 11, or variants thereof containing up to 5, 4, 3, 2, or 1 amino acid substitution in the HC-CDRs; and VL comprises: i) LC-CDR1 containing the amino acid sequence SEQ ID NO: 12, ii) LC-CDR2 containing the amino acid sequence SEQ ID NO: 13, and iii) LC-CDR3 containing the amino acid sequence SEQ ID NO: 14, or variants thereof containing up to 5, 4, 3, 2, or 1 amino acid substitution in the LC-CDRs. In some embodiments, the amino acid substitutions described above are limited to the "exemplary substitutions" shown in Table 2 of this application. In some embodiments, the amino acid substitutions are limited to the "preferred substitutions" shown in Table 2 of this application.
[0117] In some embodiments, the anti-VISTA antibody portion is a humanized antibody derived from an anti-VISTA antibody containing a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH contains: i) HC-CDR1 containing the amino acid sequence SEQ ID NO: 9, ii) HC-CDR2 containing the amino acid sequence SEQ ID NO: 10 and iii) HC-CDR3 containing the amino acid sequence SEQ ID NO: 11, and the VL contains: i) LC-CDR1 containing the amino acid sequence SEQ ID NO: 12, ii) LC-CDR2 containing the amino acid sequence SEQ ID NO: 13 and iii) LC-CDR3 containing the amino acid sequence SEQ ID NO: 14.
[0118] In some embodiments, the antibody portion comprises: HC-CDR1, HC-CDR2 and HC-CDR3, each comprising the amino acid sequences of CDR1, CDR2 and CDR3 within the VH chain region having the sequence described in SEQ ID NO: 15; and LC-CDR1, LC-CDR2 and LC-CDR3, each comprising the amino acid sequences of CDR1, CDR2 and CDR3 within the VL chain region having the sequence described in SEQ ID NO: 16.
[0119] In some embodiments, VH comprises the amino acid sequence SEQ ID NO: 15, or a variant of the amino acid sequence having at least about 80% (such as at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity; and VL comprises the amino acid sequence SEQ ID NO: 16, or a variant of the amino acid sequence having at least about 80% (such as at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity.
[0120] In some embodiments, the anti-VISTA construct includes an antibody portion comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the antibody portion competes with an antibody or antibody fragment comprising a second heavy chain variable region (VH-2) and a second light chain variable region (VL-2) for the binding antigenic determinant of VISTA, wherein VH-2 comprises: HC-CDR1 comprising the amino acid sequence SEQ ID NO: 17, HC-CDR2 comprising the amino acid sequence SEQ ID NO: 18, and HC-CDR3 comprising the amino acid sequence SEQ ID NO: 19, and VL-2 comprises: LC-CDR1 comprising the amino acid sequence SEQ ID NO: 20, LC-CDR2 comprising the amino acid sequence SEQ ID NO: 21, and LC-CDR3 comprising the amino acid sequence SEQ ID NO: 22.
[0121] In some embodiments, VH comprises: i) HC-CDR1 containing the amino acid sequence SEQ ID NO: 17, ii) HC-CDR2 containing the amino acid sequence SEQ ID NO: 18, and iii) HC-CDR3 containing the amino acid sequence SEQ ID NO: 19, or variants thereof containing up to 5, 4, 3, 2, or 1 amino acid substitution in the HC-CDRs; and VL comprises: i) LC-CDR1 containing the amino acid sequence SEQ ID NO: 20, ii) LC-CDR2 containing the amino acid sequence SEQ ID NO: 21, and iii) LC-CDR3 containing the amino acid sequence SEQ ID NO: 22, or variants thereof containing up to 5, 4, 3, 2, or 1 amino acid substitution in the LC-CDRs. In some embodiments, the amino acid substitutions described above are limited to the "exemplary substitutions" shown in Table 2 of this application. In some embodiments, the amino acid substitutions are limited to the "preferred substitutions" shown in Table 2 of this application.
[0122] In some embodiments, the anti-VISTA antibody portion is a humanized antibody derived from an anti-VISTA antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises: i) HC-CDR1 comprising the amino acid sequence SEQ ID NO: 17, ii) HC-CDR2 comprising the amino acid sequence SEQ ID NO: 18 and iii) HC-CDR3 comprising the amino acid sequence SEQ ID NO: 19, and the VL comprises: i) LC-CDR1 comprising the amino acid sequence SEQ ID NO: 20, ii) LC-CDR2 comprising the amino acid sequence SEQ ID NO: 21 and iii) LC-CDR3 comprising the amino acid sequence SEQ ID NO: 22.
[0123] In some embodiments, the antibody portion comprises: HC-CDR1, HC-CDR2 and HC-CDR3, each comprising the amino acid sequences of CDR1, CDR2 and CDR3 within the VH chain region having the sequence described in SEQ ID NO: 23; and LC-CDR1, LC-CDR2 and LC-CDR3, each comprising the amino acid sequences of CDR1, CDR2 and CDR3 within the VL chain region having the sequence described in SEQ ID NO: 24.
[0124] In some embodiments, VH comprises the amino acid sequence SEQ ID NO: 23, or a variant of an amino acid sequence having at least about 80% (such as at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity; and VL comprises the amino acid sequence SEQ ID NO: 24, or a variant of an amino acid sequence having at least about 80% (such as at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity.
[0125] In some embodiments, the anti-VISTA construct includes an antibody portion comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the antibody portion competes with an antibody or antibody fragment comprising a second heavy chain variable region (VH-2) and a second light chain variable region (VL-2) for the binding antigenic determinant of VISTA, wherein VH-2 comprises: HC-CDR1 comprising the amino acid sequence SEQ ID NO: 25, HC-CDR2 comprising the amino acid sequence SEQ ID NO: 26, and HC-CDR3 comprising the amino acid sequence SEQ ID NO: 27, and VL-2 comprises: LC-CDR1 comprising the amino acid sequence SEQ ID NO: 28, LC-CDR2 comprising the amino acid sequence SEQ ID NO: 29, and LC-CDR3 comprising the amino acid sequence SEQ ID NO: 30.
[0126] In some embodiments, VH comprises: i) HC-CDR1 containing the amino acid sequence SEQ ID NO: 25, ii) HC-CDR2 containing the amino acid sequence SEQ ID NO: 26, and iii) HC-CDR3 containing the amino acid sequence SEQ ID NO: 27, or variants thereof containing up to 5, 4, 3, 2, or 1 amino acid substitution in the HC-CDRs; and VL comprises: i) LC-CDR1 containing the amino acid sequence SEQ ID NO: 28, ii) LC-CDR2 containing the amino acid sequence SEQ ID NO: 29, and iii) LC-CDR3 containing the amino acid sequence SEQ ID NO: 30, or variants thereof containing up to 5, 4, 3, 2, or 1 amino acid substitution in the LC-CDRs. In some embodiments, the amino acid substitutions described above are limited to the "exemplary substitutions" shown in Table 2 of this application. In some embodiments, the amino acid substitutions are limited to the "preferred substitutions" shown in Table 2 of this application.
[0127] In some embodiments, the anti-VISTA antibody portion is a humanized antibody derived from an anti-VISTA antibody containing a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH contains: i) HC-CDR1 containing the amino acid sequence SEQ ID NO: 25, ii) HC-CDR2 containing the amino acid sequence SEQ ID NO: 26 and iii) HC-CDR3 containing the amino acid sequence SEQ ID NO: 27, and the VL contains: i) LC-CDR1 containing the amino acid sequence SEQ ID NO: 28, ii) LC-CDR2 containing the amino acid sequence SEQ ID NO: 29 and iii) LC-CDR3 containing the amino acid sequence SEQ ID NO: 30.
[0128] In some embodiments, the antibody portion comprises: HC-CDR1, HC-CDR2 and HC-CDR3, each comprising the amino acid sequences of CDR1, CDR2 and CDR3 within the VH chain region having the sequence described in SEQ ID NO: 31; and LC-CDR1, LC-CDR2 and LC-CDR3, each comprising the amino acid sequences of CDR1, CDR2 and CDR3 within the VL chain region having the sequence described in SEQ ID NO: 32.
[0129] In some embodiments, VH comprises the amino acid sequence SEQ ID NO: 31, or a variant of an amino acid sequence having at least about 80% (such as at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity; and VL comprises the amino acid sequence SEQ ID NO: 32, or a variant of an amino acid sequence having at least about 80% (such as at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity.
[0130] In some embodiments, the anti-VISTA construct includes an antibody portion comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the antibody portion competes with an antibody or antibody fragment comprising a second heavy chain variable region (VH-2) and a second light chain variable region (VL-2) for the binding antigenic determinant of VISTA, wherein VH-2 comprises: HC-CDR1 comprising the amino acid sequence SEQ ID NO: 33, HC-CDR2 comprising the amino acid sequence SEQ ID NO: 34, and HC-CDR3 comprising the amino acid sequence SEQ ID NO: 35, and VL-2 comprises: LC-CDR1 comprising the amino acid sequence SEQ ID NO: 36, LC-CDR2 comprising the amino acid sequence SEQ ID NO: 37, and LC-CDR3 comprising the amino acid sequence SEQ ID NO: 38.
[0131] In some embodiments, VH comprises: i) HC-CDR1 containing the amino acid sequence SEQ ID NO: 33, ii) HC-CDR2 containing the amino acid sequence SEQ ID NO: 34, and iii) HC-CDR3 containing the amino acid sequence SEQ ID NO: 35, or variants thereof containing up to 5, 4, 3, 2, or 1 amino acid substitution in the HC-CDRs; and VL comprises: i) LC-CDR1 containing the amino acid sequence SEQ ID NO: 36, ii) LC-CDR2 containing the amino acid sequence SEQ ID NO: 37, and iii) LC-CDR3 containing the amino acid sequence SEQ ID NO: 38, or variants thereof containing up to 5, 4, 3, 2, or 1 amino acid substitution in the LC-CDRs. In some embodiments, the amino acid substitutions described above are limited to the "exemplary substitutions" shown in Table 2 of this application. In some embodiments, the amino acid substitutions are limited to the "preferred substitutions" shown in Table 2 of this application.
[0132] In some embodiments, the anti-VISTA antibody portion is a humanized antibody derived from an anti-VISTA antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises: i) HC-CDR1 comprising the amino acid sequence SEQ ID NO: 33, ii) HC-CDR2 comprising the amino acid sequence SEQ ID NO: 34 and iii) HC-CDR3 comprising the amino acid sequence SEQ ID NO: 35, and the VL comprises: i) LC-CDR1 comprising the amino acid sequence SEQ ID NO: 36, ii) LC-CDR2 comprising the amino acid sequence SEQ ID NO: 37 and iii) LC-CDR3 comprising the amino acid sequence SEQ ID NO: 38.
[0133] In some embodiments, the antibody portion comprises: HC-CDR1, HC-CDR2 and HC-CDR3, each comprising the amino acid sequences of CDR1, CDR2 and CDR3 within the VH chain region having the sequence described in SEQ ID NO: 39; and LC-CDR1, LC-CDR2 and LC-CDR3, each comprising the amino acid sequences of CDR1, CDR2 and CDR3 within the VL chain region having the sequence described in SEQ ID NO: 40.
[0134] In some embodiments, VH comprises the amino acid sequence SEQ ID NO: 39, or a variant of an amino acid sequence having at least about 80% (such as at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity; and VL comprises the amino acid sequence SEQ ID NO: 40, or a variant of an amino acid sequence having at least about 80% (such as at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity.
[0135] In some embodiments, VH comprises: i) HC-CDR1 containing the amino acid sequence SEQ ID NO: 41, ii) HC-CDR2 containing the amino acid sequence SEQ ID NO: 42, and iii) HC-CDR3 containing the amino acid sequence SEQ ID NO: 11, and VL comprises: i) LC-CDR1 containing the amino acid sequence SEQ ID NO: 46, ii) LC-CDR2 containing the amino acid sequence SEQ ID NO: 13, and iii) LC-CDR3 containing the amino acid sequence SEQ ID NO: 47.
[0136] In some embodiments, the anti-VISTA antibody portion is a humanized antibody derived from an anti-VISTA antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises: i) HC-CDR1 comprising the amino acid sequence SEQ ID NO: 41, ii) HC-CDR2 comprising the amino acid sequence SEQ ID NO: 42 and iii) HC-CDR3 comprising the amino acid sequence SEQ ID NO: 11, and the VL comprises: i) LC-CDR1 comprising the amino acid sequence SEQ ID NO: 46, ii) LC-CDR2 comprising the amino acid sequence SEQ ID NO: 13 and iii) LC-CDR3 comprising the amino acid sequence SEQ ID NO: 47.
[0137] In some embodiments, VH comprises: i) HC-CDR1 containing the amino acid sequence SEQ ID NO: 43, ii) HC-CDR2 containing the amino acid sequence SEQ ID NO: 44, and iii) HC-CDR3 containing the amino acid sequence SEQ ID NO: 45, and VL comprises: i) LC-CDR1 containing the amino acid sequence SEQ ID NO: 54, ii) LC-CDR2 containing the amino acid sequence SEQ ID NO: 55, and iii) LC-CDR3 containing the amino acid sequence SEQ ID NO: 56.
[0138] In some embodiments, the anti-VISTA antibody portion is a humanized antibody derived from an anti-VISTA antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises: i) HC-CDR1 comprising the amino acid sequence SEQ ID NO: 43, ii) HC-CDR2 comprising the amino acid sequence SEQ ID NO: 44 and iii) HC-CDR3 comprising the amino acid sequence SEQ ID NO: 45, and the VL comprises: i) LC-CDR1 comprising the amino acid sequence SEQ ID NO: 54, ii) LC-CDR2 comprising the amino acid sequence SEQ ID NO: 55 and iii) LC-CDR3 comprising the amino acid sequence SEQ ID NO: 56.
[0139] In some embodiments, VH comprises: i) HC-CDR1 containing the amino acid sequence SEQ ID NO: 43, ii) HC-CDR2 containing the amino acid sequence SEQ ID NO: 52, and iii) HC-CDR3 containing the amino acid sequence SEQ ID NO: 45, and VL comprises: i) LC-CDR1 containing the amino acid sequence SEQ ID NO: 54, ii) LC-CDR2 containing the amino acid sequence SEQ ID NO: 55, and iii) LC-CDR3 containing the amino acid sequence SEQ ID NO: 56.
[0140] In some embodiments, the anti-VISTA antibody portion is a humanized antibody derived from an anti-VISTA antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises: i) HC-CDR1 comprising the amino acid sequence SEQ ID NO: 43, ii) HC-CDR2 comprising the amino acid sequence SEQ ID NO: 52 and iii) HC-CDR3 comprising the amino acid sequence SEQ ID NO: 45, and the VL comprises: i) LC-CDR1 comprising the amino acid sequence SEQ ID NO: 54, ii) LC-CDR2 comprising the amino acid sequence SEQ ID NO: 55 and iii) LC-CDR3 comprising the amino acid sequence SEQ ID NO: 56.
[0141] In some embodiments, VH comprises: i) HC-CDR1 containing the amino acid sequence SEQ ID NO: 43, ii) HC-CDR2 containing the amino acid sequence SEQ ID NO: 52, and iii) HC-CDR3 containing the amino acid sequence SEQ ID NO: 45, and VL comprises: i) LC-CDR1 containing the amino acid sequence SEQ ID NO: 54, ii) LC-CDR2 containing the amino acid sequence SEQ ID NO: 55, and iii) LC-CDR3 containing the amino acid sequence SEQ ID NO: 57.
[0142] In some embodiments, the anti-VISTA antibody portion is a humanized antibody derived from an anti-VISTA antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises: i) HC-CDR1 comprising the amino acid sequence SEQ ID NO: 43, ii) HC-CDR2 comprising the amino acid sequence SEQ ID NO: 52 and iii) HC-CDR3 comprising the amino acid sequence SEQ ID NO: 45, and the VL comprises: i) LC-CDR1 comprising the amino acid sequence SEQ ID NO: 54, ii) LC-CDR2 comprising the amino acid sequence SEQ ID NO: 55 and iii) LC-CDR3 comprising the amino acid sequence SEQ ID NO: 57.
[0143] In some embodiments, VH comprises: i) HC-CDR1 containing the amino acid sequence SEQ ID NO: 43, ii) HC-CDR2 containing the amino acid sequence SEQ ID NO: 44, and iii) HC-CDR3 containing the amino acid sequence SEQ ID NO: 45; and VL comprises: i) LC-CDR1 containing the amino acid sequence SEQ ID NO: 54, ii) LC-CDR2 containing the amino acid sequence SEQ ID NO: 55, and iii) LC-CDR3 containing the amino acid sequence SEQ ID NO: 57.
[0144] In some embodiments, the anti-VISTA antibody portion is a humanized antibody derived from an anti-VISTA antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises: i) HC-CDR1 comprising the amino acid sequence SEQ ID NO: 43, ii) HC-CDR2 comprising the amino acid sequence SEQ ID NO: 44 and iii) HC-CDR3 comprising the amino acid sequence SEQ ID NO: 45, and the VL comprises: i) LC-CDR1 comprising the amino acid sequence SEQ ID NO: 54, ii) LC-CDR2 comprising the amino acid sequence SEQ ID NO: 55 and iii) LC-CDR3 comprising the amino acid sequence SEQ ID NO: 57.
[0145] In some embodiments, VH comprises: i) HC-CDR1 containing the amino acid sequence SEQ ID NO: 43, ii) HC-CDR2 containing the amino acid sequence SEQ ID NO: 58, and iii) HC-CDR3 containing the amino acid sequence SEQ ID NO: 45, and VL comprises: i) LC-CDR1 containing the amino acid sequence SEQ ID NO: 48, ii) LC-CDR2 containing the amino acid sequence SEQ ID NO: 49, and iii) LC-CDR3 containing the amino acid sequence SEQ ID NO: 53.
[0146] In some embodiments, the anti-VISTA antibody portion is a humanized antibody derived from an anti-VISTA antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises: i) HC-CDR1 comprising the amino acid sequence SEQ ID NO: 43, ii) HC-CDR2 comprising the amino acid sequence SEQ ID NO: 58 and iii) HC-CDR3 comprising the amino acid sequence SEQ ID NO: 45, and the VL comprises: i) LC-CDR1 comprising the amino acid sequence SEQ ID NO: 48, ii) LC-CDR2 comprising the amino acid sequence SEQ ID NO: 49 and iii) LC-CDR3 comprising the amino acid sequence SEQ ID NO: 53.
[0147] In some embodiments, the construct comprises or is an antibody or an antigen-binding fragment thereof selected from the group consisting of: full-length antibody, bispecific antibody, single-chain Fv (scFv) fragment, Fab fragment, Fab' fragment, F(ab')2, Fv fragment, disulfide bond stabilized Fv fragment (dsFv), (dsFv)2, VHH, Fv-Fc fusion, scFv-Fc fusion, scFv-Fv fusion, bifunctional antibody, trifunctional antibody and tetrafunctional antibody.
[0148] In some embodiments, the anti-VISTA antibody is a full-length antibody.
[0149] In some embodiments, the anti-VISTA antibody portion is scFv.
[0150] In some embodiments, the anti-VISTA antibody portion described above comprises an Fc fragment of an immunoglobulin selected from the group consisting of IgG, IgA, IgD, IgE, IgM, and combinations thereof and hybrids thereof. In some embodiments, the anti-VISTA antibody portion or full-length antibody described above comprises an Fc fragment of an immunoglobulin selected from the group consisting of IgG1, IgG2, IgG3, IgG4, and combinations thereof and hybrids thereof. In some embodiments, the effector function of the Fc fragment is weakened compared to the corresponding wild-type Fc fragment. In some embodiments, the effector function of the Fc fragment is enhanced compared to the corresponding wild-type Fc fragment.
[0151] In some embodiments, the antibody portion comprises a humanized antibody of any of the antibody portions described herein.
[0152] In some embodiments, the anti-VISTA antibody partially binds to both human VISTA and cynomolgus monkey VISTA. In some embodiments, the anti-VISTA antibody partially binds to both human VISTA and mouse VISTA. In some embodiments, the anti-VISTA antibody partially binds to human VISTA, cynomolgus monkey VISTA, and mouse VISTA. In some embodiments, the anti-VISTA antibody partially does not bind to cynomolgus monkey VISTA and / or mouse VISTA.
[0153] In some embodiments, the antibody of the anti-VISTA construct partially activates the downstream signaling pathway of VISTA. In some embodiments, the anti-VISTA construct is a VISTA-enhancing antibody.
[0154] In some embodiments, compared to a reference construct (e.g., a corresponding construct that does not activate VISTA, such as a corresponding construct containing a reference activating anti-VISTA antibody such as 1E8), the antibody portion of the anti-VISTA construct activates or enhances the downstream signaling pathways of VISTA by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, or 70%).
[0155] In some embodiments, the anti-VISTA construct comprises or is an anti-VISTA fusion protein. In some embodiments, the anti-VISTA construct comprises an anti-VISTA antibody portion (e.g., anti-VISTA scFv) and a second portion. In some embodiments, the second portion comprises a half-life extension portion. In some embodiments, the half-life extension portion is an albumin-binding portion (e.g., an albumin-binding antibody portion). In some embodiments, the anti-VISTA antibody portion and the half-life extension portion are linked via a linker (such as a peptide linker, such as a GS linker).
[0156] In some embodiments, the anti-VISTA construct comprises or is an anti-VISTA immune conjugate comprising an anti-VISTA antibody portion (such as any of the VISTA antibody portions described herein) and a second agent. In some embodiments, the second agent is a therapeutic agent. In some embodiments, the second agent is a label.
[0157] In some embodiments, VISTA is human VISTA. a) Antibody affinity
[0158] The binding specificity of the antibody moiety can be experimentally determined by methods known in this technique. Such methods include, but are not limited to, Western ink dot assay, ELISA, RIA, ECL, IRMA, EIA, BIACORE™ assay, and peptide scanning.
[0159] In some embodiments, the KD of the binding between the antibody portion and VISTA is about 10⁻⁷M to about 10⁻¹²M, about 10⁻⁷M to about 10⁻⁸M, about 10⁻⁸M to about 10⁻⁹M, about 10⁻⁹M to about 10⁻¹⁰M, about 10⁻¹⁰M to about 10⁻¹¹M, about 10⁻¹¹M to about 10⁻¹²M, about 10⁻⁷M to about 10⁻¹²M, about 10⁻⁸M to about 10⁻¹²M, about 10⁻⁹M to about 10⁻¹²M, about 10⁻¹⁰M to about 10⁻¹²M, about 10⁻⁷M to about 10⁻¹¹M, about 10⁻⁹M to about 10⁻¹¹M, about 10⁻⁷M to about 10⁻¹⁰M, about 10⁻⁸M to about 10⁻¹⁰M, or about 10⁻⁷M to about 10⁻⁹M. In some embodiments, the KD of the antibody binding to VISTA is higher than any one of about 10⁻⁷ M, 10⁻⁸ M, 10⁻⁹ M, 10⁻¹⁰ M, 10⁻¹¹ M, or 10⁻¹² M. In some embodiments, VISTA is human VISTA.
[0160] In some embodiments, the Kon of the binding between the antibody portion and VISTA is about 103 M-1s-1 to about 108 M-1s-1, about 103 M-1s-1 to about 104 M-1s-1, about 104 M-1s-1 to about 105 M-1s-1, about 105 M-1s-1 to about 106 M-1s-1, about 106 M-1s-1 to about 107 M-1s-1, or about 107 M-1s-1 to about 108 M-1s-1. In some embodiments, the Kon of binding between the antibody portion and VISTA is about 10³ M⁻¹ s⁻¹ to about 10⁵ M⁻¹ s⁻¹, about 10⁴ M⁻¹ s⁻¹ to about 10⁶ M⁻¹ s⁻¹, about 10⁵ M⁻¹ s⁻¹ to about 10⁷ M⁻¹ s⁻¹, about 10⁶ M⁻¹ s⁻¹ to about 10⁸ M⁻¹ s⁻¹, about 10⁴ M⁻¹ s⁻¹ to about 10⁷ M⁻¹ s⁻¹, or about 10⁵ M⁻¹ s⁻¹ to about 10⁸ M⁻¹ s⁻¹. In some embodiments, the Kon of binding between the antibody portion and VISTA does not exceed any one of about 10³ M⁻¹ s⁻¹, 10⁴ M⁻¹ s⁻¹, 10⁵ M⁻¹ s⁻¹, 10⁶ M⁻¹ s⁻¹, 10⁷ M⁻¹ s⁻¹, or 10⁸ M⁻¹ s⁻¹. In some embodiments, VISTA is human VISTA.
[0161] In some embodiments, the Koff of the binding between the antibody portion and VISTA is about 1 s⁻¹ to about 10⁻⁶ s⁻¹, about 1 s⁻¹ to about 10⁻² s⁻¹, about 10⁻² s⁻¹ to about 10⁻³ s⁻¹, about 10⁻³ s⁻¹ to about 10⁻⁴ s⁻¹, about 10⁻⁴ s⁻¹ to about 10⁻⁵ s⁻¹, about 10⁻⁵ s⁻¹ to about 10⁻⁶ s⁻¹, about 1 s⁻¹ to about 10⁻⁵ s⁻¹, about 10⁻² s⁻¹ to about 10⁻⁶ s⁻¹, about 10⁻³ s⁻¹ to about 10⁻⁶ s⁻¹, about 10⁻⁴ s⁻¹ to about 10⁻⁶ s⁻¹, about 10⁻² s⁻¹ to about 10⁻⁵ s⁻¹, or about 10⁻³ s⁻¹ to about 10⁻⁵ s⁻¹. In some embodiments, the Koff of the binding between the antibody portion and VISTA is at least about 1 s⁻¹, 10⁻² s⁻¹, 10⁻³ s⁻¹, 10⁻⁴ s⁻¹, 10⁻⁵ s⁻¹, or 10⁻⁶ s⁻¹. In some embodiments, VISTA is human VISTA.
[0162] In some embodiments, the binding affinity of the anti-VISTA antibody portion or the anti-VISTA construct is higher than that of existing anti-VISTA antibodies (e.g., anti-human VISTA antibodies, such as 1E8) (e.g., lower KD value). b) Chimeric or humanized antibodies
[0163] In some embodiments, the anti-VISTA antibody is a chimeric antibody. In some embodiments, the chimeric antibody includes a non-human variable region (e.g., a variable region derived from a mouse) and a human constant region. In some embodiments, the chimeric antibody is a "class-switched" antibody, wherein the class or subclass has changed from the class or subclass of the parent antibody. The chimeric antibody includes its antigen-binding fragment.
[0164] In some embodiments, the anti-VISTA antibody is a humanized antibody. Typically, non-human antibodies can be humanized to reduce immunogenicity to humans while retaining the specificity and affinity of the parent non-human antibody. Generally, a humanized antibody comprises one or more variable domains, wherein the HVR (e.g., CDR) (or a portion thereof) is derived from a non-human antibody, and the FR (or a portion thereof) is derived from a human antibody sequence. The humanized antibody may also, where appropriate, comprise at least a portion of a human constant region. In some embodiments, some FR residues in the humanized antibody are substituted with corresponding residues from a non-human antibody (e.g., an antibody from which HVR residues are derived) to, for example, restore or improve antibody specificity or affinity.
[0165] Humanized antibodies and their preparation methods are reviewed in, for example, Almagro and Fransson, Front. Biosci. 13:1619-1633 (2008), and further described in, for example, Riechmann et al., Nature 332:323-329 (1988); Queen et al., Proc. Nat'l Acad. Sci. USA 86:10029-10033 (1989); US Patent Nos. 5,821,337, 7,527,791, 6,982,321 and 7,087,409; Kashmiri et al., Methods 36:25-34 (2005) (describing SDR (a-CDR) transplantation); Padlan, Mol. Immunol. 28:489-498 (1991). (Description of "resurfacing"); Dall'Acqua et al., Methods36:43-60 (2005) (Description of "FR resurfacing"); and Osbourn et al., Methods36:61-68 (2005) and Klimka et al., Br. J. Cancer, 83:252-260 (2000) (Description of "guided selection" method for FR resurfacing).
[0166] Human scaffold regions that can be used for humanization include, but are not limited to: scaffold regions selected using the "best-fit" method (see, for example, Sims et al., J. Immunol. 151:2296 (1993)); scaffold regions derived from common sequences of human antibodies with specific subgroups having light or heavy chain variable regions (see, for example, Carter et al., Proc. Natl. Acad. Sci. USA, 89:4285 (1992); and Presta et al., J. Immunol., 151:2623 (1993)); human maturation (somatic mutation) scaffold regions or human germline scaffold regions (see, for example, Almagro and Fransson, Front. Biosci. 13:1619-1633 (2008)); and scaffold regions derived from screening FR libraries (see, for example, Baca et al., J. Biol. Chem.). 272:10678-10684 (1997) and Rosok et al., J. Biol. Chem. 271:22611-22618 (1996)).
[0167] It should be understood that the humanization of mouse-derived antibodies is a common and frequently used technique. Therefore, it should be understood that any and all humanized forms of the anti-VISTA antibodies disclosed in the sequence listing may be used in preclinical or clinical settings. In the event that any of the mentioned anti-VISTA antibodies or humanized forms of their antigen-binding regions are used in such preclinical or clinical settings, the subsequently humanized form is expected to have the same or similar biological activity and profile as the original non-humanized form. c) Human Antibodies
[0168] In some embodiments, the anti-VISTA antibody is partially a human antibody (referred to as a human domain antibody or human DAb). Human antibodies can be generated using various techniques known in this art. Human antibodies are generally described in van Dijk and van de Winkel, Curr Opin Pharmacol. 5: 368-74 (2001), Lonberg, Curr. Opin. Immunol. 20:450-459 (2008), and Chen, Mol. Immunol. 47(4):912-21 (2010). Transgenic mice or rats capable of generating fully human single-domain antibodies (or DAbs) are known in this art. See, for example, US20090307787A1, US Patent No. 8,754,287, US20150289489A1, US20100122358A1, and WO2004049794.
[0169] Human antibodies (e.g., human DAbs) can be prepared by administering immunogens to transgenic animals modified to produce intact human antibodies in response to antigen challenge or to produce intact antibodies with human variable regions. These animals typically contain all or part of the human immunoglobulin loci, which replace endogenous immunoglobulin loci, or are located extrachromosomally or randomly integrated into the animal's chromosome. In such transgenic mice, endogenous immunoglobulin loci are generally inactive. For a review of methods for obtaining human antibodies from self-transgenic animals, see Lonberg, Nat. Biotech. 23:1117-1125 (2005). See also, for example, U.S. Patent Nos. 6,075,181 and 6,150,584 describing XENOMOUSE™ technology; U.S. Patent No. 5,770,429 describing HUMAB® technology; U.S. Patent No. 7,041,870 describing KM MOUSE® technology; and U.S. Patent Application Publication No. US 2007 / 0061900 describing VELOCIMOUSE® technology. The human variable region of intact antibodies produced from such animals can be further modified, for example, by combining with different human constant regions.
[0170] Human antibodies (e.g., human DAbs) can also be prepared using fusion tumor-based methods. Human myeloma and mouse-human fusion myeloma cell lines used to produce human monoclonal antibodies have been described (see, for example, Kozbor J. Immunol., 133: 3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987); and Boerner et al., J. Immunol., 147: 86 (1991)). Human antibodies produced via human B-cell fusion tumor technology are also described in Li et al., Proc. Natl. Acad. Sci. USA, 103:3557-3562 (2006). Other methods include, for example, those described in U.S. Patent No. 7,189,826 (describing the production of monoclonal human IgM antibodies from fusion tumor cell lines) and Ni, Xiandai Mianyixue 26(4):265-268 (2006) (describing human-human fusion tumors). Human fusion tumor technology (trioma technology) is also described in Vollmers and Brandlein, Histology and Histopathology, 20(3):927-937 (2005) and Vollmers and Brandlein, Methods and Findings in Experimental and Clinical Pharmacology, 27(3):185-91 (2005).
[0171] Human antibodies (e.g., human DAbs) can also be generated by isolating Fv-pure variable domain sequences selected from human-derived phage presentation libraries. These variable domain sequences can then be combined with desired human constant domains. Techniques for selecting human antibodies from antibody libraries are described below. d) Library-derived antibodies
[0172] The anti-VISTA antibody portion described herein can be isolated by screening a library of antibodies possessing one or more desired activities. For example, various methods are known in this art for generating phage presentation libraries and screening such libraries for antibodies possessing desired binding characteristics. Such methods are reviewed in, for example, Hoogenboom et al., Methods in Molecular Biology 178:1-37 (edited by O'Brien et al., Human Press, Totowa, NJ, 2001), and further described in, for example, McCafferty et al., Nature 348:552-554; Clackson et al., Nature 352:624-628 (1991); Marks et al., J. Mol. Biol. 222:581-597 (1992); Marks and Bradbury, Methods in Molecular Biology 248:161-175 (edited by Lo, Human Press, Totowa, NJ, 2003); Sidhu et al., J. Mol. Biol. 338(2):299-310 (2004); Lee et al., J. Mol. Biol. 340(5): Methods for constructing single-domain antibody libraries have been described, for example, in U.S. Patent No. 7,371,849. References include Fellouse, Proc. Natl. Acad. Sci. USA 101(34): 12467-12472 (2004); and Lee et al., J. Immunol. Methods 284(1-2): 119-132 (2004).
[0173] In some phage presentation methods, lineages of the VH and VL genes are selected by polymerase chain reaction (PCR) and randomly recombined in a phage library, followed by screening for antigen-binding phages as described in Winter et al., Ann. Rev. Immunol. 12: 433-455 (1994). Phages typically present antibody fragments as scFv or Fab fragments. High-affinity antibodies against immunogens are provided from an immune-derived library without the need to construct fusion tumors. Alternatively, native lineages (e.g., from humans) can be selected to provide a single antibody source against a wide range of non-autoantigens and autoantigens without any immunization, as described in Griffiths et al., EMBO J, 12: 725-734 (1993). Ultimately, the original library can also be synthesized by selecting unrearranged V gene segments from stem cells and using PCR primers containing random sequences to encode the hypervariable CDR3 region and achieve in vitro rearrangement, as described by Hoogenboom and Winter, J. Mol. Biol., 227: 381-388 (1992). Patent publications describing human antibody phage libraries include, for example, U.S. Patent No. 5,750,373 and U.S. Patent Publications Nos. 2005 / 0079574, 2005 / 0119455, 2005 / 0266000, 2007 / 0117126, 2007 / 0160598, 2007 / 0237764, 2007 / 0292936, and 2009 / 0002360.
[0174] Antibodies or antibody fragments isolated from human antibody libraries are considered human antibodies or human antibody fragments in this paper. e) Substitution, insertion, deletion and variants
[0175] In some embodiments, antibody variants having one or more amino acid substitutions are provided. Sites of interest for inducing substitutional mutations include HVR (or CDR) and FR. Conserved substitutions are shown under the heading "Preferred Substitutions" in Table 2. Further substantial variations are provided under the heading "Illustrative Substitutions" in Table 2, and are further described below regarding the categories of amino acid side chains. Amino acid substitutions can be introduced into the antibody of interest, and products with desired activities can be screened, such as maintaining / improving antigen binding, reducing immunogenicity, or improving ADCC or CDC. Table 2. Amino Acid Substitutions Original residues Exemplary substitution Better alternative Ala (A) Val; Leu; Ile Val Arg (R) Lys; Gln; Asn Lys Asn (N) Gln; His; Asp, Lys; Arg Gln Asp (D) Glu; Asn Glu Cys (C) Ser; Ala Ser Gln (Q) Asn; Glu Asn Glu (E) Asp; Gln Asp Gly (G) Ala Ala His (H) Asn; Gln; Lys; Arg Arg Ile (I) Leu; Val; Met; Ala; Phe; norleucine Leu Leu (L) norleucine; Ile; Val; Met; Ala; Phe Ile Lys (K) Arg; Gln; Asn Arg Met (M) Leu; Phe; Ile Leu Phe (F) Trp; Leu; Val; Ile; Ala; Tyr Tyr Pro (P) Ala Ala Ser (S) Thr Thr Thr (T) Val; Ser Ser Trp (W) Tyr; Phe Tyr Tyr (Y) Trp; Phe; Thr; Ser Phe Val (V) Ile; Leu; Met; Phe; Ala; Leucine Leu
[0176] Amino acids can be grouped according to common side chain characteristics: (1) Hydrophobic: normal leucine, Met, Ala, Val, Leu, Ile; (2) Neutral hydrophilic: Cys, Ser, Thr, Asn, Gln; (3) Acidic: Asp, Glu; (4) Basic: His, Lys, Arg; (5) Residues that affect chain orientation: Gly, Pro; and (6) Aromatic: Trp, Tyr, Phe.
[0177] Non-conservative substitution will necessarily involve replacing members of one of these categories with members of another category.
[0178] One type of substitution variant involves replacing one or more hypervariable residues of a parent antibody (e.g., humanized or human antibody). Generally, the resulting variant, selected for further research, will have modifications (e.g., improvements) in certain biological properties relative to the parent antibody (e.g., increased affinity, decreased immunogenicity) and / or will substantially retain certain biological properties of the parent antibody. An exemplary substitution variant is an affinity-maturated antibody, which can be conveniently generated, for example, using phage-based affinity maturation techniques (such as those described herein). In short, one or more HVR residues are mutated, and the variant antibody is presented on a phage and screened for specific biological activities (e.g., binding affinity).
[0179] Modifications (e.g., substitutions) can be made in the HVR, for example, to improve antibody affinity. Such modifications can be made in HVR "hotspots" (i.e., codon-encoded residues that undergo frequent mutations during somatic maturation) (see, for example, Chowdhury, Methods Mol. Biol. 207:179-196 (2008)) and / or SDR (a-CDR), where the binding affinity of the resulting variants VH or VL is tested. Affinity maturation by constructing secondary libraries and reselecting from them has been described, for example, in Hoogenboom et al., Methods in Molecular Biology 178:1-37 (edited by O'Brien et al., Human Press, Totowa, NJ, (2001)). In some embodiments of affinity maturation, diversity is introduced into the variants selected for maturation by any of various methods (e.g., error-prone PCR, strand shuffling, or oligonucleotide directed mutation induction). A secondary library is then generated. This library is then screened to identify any antibody variants with the desired affinity. Another method for introducing diversity involves an HVR-guided approach that randomly groups several HVR residues (e.g., 4 to 6 residues at a time). HVR residues involved in antigen binding can be specifically identified, for example, using alanine scanning mutation induction or modeling. CDR-H3 and CDR-L3 are often targeted in particular.
[0180] In some embodiments, substitution, insertion, or deletion may occur within one or more HVRs, as long as such changes do not substantially reduce the antibody's ability to bind to the antigen. For example, conserved changes that do not substantially reduce binding affinity (e.g., conserved substitutions as provided herein) may be made in the HVR. Such changes may be located outside the HVR "hotspot" or CDR.
[0181] A method for identifying targetable antibody residues or regions induced by mutations is called "alanine-scanning mutation induction," as described by Cunningham and Wells (1989) Science, 244:1081-1085. In this method, residues or groups of target residues (e.g., charged residues such as Arg, Asp, His, Lys, and Glu) are identified and replaced by neutral or negatively charged amino acids (e.g., alanine or polyalanine) to determine whether the interaction between the antibody and the antigen is affected. Other substitutions may be introduced at the amino acid sites, exhibiting functional sensitivity to the initial substitution. Alternatively, the crystal structure of the antigen-antibody complex is used to identify contact points between the antibody and the antigen. Such contact residues and adjacent residues may be targeted as substitution candidates or excluded from substitution candidate selection. Variants may be screened to determine whether they contain the desired properties.
[0182] Amino acid sequence insertion includes amino-terminal and / or carboxyl-terminal fusion of a polypeptide ranging in length from one residue to one hundred or more residues, and intra-sequence insertion of one or more amino acid residues. Examples of terminal insertion include antibodies having an N-terminal methionine residue. Other insertion variants of antibody molecules include fusions of the N-terminus or C-terminus of an antibody with an enzyme (e.g., for ADEPT) or a polypeptide that prolongs the serum half-life of the antibody. f) Glycosylation variants
[0183] In some embodiments, the anti-VISTA antibody portion is modified to increase or decrease the degree of glycosylation of the construct. Adding or removing glycosylation sites on the antibody can be conveniently achieved by altering the amino acid sequence to create or remove one or more glycosylation sites.
[0184] In cases where the antibody moiety includes an Fc region, the carbohydrates linked to it can be modified. Native antibodies produced by mammalian cells typically contain branched-chain biantennary oligosaccharides, which are generally linked to Asn297 of the CH2 domain of the Fc region via N-bonds. See, for example, Wright et al., TIBTECH 15:26-32 (1997). Oligosaccharides may include various carbohydrates such as mannose, N-acetylglucosamine (GlcNAc), galactose, and sialic acid, as well as fucose linked to GlcNAc in the "backbone" of the biantennary oligosaccharide structure. In some embodiments, the oligosaccharides in the antibody moiety can be modified to produce antibody variants with certain improved properties.
[0185] In one embodiment, the anti-VISTA antibody portion has a carbohydrate structure lacking fucose linked (directly or indirectly) to the Fc region. For example, the amount of fucose in such antibodies may be 1% to 80%, 1% to 65%, 5% to 65%, or 20% to 40%. The amount of fucose is determined by calculating the average amount of fucose at Asn297 within the glycan chain relative to the sum of all sugar structures (e.g., complex, hybrid, and high-mannose structures) linked to Asn297, as measured by MALDI-TOF mass spectrometry, as described, for example, in WO 2008 / 077546. Asn297 refers to the aspartic acid residue located at approximately position 297 (EU number of the Fc region residue) in the Fc region; however, due to slight sequence variations in the antibody, Asn297 may also be located approximately ±3 amino acids upstream or downstream of position 297, i.e., between positions 294 and 300. Such fucosylation variants may possess improved ADCC function. See, for example, U.S. Patent Publication No. US 2003 / 0157108 (Presta, L.); and US 2004 / 0093621 (Kyowa Hakko Kogyo Co., Ltd.). Examples of public disclosures related to antibody variants with "defucosylation" or "fucosylation" include: US 2003 / 0157108; WO 2000 / 61739; WO 2001 / 29246; US 2003 / 0115614; US 2002 / 0164328; US 2004 / 0093621; US 2004 / 0132140; US 2004 / 0110704; US 2004 / 0110282; US 2004 / 0109865; WO 2003 / 085119; WO 2003 / 084570; WO 2005 / 035586; WO 2005 / 035778; WO2005 / 053742; WO2002 / 031140; Okazaki et al. J. Mol. Biol. 336:1239-1249 (2004); Yamane-Ohnuki et al. Biotech. Bioeng. 87: 614 (2004).Examples of cell lines capable of producing defucosylated antibodies include Lec13 CHO cells lacking protein fucosylation (Ripka et al. Arch. Biochem. Biophys. 249:533-545 (1986); US Patent Application No. US 2003 / 0157108 A1, Presta, L; and WO 2004 / 056312 A1, Adams et al., especially example 11) and gene knockout cell lines, such as α-1,6-fucosylation gene FUT8 gene knockout CHO cells (see, for example, Yamane-Ohnuki et al. Biotech. Bioeng. 87: 614 (2004); Kanda, Y. et al. Biotechnol. Bioeng., 94(4):680-688 (2006); and WO2003 / 085107).
[0186] In some embodiments, the anti-VISTA antibody portion has a fractionated oligosaccharide, for example, wherein the biantennary oligosaccharide linked to the Fc region of the antibody is fractionated by GlcNAc. Such antibody variants may have reduced fucosylation and / or improved ADCC function. Examples of such antibody variants are described, for example, in WO 2003 / 011878 (Jean-Mairet et al.); U.S. Patent No. 6,602,684 (Umana et al.); and US 2005 / 0123546 (Umana et al.). Antibody variants in which at least one galactose residue in the oligosaccharide is linked to the Fc region are also provided. Such antibody variants may have improved CDC function. Such antibody variants are described, for example, in WO 1997 / 30087 (Patel et al.); WO 1998 / 58964 (Raju, S.); and WO 1999 / 22764 (Raju, S.). g) Fc region variants
[0187] In some embodiments, the anti-VISTA antibody portion includes an Fc fragment.
[0188] The terms "Fc region," "Fc domain," "Fc fragment," or "Fc" refer to the C-terminal non-antigen-binding region of an immunoglobulin heavy chain containing at least a portion of a constant region. This terminology includes native Fc regions and variant Fc regions. In some embodiments, the human IgG heavy chain Fc region extends from Cys226 to the C-terminus of the heavy chain. However, the C-terminal lysine (Lys447) of the Fc region may or may not be present without affecting the structure or stability of the Fc region. Unless otherwise specified herein, the amino acid residues in the IgG or Fc region are numbered according to the antibody EU numbering system, also known as the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991.
[0189] In some embodiments, the Fc fragment is derived from immunoglobulins selected from the group consisting of IgG, IgA, IgD, IgE, IgM, and combinations thereof. In some embodiments, the Fc fragment is derived from immunoglobulins selected from the group consisting of IgG1, IgG2, IgG3, IgG4, and combinations thereof.
[0190] In some embodiments, the effector function of the Fc fragment is reduced compared to the corresponding wild-type Fc fragment (such as by a reduction of at least about 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, or 95% as measured by antibody-dependent cytotoxicity (ADCC) levels).
[0191] In some embodiments, the Fc fragment is an IgG1 Fc fragment. In some embodiments, the IgG1 Fc fragment contains an L234A mutation and / or an L235A mutation. In some embodiments, the IgG1 Fc fragment contains an L235A mutation and / or a G237A mutation. In some embodiments, the Fc fragment is an IgG2 or IgG4 Fc fragment. In some embodiments, the Fc fragment is an IgG4 Fc fragment containing S228P, F234A, and / or L235A mutations. In some embodiments, the Fc fragment contains an N297A mutation. In some embodiments, the Fc fragment contains an N297G mutation.
[0192] In some embodiments, one or more amino acid modifications may be introduced into the Fc region of the antibody moiety to generate an Fc region variant. The Fc region variant may comprise a human Fc region sequence (e.g., human IgG1, IgG2, IgG3, or IgG4 Fc region) containing amino acid modifications (e.g., substitutions) at one or more amino acid sites.
[0193] In some embodiments, the Fc fragment possesses some, but not all, effector functions, making it an ideal candidate for applications where the half-life of a portion of the antibody in vivo is critical, while certain effector functions (such as complement and ADCC) are unnecessary or detrimental. In vitro and / or in vivo cytotoxicity assays can be performed to confirm a reduction / elimination of CDC and / or ADCC activity. For example, Fc receptor (FcR) binding assays can be performed to confirm the lack of FcγR binding (and therefore likely a lack of ADCC activity) but retention of FcRn binding capacity. Primary NK cells, used to mediate ADCC, express only FcγRIII, while monocytes express FcγRI, FcγRII, and FcγRIII. FcR expression on hematopoietic cells is summarized in Table 2 on page 464 of Ravetch and Kinet, Annu. Rev. Immunol. 9:457-492 (1991). Non-limiting examples of in vitro assays for assessing ADCC activity of molecules of interest are described in U.S. Patent No. 5,500,362 (see, for example, Hellstrom, I. et al., Proc. Nat'l Acad. Sci. USA 83:7059-7063 (1986)) and Hellstrom, I. et al., Proc. Nat'l Acad. Sci. USA 82:1499-1502 (1985); and No. 5,821,337 (see Bruggemann, M. et al., J. Exp. Med. 166:1351-1361 (1987)). Alternatively, non-radioactive analytical methods may be used (see, for example, ACTI™ non-radioactive cytotoxicity assay for flow cytometry (Cell Technology, Inc. Mountain View, CA); and CytoTox 96® non-radioactive cytotoxicity assay (Promega, Madison, WI)). Effector cells suitable for this type of analysis include peripheral blood monocytes (PBMCs) and natural killer (NK) cells. Alternatively, the ADCC activity of the molecule of interest can be assessed in vivo in animal models, such as those described by Clynes et al., Proc Nat'l Acad Sci USA 95:652-656 (1998). C1q binding assays can also be performed to confirm that the antibody does not bind C1q and therefore lacks CDC activity. See, for example, C1q and C3c binding ELISAs in WO 2006 / 029879 and WO 2005 / 100402.To assess complement activation, CDC analysis can be performed (see, for example, Gazzano-Santoro et al., J. Immunol. Methods 202:163 (1996); Cragg, MS et al., Blood 101:1045-1052 (2003); and Cragg, MS and MJ Glennie, Blood 103:2738-2743 (2004)). Alternatively, methods known in this technique (see, for example, Petkova, SB et al., Int'l. Immunol. 18(12):1759-1769 (2006)) can be used to determine FcRn binding and in vivo clearance / half-life.
[0194] Antibodies with reduced effector function include those having substitutions of one or more of residues 238, 265, 269, 270, 297, 327, and 329 in the Fc region (US Patent No. 6,737,056). Such Fc mutants include Fc mutants having substitutions at two or more of amino acid positions 265, 269, 270, 297, and 327, including the so-called "DANA" Fc mutant with residues 265 and 297 substituted with alanine (US Patent No. 7,332,581). In some embodiments, the Fc fragment contains the N297A mutation. In some embodiments, the Fc fragment contains the N297G mutation.
[0195] Describes certain antibody variants with improved or weakened FcR binding. (See, for example, U.S. Patent No. 6,737,056; WO 2004 / 056312 and Shields et al., J. Biol. Chem. 9(2): 6591-6604 (2001).)
[0196] In some embodiments, the Fc fragment is an IgG1 Fc fragment. In some embodiments, the IgG1 Fc fragment contains an L234A mutation and / or an L235A mutation. In some embodiments, the IgG1 Fc fragment contains an L235A mutation and / or a G237A mutation. In some embodiments, the Fc fragment is an IgG2 or IgG4 Fc fragment. In some embodiments, the Fc fragment is an IgG4 Fc fragment containing S228P, F234A, and / or L235A mutations.
[0197] In some embodiments, the antibody portion comprises an Fc region having one or more amino acid substitutions that improve ADCC, such as substitutions at positions 298, 333 and / or 334 (EU numbers of residues) of the Fc region.
[0198] In some embodiments, the alteration occurs in the Fc region, resulting in altered (i.e., improved or reduced) C1q binding and / or complement-dependent cytotoxicity (CDC), as described, for example, in U.S. Patent No. 6,194,551, WO 99 / 51642 and Idusogie et al. J. Immunol. 164: 4178-4184 (2000).
[0199] In some embodiments, the Fc fragment has one or more mutations at Thr250, Met252, Ser254, The256, Thr307, Glu 380, Met428, His433 and / or Asn 434.
[0200] In some embodiments, the antibody variant includes a variant Fc region comprising one or more amino acid substitutions that alter the half-life and / or alter the binding to the neonatal Fc receptor (FcRn). Antibodies with prolonged half-life and improved binding to the neonatal Fc receptor (FcRn) responsible for transferring maternal IgG to the fetus (Guyer et al., J. Immunol. 117:587 (1976) and Kim et al., J. Immunol. 24:249 (1994)) are described in US2005 / 0014934A1 (Hinton et al.). Those antibodies comprise an Fc region having one or more substitutions that alter the binding of the Fc region to the FcRn. Such Fc variants include Fc variants having substitutions at one or more of the residues in the Fc region, such as a substitution at Fc region residue 434 (US Patent No. 7,371,826).
[0201] For other examples of Fc region variants, see also Duncan and Winter, Nature 322:738-40 (1988); U.S. Patent No. 5,648,260; U.S. Patent No. 5,624,821; and WO 94 / 29351. h) Cysteine-engineered antibody variants
[0202] In some embodiments, it may be necessary to generate a cysteine-engineered antibody moiety, such as "thioMAb," wherein one or more residues of the antibody are substituted with cysteine residues. In certain embodiments, the substituted residues are located at accessible sites on the antibody. By substituting those residues with cysteine, reactive thiols are thereby positioned at accessible sites on the antibody and can be used to bind the antibody to other moieties (such as pharmaceutical moieties or linker-pharmaceutical moieties) to produce an immunoconjugate as further described herein. In some embodiments, any one or more of the following residues may be substituted with cysteine: A118 (EU number) of the heavy chain; and S400 (EU number) of the Fc region of the heavy chain. Cysteine-engineered antibody moieties may be generated as described, for example, in U.S. Patent No. 7,521,541. i) Antibody derivatives
[0203] In some embodiments, the antibody portion described herein may be further modified to include other non-protein portions known in the art and readily available. Suitable portions for antibody derivatization include, but are not limited to, water-soluble polymers. Non-limiting examples of water-soluble polymers include, but are not limited to, polyethylene glycol (PEG), ethylene glycol / propylene glycol copolymers, carboxymethyl cellulose, polydextrose, polyvinyl alcohol, polyvinylpyrrolidone, poly-1,3-dioxane, poly-1,3,6-trimethylammonium chloride, ethylene / maleic anhydride copolymers, polyamino acids (homopolymers or random copolymers), and polydextrose or poly(n-vinylpyrrolidone) polyethylene glycol, propylene glycol homopolymers, polyoxypropylene / ethylene oxide copolymers, polyoxyethylene polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof. Polyethylene glycol propionaldehyde may be advantageous in manufacturing due to its stability in water. The polymer may have any molecular weight and may be branched or unbranched. The number of polymers attached to the antibody can vary, and if more than one polymer is attached, the polymers can be the same or different molecules. Generally, the number and / or type of polymers used for derivatization can be determined based on considerations including, but not limited to, the specific properties or functions of the antibody to be improved, and whether the antibody derivative will be used for diagnostic purposes under specific conditions.
[0204] In some embodiments, the antibody portion may be further modified to include one or more bioactive proteins, peptides, or fragments thereof. As used interchangeably herein, "bioactive" or "biologically active" means exhibiting biological activity in vivo to perform a specific function. For example, it may mean combining with specific biomolecules such as proteins, DNA, etc., and subsequently promoting or inhibiting the activity of such biomolecules. In some embodiments, bioactive proteins or fragments thereof include proteins and peptides administered to a patient as active pharmaceutical substances for the prevention or treatment of diseases or symptoms; proteins and peptides for diagnostic purposes, such as enzymes for diagnostic tests or in vitro analyses; and proteins and peptides administered to a patient to prevent diseases, such as vaccines. III. Preparation Method
[0205] In some embodiments, a method is provided for preparing an anti-VISTA construct or antibody portion that specifically binds to VISTA, and a composition, such as a polynucleotide, nucleic acid construct, carrier, host cell, or culture medium, generated during the preparation of the anti-VISTA construct or antibody portion. The anti-VISTA construct or antibody portion or composition described herein can be prepared by a variety of processes described generally below and in more detail in the examples. Antibody performance and production
[0206] The antibodies described herein can be prepared using any known method of this technology, including those described below and in the examples. Monoclonal antibodies
[0207] Monoclonal antibodies can be obtained from a substantially homogeneous antibody population (i.e., the individual antibodies comprising the population are identical, except for small amounts of possibly naturally occurring mutations and / or post-translational modifications (e.g., isomerization, amide). Therefore, the modifier "monoclonal" indicates that the antibody is not a mixture of discrete antibodies. For example, monoclonal antibodies can be prepared by the fusion tumor method first described in Kohler et al., Nature, 256:495 (1975), or by the recombinant DNA method (US Patent No. 4,816,567). In the fusion tumor method, mice or other suitable host animals (such as hamsters or llamas) are immunized to produce lymphocytes, which produce or are capable of producing antibodies that specifically bind to proteins used for immunization, as described above. Alternatively, lymphocytes can be immunized in vitro. Subsequently, a suitable fusion agent (such as polyethylene glycol) is used to fuse lymphocytes with myeloma cells to form fusion tumor cells (Goding, Monoclonal Antibodies: Principles and Practice, pp. 59-103 (Academic Press, 1986)). See also Example 1 for information on camel immunity.
[0208] Immunosuppressants typically include antigenic proteins or fusion variants thereof. Generally, peripheral blood lymphocytes (“PBLs”) are used if human-derived cells are required, or spleen cells or lymph node cells are used if non-human mammalian-derived cells are required. The lymphocytes are then fused with immortalized cell lines using a suitable fusion agent (such as polyethylene glycol) to form fusion tumor cells. (Goding, Monoclonal Antibodies: Principles and Practice, Academic Press (1986), pp. 59-103.)
[0209] Immortalized cell lines are typically transformed mammalian cells, particularly rodent, bovine, and human myeloma cells. Rat or mouse myeloma cell lines are commonly used. The resulting fusion tumor cells are seeded and grown in a suitable culture medium, preferably containing one or more substances that inhibit the growth or survival of the non-fusion parental myeloma cells. For example, if the parental myeloma cells lack the enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT or HPRT), the culture medium used for fusion tumors will typically include hypoxanthine, aminopterin, and thymidine (HAT medium), substances that inhibit the growth of HGPRT-deficient cells.
[0210] Preferred immortalized myeloma cells are those that are efficiently fused, support stable and large-volume antibody production from selected antibody-producing cells, and are sensitive to culture media such as HAT medium. Preferred are murine myeloma strains, such as murine myeloma strains derived from MOPC-21 and MPC-11 mouse tumors available from the Salk Institute Cell Distribution Center, San Diego, Calif. USA, and SP-2 cells (and their derivatives, such as X63-Ag8-653) available from the American Type Culture Collection, Manassas, Va. USA. Human myeloma and mouse-human fusion myeloma cell lines for producing human monoclonal antibodies have also been described (Kozbor, J., Immunol., 133:3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987)).
[0211] The production of monoclonal antibodies against antigens in the culture medium of fusion tumor cells was analyzed. Preferably, the binding specificity of monoclonal antibodies produced by fusion tumor cells was determined by immunoprecipitation or by in vitro binding assays (such as radioimmunoassay (RIA) or enzyme-linked immunosorbent assay (ELISA)).
[0212] The presence of monoclonal antibodies against a desired antigen in the culture medium for culturing fusion tumor cells can be analyzed. Preferably, the binding affinity and specificity of the monoclonal antibody can be determined by immunoprecipitation or by in vitro binding assays (such as radioimmunoassay (RIA) or enzyme-linked assay (ELISA)). Such techniques and analyses are known in this art. For example, binding affinity can be determined by Scatchard analysis as described by Munson et al., Anal. Biochem., 107:220 (1980).
[0213] After identifying fusion tumor cells that produce antibodies with the desired specificity, affinity, and / or activity, pure lines can be proliferated using a limited dilution procedure and grown using standard methods (Goding, see above). Suitable media for this purpose include, for example, D-MEM or RPMI-1640 media. Cell sorting instruments can also be used. In addition, fusion tumor cells can grow in vivo in the form of tumors in mammals.
[0214] Monoclonal antibodies secreted by subpure lines can be appropriately separated from culture medium, ascites fluid or serum by conventional immunoglobulin purification procedures, such as protein A-agarose, hydroxyapatite chromatography, gel electrophoresis, dialysis or affinity chromatography.
[0215] Monoclonal antibodies can also be prepared using recombinant DNA methods, such as those described in U.S. Patent No. 4,816,567 and as described above. DNA encoding monoclonal antibodies can be isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that can specifically bind to genes encoding the heavy and light chains of murine antibodies). Fusion tumor cells serve as a preferred source of such DNA. Once isolated, the DNA can be placed in an expression vector and then transfected into host cells that do not produce additional immunoglobulins, such as E. coli cells, monkey COS cells, HEK cells, Chinese hamster ovary (CHO) cells, or myeloma cells, to synthesize monoclonal antibodies in such recombinant host cells. Review articles on recombinant expression in bacteria with DNA encoding antibodies include Skerra et al., Curr. Opinion in Immunol., 5:256-262 (1993) and Plückthun, Immunol. Revs. 130:151-188 (1992).
[0216] In another embodiment, antibodies can be isolated from an antibody phage library produced using the techniques described in McCafferty et al., Nature 348:552-554 (1990). Clackson et al., Nature, 352:624-628 (1991) and Marks et al., J. Mol. Biol., 222:581-597 (1991) describe the isolation of mouse and human antibodies, respectively, using phage libraries. Subsequent publications describe the generation of high-affinity (nM range) human antibodies by strand truncation (Marks et al., Bio / Technology, 10:779-783 (1992)), and combined infection and in vivo recombination as a strategy for constructing very large phage libraries (Waterhouse et al., Nucl. Acids Res., 21:2265-2266 (1993)). Therefore, these technologies are a viable alternative to traditional monoclonal antibody fusion tumor technology for isolating monoclonal antibodies.
[0217] DNA can also be modified, for example, by replacing the constant domains of the human heavy and light chains with coding sequences instead of homologous mouse sequences (US 4,816,567; Morrison et al., Proc. Natl Acad. Sci. USA, 81:6851 (1984)) or by covalently attaching all or part of the coding sequence of a non-immunoglobulin polypeptide to an immunoglobulin coding sequence. Typically, such non-immunoglobulin polypeptides are used to replace the constant domain of an antibody, or to replace the variable domain of one antigen-binding site of an antibody, to produce chimeric bivalent antibodies that include one antigen-specific antigen-binding site and another antigen-binding site specific to a different antigen.
[0218] The monoclonal antibodies described herein may be monovalent, and their preparation is well known in the art. For example, one method involves the recombinant expression of immunoglobulin light chains and modified heavy chains. Typically, the heavy chain is truncated at any point in the Fc region to prevent heavy chain cross-linking. Alternatively, the relevant cysteine residues may be substituted or deleted by another amino acid residue to prevent cross-linking. In vitro methods are also suitable for the preparation of monovalent antibodies. Antibody digestion to produce fragments, especially Fab fragments, can be performed using conventional techniques known in the art.
[0219] Chimeric or hybrid antibodies can also be prepared in vitro using known methods of synthetic protein chemistry (including methods involving cross-linking agents). For example, immunotoxins can be constructed using disulfide exchange reactions or by forming thioether bonds. Examples of reagents suitable for this purpose include iminothiolates and methyl-4-mercaptobutylimide. Nucleic acid molecules encoding the antibody moiety
[0220] In some embodiments, a polynucleotide is provided that encodes any of the anti-VISTA constructs or antibody portions described herein. In some embodiments, a polynucleotide prepared using any of the methods described herein is provided. In some embodiments, a nucleic acid molecule comprises a polynucleotide that encodes a heavy chain or light chain of an antibody portion (e.g., an anti-VISTA antibody portion). In some embodiments, a nucleic acid molecule comprises both a polynucleotide encoding a heavy chain of an antibody portion (e.g., an anti-VISTA antibody portion) and a polynucleotide encoding a light chain. In some embodiments, a first nucleic acid molecule comprises a first polynucleotide encoding a heavy chain and a second nucleic acid molecule comprises a second polynucleotide encoding a light chain.
[0221] In some such embodiments, the heavy and light chains are represented by a single nucleic acid molecule, or by two separate nucleic acid molecules in the form of two separate polypeptides. In some embodiments, such as when the antibody is scFv, a single polynucleotide encodes a single polypeptide comprising both a heavy and light chain linked together.
[0222] In some embodiments, the polynucleotide encoding the heavy or light chain of the antibody moiety (e.g., the anti-VISTA antibody moiety) comprises a nucleotide sequence encoding a leader sequence located at the N-terminus of the heavy or light chain during translation. As discussed above, the leader sequence may be a native heavy or light chain leader sequence or another heterologous leader sequence.
[0223] In some embodiments, the polynucleotide is DNA. In some embodiments, the polynucleotide is RNA. In some embodiments, the RNA is mRNA.
[0224] Nucleic acid molecules can be constructed using recombinant DNA techniques known in this art. In some embodiments, the nucleic acid molecule is an expression vector suitable for expression in a selected host cell. Nucleic acid construct
[0225] In some embodiments, a nucleic acid construct is provided that comprises any of the polynucleotides described herein. In some embodiments, a nucleic acid construct prepared using any of the methods described herein is provided.
[0226] In some embodiments, the nucleic acid construct further includes a promoter operatively linked to the polynucleotide. In some embodiments, the polynucleotide corresponds to a gene, wherein the promoter is a wild-type promoter of the gene. Vector
[0227] In some embodiments, a vector is provided that comprises any polynucleotide encoding a heavy chain and / or light chain of any antibody moiety (e.g., an anti-VISTA antibody moiety) or a nucleic acid construct described herein. In some embodiments, a vector prepared using any of the methods described herein is provided. Vectors are also provided that comprise a polynucleotide encoding any anti-VISTA construct described herein, such as an antibody, scFv, fusion protein, or other form of construct (e.g., anti-VISTA scFv). Such vectors include, but are not limited to, DNA vectors, phage vectors, viral vectors, retroviral vectors, etc. In some embodiments, the vector comprises a first polynucleotide sequence encoding a heavy chain and a second polynucleotide sequence encoding a light chain. In some embodiments, the heavy chain and light chain are represented by the vector as two separate polypeptides. In some embodiments, the heavy chain and light chain are represented as part of a single polypeptide, such as when the antibody is scFv.
[0228] In some embodiments, the first vector comprises a polynucleotide encoding a heavy chain and the second vector comprises a polynucleotide encoding a light chain. In some embodiments, the first and second vectors are transfected into host cells in similar amounts (such as similar molar amounts or similar mass). In some embodiments, the first and second vectors are transfected into host cells at a molar ratio or mass ratio between 5:1 and 1:5. In some embodiments, a mass ratio between a vector encoding a heavy chain and a vector encoding a light chain is used between 1:1 and 1:5. In some embodiments, a mass ratio between a vector encoding a heavy chain and a vector encoding a light chain is used between 1:2.
[0229] In some embodiments, an optimized vector is selected to express the peptide in CHO or CHO-derived cells or in NSO cells. Illustrative examples of such vectors are described, for example, in Running Deer et al., Biotechnol. Prog. 20:880-889 (2004). Host cells
[0230] In some embodiments, a host cell is provided that comprises any of the polypeptides, nucleic acid constructs, and / or vectors described herein. In some embodiments, a host cell prepared using any of the methods described herein is provided. In some embodiments, the host cell is capable of producing any of the antibody portions described herein under fermentation conditions.
[0231] In some embodiments, the antibody moiety described herein (e.g., the anti-VISTA antibody moiety) may be expressed in prokaryotic cells, such as bacterial cells; or eukaryotic cells, such as fungal cells (e.g., yeast), plant cells, insect cells, and mammalian cells. Such expression may be performed, for example, according to procedures known in the art. Exemplary eukaryotic cells that may be used to express the peptide include, but are not limited to, COS cells, including COS 7 cells; 293 cells, including 293-6E cells; CHO cells, including CHO-S, CHO-GS, DG44, Lec13 CHO cells, and FUT8 CHO cells; PER.C6® cells (Crucell); HEK cells and NSO cells. In some embodiments, the antibody moiety described herein (e.g., the anti-VISTA antibody moiety) may be expressed in yeast. See, for example, U.S. Publication No. 2006 / 0270045 A1. In some embodiments, a particular eukaryotic host cell is selected based on its ability to perform the desired post-translational modifications to the heavy and / or light chains of the antibody moiety. For example, in some embodiments, CHO cells produce peptides that are more sialylated than the same peptides produced by 293 cells.
[0232] The introduction of one or more nucleic acids into the desired host cells can be achieved by any method, including but not limited to calcium phosphate transfection, DEAE-polydextrose-mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, etc. Non-limiting illustrative methods are described, for example, in Sambrook et al., Molecular Cloning, A Laboratory Manual, 3rd edition, Cold Spring Harbor Laboratory Press (2001). Nucleic acids can be transiently or stably transfected into the desired host cells by any suitable method.
[0233] This application also provides a host cell comprising any of the polynucleotides or vectors described herein. In some embodiments, the present invention provides a host cell comprising an anti-VISTA antibody. Any host cell capable of overexpressing heterologous DNA may be used to isolate genes encoding antibodies, peptides, or proteins of interest. Non-limiting examples of mammalian host cells include, but are not limited to, COS, HeLa, and CHO cells. See also PCT Publication WO 87 / 04462. Suitable non-mammalian host cells include prokaryotes (such as E. coli or B. subtillis) and yeasts (such as Saccharomyces cerevisiae, Saccharomyces pombe, or Kluyveromyces lactis).
[0234] In some embodiments, the antibody is partially generated in a cell-free system. Non-limiting illustrative cell-free systems are described, for example, in Sitaraman et al., Methods Mol. Biol. 498: 229-44 (2009); Spirin, Trends Biotechnol. 22: 538-45 (2004); Endo et al., Biotechnol. Adv. 21: 695-713 (2003). Culture medium
[0235] In some embodiments, a culture medium is provided that comprises any antibody moiety, polynucleotide, nucleic acid construct, vector, and / or host cell described herein. In some embodiments, a culture medium prepared using any of the methods described herein is provided.
[0236] In some embodiments, the culture medium contains hypoxanthine, aminopterin, and / or thymidine (e.g., HAT medium). In some embodiments, the culture medium does not contain serum. In some embodiments, the culture medium contains serum. In some embodiments, the culture medium is D-MEM or RPMI-1640 medium.
[0237] In some embodiments, the culture medium is chemically defined. In some embodiments, the culture medium is specifically obtained for a particular cell line (e.g., CHO GS cells). Purification of the antibody portion
[0238] Anti-VISTA constructs can be purified by any suitable method. Such methods include, but are not limited to, the use of affinity matrices or hydrophobic interaction chromatography. Suitable affinity ligands include ROR1 ECD and ligands that bind the constant region of the antibody. For example, protein A, protein G, protein A / G, or antibody affinity columns can be used to bind the constant region and purify anti-VISTA constructs containing the Fc fragment. Hydrophobic interaction chromatography (e.g., butyl or phenyl columns) is also suitable for purifying some peptides, such as antibodies. Ion exchange chromatography (e.g., anion exchange chromatography and / or cation exchange chromatography) is also suitable for purifying some peptides, such as antibodies. Mixed-mode chromatography (e.g., reverse-phase / anion exchange, reverse-phase / cation exchange, hydrophilic interaction / anion exchange, hydrophilic interaction / cation exchange, etc.) is also suitable for purifying some peptides, such as antibodies. Many methods for purifying peptides are known in this technique. V. Treatment Methods
[0239] This document also provides methods for treating an individual's disease or condition or modulating an immune response (e.g., inhibiting T cell proliferation), or modulating an individual's immune response (e.g., inhibiting T cell proliferation). These methods involve administering the anti-construct described herein to an individual (e.g., a mammal, such as a human).
[0240] In some embodiments, a method of treating an individual's disease or condition or modulating an immune response (e.g., inhibiting T cell proliferation) is provided, comprising administering to the individual an effective amount of the anti-VISTA construct described herein. In some embodiments, the disease or condition is associated with an immune system dysregulation. In some embodiments, the disease or condition is an autoimmune disease, inflammation, infection, graft-versus-host disease (GvHD), or a transplant-related condition. In some embodiments, the autoimmune disease is selected from cutaneous lupus, rheumatoid arthritis, psoriasis, autoimmune intestinal disease, systemic lupus erythematosus (SLE), and discoid lupus erythematosus (DLE).
[0241] In some embodiments, a method of treating an individual's disease or condition or modulating an immune response (e.g., inhibiting T cell proliferation) is provided, comprising administering to the individual an effective amount of an anti-VISTA construct comprising an antibody portion comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the antibody portion competes with an antibody or antibody fragment comprising a second heavy chain variable region (VH-2) and a second light chain variable region (VL-2) for VISTA binding antigen determinants, wherein VH-2 comprises: HC-CDR1 comprising the amino acid sequence SEQ ID NO: 1, HC-CDR2 comprising the amino acid sequence SEQ ID NO: 2, and HC-CDR3 comprising the amino acid sequence SEQ ID NO: 3, and VL-2 comprises: LC-CDR1 comprising the amino acid sequence SEQ ID NO: 4, LC-CDR2 comprising the amino acid sequence SEQ ID NO: 5, and LC-CDR3 comprising the amino acid sequence SEQ ID NO: 6. In some embodiments, VH comprises: i) HC-CDR1 containing the amino acid sequence SEQ ID NO: 1, ii) HC-CDR2 containing the amino acid sequence SEQ ID NO: 2, and iii) HC-CDR3 containing the amino acid sequence SEQ ID NO: 3, or variants thereof containing up to 5, 4, 3, 2, or 1 amino acid substitution in the HC-CDRs; and VL comprises: i) LC-CDR1 containing the amino acid sequence SEQ ID NO: 4, ii) LC-CDR2 containing the amino acid sequence SEQ ID NO: 5, and iii) LC-CDR3 containing the amino acid sequence SEQ ID NO: 6, or variants thereof containing up to 5, 4, 3, 2, or 1 amino acid substitution in the LC-CDRs. In some embodiments, the anti-VISTA antibody portion is a humanized antibody derived from an anti-VISTA antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises: i) HC-CDR1 comprising the amino acid sequence SEQ ID NO: 1, ii) HC-CDR2 comprising the amino acid sequence SEQ ID NO: 2 and iii) HC-CDR3 comprising the amino acid sequence SEQ ID NO: 3, and the VL comprises: i) LC-CDR1 comprising the amino acid sequence SEQ ID NO: 4, ii) LC-CDR2 comprising the amino acid sequence SEQ ID NO: 5 and iii) LC-CDR3 comprising the amino acid sequence SEQ ID NO: 6.In some embodiments, VH comprises the amino acid sequence SEQ ID NO: 7, or a variant of an amino acid sequence having at least about 80% sequence identity (such as at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%); and VL comprises the amino acid sequence SEQ ID NO: 8, or a variant of an amino acid sequence having at least about 80% sequence identity (such as at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%). In some embodiments, the disease or condition is associated with an immune system disorder. In some embodiments, the disease or condition is an autoimmune disease, inflammation, infection, graft-versus-host disease (GvHD), or a transplant-related condition. In some embodiments, the autoimmune disease is selected from cutaneous lupus, rheumatoid arthritis, psoriasis, autoimmune intestinal disease, systemic lupus erythematosus (SLE), and discoid lupus erythematosus (DLE).
[0242] In some embodiments, a method for treating an individual's disease or condition or modulating an immune response (e.g., inhibiting T cell proliferation) is provided, comprising administering to the individual an effective amount of an anti-VISTA construct comprising an antibody portion comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the antibody portion competes with an antibody or antibody fragment comprising a second heavy chain variable region (VH-2) and a second light chain variable region (VL-2) for the binding antigenic determinant of VISTA, wherein VH-2 comprises: HC-CDR1 comprising the amino acid sequence SEQ ID NO: 9, HC-CDR2 comprising the amino acid sequence SEQ ID NO: 10, and HC-CDR3 comprising the amino acid sequence SEQ ID NO: 11, and VL-2 comprises: LC-CDR1 comprising the amino acid sequence SEQ ID NO: 12, LC-CDR2 comprising the amino acid sequence SEQ ID NO: 13, and LC-CDR3 comprising the amino acid sequence SEQ ID NO: 14. LC-CDR3 of 14. In some embodiments, VH comprises: i) HC-CDR1 containing the amino acid sequence SEQ ID NO: 9, ii) HC-CDR2 containing the amino acid sequence SEQ ID NO: 10, and iii) HC-CDR3 containing the amino acid sequence SEQ ID NO: 11, or variants thereof containing up to 5, 4, 3, 2, or 1 amino acid substitution in the HC-CDRs; and VL comprises: i) LC-CDR1 containing the amino acid sequence SEQ ID NO: 12, ii) LC-CDR2 containing the amino acid sequence SEQ ID NO: 13, and iii) LC-CDR3 containing the amino acid sequence SEQ ID NO: 14, or variants thereof containing up to 5, 4, 3, 2, or 1 amino acid substitution in the LC-CDRs. In some embodiments, the anti-VISTA antibody portion is a humanized antibody derived from an anti-VISTA antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises: i) HC-CDR1 comprising the amino acid sequence SEQ ID NO: 9, ii) HC-CDR2 comprising the amino acid sequence SEQ ID NO: 10, and iii) HC-CDR3 comprising the amino acid sequence SEQ ID NO: 11, and the VL comprises: i) LC-CDR1 comprising the amino acid sequence SEQ ID NO: 12, ii) LC-CDR2 comprising the amino acid sequence SEQ ID NO: 13, and iii) LC-CDR3 comprising the amino acid sequence SEQ ID NO: 14.In some embodiments, VH comprises the amino acid sequence SEQ ID NO: 15, or a variant of an amino acid sequence having at least about 80% sequence identity (such as at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%); and VL comprises the amino acid sequence SEQ ID NO: 16, or a variant of an amino acid sequence having at least about 80% sequence identity (such as at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%). In some embodiments, the disease or condition is associated with an immune system disorder. In some embodiments, the disease or condition is an autoimmune disease, inflammation, infection, graft-versus-host disease (GvHD), or a transplant-related condition. In some embodiments, the autoimmune disease is selected from cutaneous lupus, rheumatoid arthritis, psoriasis, autoimmune intestinal disease, systemic lupus erythematosus (SLE), and discoid lupus erythematosus (DLE).
[0243] In some embodiments, a method for treating an individual's disease or condition or modulating an immune response (e.g., inhibiting T cell proliferation) is provided, comprising administering to the individual an effective amount of an anti-VISTA construct comprising an antibody portion comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the antibody portion competes with an antibody or antibody fragment comprising a second heavy chain variable region (VH-2) and a second light chain variable region (VL-2) for the binding antigenic determinant of VISTA, wherein VH-2 comprises: HC-CDR1 comprising the amino acid sequence SEQ ID NO: 17, HC-CDR2 comprising the amino acid sequence SEQ ID NO: 18, and HC-CDR3 comprising the amino acid sequence SEQ ID NO: 19, and VL-2 comprises: LC-CDR1 comprising the amino acid sequence SEQ ID NO: 20, LC-CDR2 comprising the amino acid sequence SEQ ID NO: 21, and LC-CDR3 comprising the amino acid sequence SEQ ID NO: 20, and LC-CDR2 comprising the amino acid sequence SEQ ID NO: 21, and LC-CDR2 comprising the amino acid sequence SEQ ID NO: 20 ... LC-CDR3 of 22. In some embodiments, VH comprises: i) HC-CDR1 containing the amino acid sequence SEQ ID NO: 17, ii) HC-CDR2 containing the amino acid sequence SEQ ID NO: 18, and iii) HC-CDR3 containing the amino acid sequence SEQ ID NO: 19, or variants thereof containing up to 5, 4, 3, 2, or 1 amino acid substitutions in such HC-CDRs; and VL comprises: i) LC-CDR1 containing the amino acid sequence SEQ ID NO: 20, ii) LC-CDR2 containing the amino acid sequence SEQ ID NO: 21, and iii) LC-CDR3 containing the amino acid sequence SEQ ID NO: 22, or variants thereof containing up to 5, 4, 3, 2, or 1 amino acid substitutions in such LC-CDRs. In some embodiments, the anti-VISTA antibody portion is a humanized antibody derived from an anti-VISTA antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises: i) HC-CDR1 comprising the amino acid sequence SEQ ID NO: 17, ii) HC-CDR2 comprising the amino acid sequence SEQ ID NO: 18, and iii) HC-CDR3 comprising the amino acid sequence SEQ ID NO: 19, and the VL comprises: i) LC-CDR1 comprising the amino acid sequence SEQ ID NO: 20, ii) LC-CDR2 comprising the amino acid sequence SEQ ID NO: 21, and iii) LC-CDR3 comprising the amino acid sequence SEQ ID NO: 22.In some embodiments, VH comprises the amino acid sequence SEQ ID NO: 23, or a variant of an amino acid sequence having at least about 80% sequence identity (such as at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%); and VL comprises the amino acid sequence SEQ ID NO: 24, or a variant of an amino acid sequence having at least about 80% sequence identity (such as at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%). In some embodiments, the disease or condition is associated with an immune system disorder. In some embodiments, the disease or condition is an autoimmune disease, inflammation, infection, graft-versus-host disease (GvHD), or a transplant-related condition. In some embodiments, the autoimmune disease is selected from cutaneous lupus, rheumatoid arthritis, psoriasis, autoimmune intestinal disease, systemic lupus erythematosus (SLE), and discoid lupus erythematosus (DLE).
[0244] In some embodiments, a method for treating an individual's disease or condition or modulating an immune response (e.g., inhibiting T cell proliferation) is provided, comprising administering to the individual an effective amount of an anti-VISTA construct comprising an antibody portion comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the antibody portion competes with an antibody or antibody fragment comprising a second heavy chain variable region (VH-2) and a second light chain variable region (VL-2) for VISTA binding antigen determinants, wherein VH-2 comprises: HC-CDR1 comprising the amino acid sequence SEQ ID NO: 25, HC-CDR2 comprising the amino acid sequence SEQ ID NO: 26, and HC-CDR3 comprising the amino acid sequence SEQ ID NO: 27, and VL-2 comprises: LC-CDR1 comprising the amino acid sequence SEQ ID NO: 28, LC-CDR2 comprising the amino acid sequence SEQ ID NO: 29, and LC-CDR3 comprising the amino acid sequence SEQ ID NO: 29, and LC-CDR2 ... LC-CDR3 of 30. In some embodiments, VH comprises: i) HC-CDR1 containing the amino acid sequence SEQ ID NO: 25, ii) HC-CDR2 containing the amino acid sequence SEQ ID NO: 26, and iii) HC-CDR3 containing the amino acid sequence SEQ ID NO: 27, or variants thereof containing up to 5, 4, 3, 2, or 1 amino acid substitutions in the HC-CDRs; and VL comprises: i) LC-CDR1 containing the amino acid sequence SEQ ID NO: 28, ii) LC-CDR2 containing the amino acid sequence SEQ ID NO: 29, and iii) LC-CDR3 containing the amino acid sequence SEQ ID NO: 30, or variants thereof containing up to 5, 4, 3, 2, or 1 amino acid substitutions in the LC-CDRs. In some embodiments, the anti-VISTA antibody portion is a humanized antibody derived from an anti-VISTA antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises: i) HC-CDR1 comprising the amino acid sequence SEQ ID NO: 25, ii) HC-CDR2 comprising the amino acid sequence SEQ ID NO: 26, and iii) HC-CDR3 comprising the amino acid sequence SEQ ID NO: 27, and the VL comprises: i) LC-CDR1 comprising the amino acid sequence SEQ ID NO: 28, ii) LC-CDR2 comprising the amino acid sequence SEQ ID NO: 29, and iii) LC-CDR3 comprising the amino acid sequence SEQ ID NO: 30.In some embodiments, VH comprises the amino acid sequence SEQ ID NO: 31, or a variant of an amino acid sequence having at least about 80% sequence identity (such as at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%); and VL comprises the amino acid sequence SEQ ID NO: 32, or a variant of an amino acid sequence having at least about 80% sequence identity (such as at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%). In some embodiments, the disease or condition is associated with an immune system disorder. In some embodiments, the disease or condition is an autoimmune disease, inflammation, infection, graft-versus-host disease (GvHD), or a transplant-related condition. In some embodiments, the autoimmune disease is selected from cutaneous lupus, rheumatoid arthritis, psoriasis, autoimmune intestinal disease, systemic lupus erythematosus (SLE), and discoid lupus erythematosus (DLE).
[0245] In some embodiments, a method of treating an individual's disease or condition or modulating an immune response (e.g., inhibiting T cell proliferation) is provided, comprising administering to the individual an effective amount of an anti-VISTA construct comprising an antibody portion comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the antibody portion competes with an antibody or antibody fragment comprising a second heavy chain variable region (VH-2) and a second light chain variable region (VL-2) for VISTA binding antigen determinants, wherein VH-2 comprises: HC-CDR1 comprising the amino acid sequence SEQ ID NO: 33, HC-CDR2 comprising the amino acid sequence SEQ ID NO: 34, and HC-CDR3 comprising the amino acid sequence SEQ ID NO: 35, and VL-2 comprises: LC-CDR1 comprising the amino acid sequence SEQ ID NO: 36, LC-CDR2 comprising the amino acid sequence SEQ ID NO: 37, and LC-CDR2 comprising the amino acid sequence SEQ ID NO: 36, and ... LC-CDR3 of SEQ ID NO: 38. In some embodiments, VH comprises: i) HC-CDR1 containing the amino acid sequence SEQ ID NO: 33, ii) HC-CDR2 containing the amino acid sequence SEQ ID NO: 34, and iii) HC-CDR3 containing the amino acid sequence SEQ ID NO: 35, or variants thereof containing up to 5, 4, 3, 2, or 1 amino acid substitutions in the HC-CDRs; and VL comprises: i) LC-CDR1 containing the amino acid sequence SEQ ID NO: 36, ii) LC-CDR2 containing the amino acid sequence SEQ ID NO: 37, and iii) LC-CDR3 containing the amino acid sequence SEQ ID NO: 38, or variants thereof containing up to 5, 4, 3, 2, or 1 amino acid substitutions in the LC-CDRs. In some embodiments, the anti-VISTA antibody portion is a humanized antibody derived from an anti-VISTA antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises: i) HC-CDR1 comprising the amino acid sequence SEQ ID NO: 33, ii) HC-CDR2 comprising the amino acid sequence SEQ ID NO: 34, and iii) HC-CDR3 comprising the amino acid sequence SEQ ID NO: 35, and the VL comprises: i) LC-CDR1 comprising the amino acid sequence SEQ ID NO: 36, ii) LC-CDR2 comprising the amino acid sequence SEQ ID NO: 37, and iii) LC-CDR3 comprising the amino acid sequence SEQ ID NO: 38.In some embodiments, VH comprises the amino acid sequence SEQ ID NO: 39, or a variant of an amino acid sequence having at least about 80% sequence identity (such as at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%); and VL comprises the amino acid sequence SEQ ID NO: 40, or a variant of an amino acid sequence having at least about 80% sequence identity (such as at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%). In some embodiments, the disease or condition is associated with an immune system disorder. In some embodiments, the disease or condition is an autoimmune disease, inflammation, infection, graft-versus-host disease (GvHD), or a transplant-related condition. In some embodiments, the autoimmune disease is selected from cutaneous lupus, rheumatoid arthritis, psoriasis, autoimmune intestinal disease, systemic lupus erythematosus (SLE), and discoid lupus erythematosus (DLE).
[0246] In some embodiments, the amino acid substitutions described above are limited to the "exemplary substitutions" shown in Table 2 of this application. In some embodiments, such amino acid substitutions are limited to the "preferred substitutions" shown in Table 2 of this application.
[0247] In some embodiments, a method of treating an individual's disease or condition or modulating an immune response (e.g., inhibiting T cell proliferation) is provided, comprising administering to the individual an effective amount of an anti-VISTA construct, the anti-VISTA construct comprising an antibody portion comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises: i) HC-CDR1 comprising the amino acid sequence SEQ ID NO: 41, ii) HC-CDR2 comprising the amino acid sequence SEQ ID NO: 42 or 51, and iii) HC-CDR3 comprising the amino acid sequence SEQ ID NO: 11, and the VL comprises: i) LC-CDR1 comprising the amino acid sequence SEQ ID NO: 46, ii) LC-CDR2 comprising the amino acid sequence SEQ ID NO: 13, and iii) LC-CDR3 comprising the amino acid sequence SEQ ID NO: 47.
[0248] In some embodiments, a method of treating an individual's disease or condition or modulating an immune response (e.g., inhibiting T cell proliferation) is provided, comprising administering to the individual an effective amount of an anti-VISTA construct, the anti-VISTA construct comprising an antibody portion comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises: i) HC-CDR1 comprising the amino acid sequence SEQ ID NO: 43, ii) HC-CDR2 comprising the amino acid sequence SEQ ID NO: 44 or 52, and iii) HC-CDR3 comprising the amino acid sequence SEQ ID NO: 45, and the VL comprises: i) LC-CDR1 comprising the amino acid sequence SEQ ID NO: 54, ii) LC-CDR2 comprising the amino acid sequence SEQ ID NO: 55, and iii) LC-CDR3 comprising the amino acid sequence SEQ ID NO: 56 or 57. In some embodiments, the disease or condition is associated with an immune system dysregulation. In some embodiments, the disease or condition is an autoimmune disease, inflammation, infection, graft-versus-host disease (GvHD), or a transplant-related condition. In some embodiments, the autoimmune disease is selected from cutaneous lupus, rheumatoid arthritis, psoriasis, autoimmune intestinal disease, systemic lupus erythematosus (SLE), and discoid lupus erythematosus (DLE).
[0249] In some embodiments, a method of treating an individual's disease or condition or modulating an immune response (e.g., inhibiting T cell proliferation) is provided, comprising administering to the individual an effective amount of an anti-VISTA construct, the anti-VISTA construct comprising an antibody portion comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises: i) HC-CDR1 comprising the amino acid sequence SEQ ID NO: 41 or 43, ii) HC-CDR2 comprising any of the amino acid sequences SEQ ID NO: 58, and iii) HC-CDR3 comprising the amino acid sequence SEQ ID NO: 11 or 45, and the VL comprises: i) LC-CDR1 comprising the amino acid sequence SEQ ID NO: 48, ii) LC-CDR2 comprising the amino acid sequence SEQ ID NO: 49, and iii) LC-CDR3 comprising the amino acid sequence SEQ ID NO: 50 or 53. In some embodiments, the disease or condition is associated with an immune system dysregulation. In some embodiments, the disease or condition is an autoimmune disease, inflammation, infection, graft-versus-host disease (GvHD), or a transplant-related condition. In some embodiments, the autoimmune disease is selected from cutaneous lupus, rheumatoid arthritis, psoriasis, autoimmune intestinal disease, systemic lupus erythematosus (SLE), and discoid lupus erythematosus (DLE).
[0250] In some embodiments, the anti-VISTA construct used to modulate an individual's immune response or regulate immune cells (e.g., T cells) inhibits T cell proliferation by at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%, compared to a corresponding construct containing a reference activating anti-VISTA antibody (e.g., 1E8). In some embodiments, the anti-VISTA construct used to modulate an individual's immune response or regulate immune cells (e.g., T cells) inhibits T cell proliferation by at least about 5%, 10%, 15%, 20%, or 25%, compared to a corresponding construct containing a reference activating anti-VISTA antibody (e.g., 1E8).
[0251] In some embodiments, a method of modulating cells (e.g., immune cells) is provided, comprising contacting the immune cells with an anti-VISTA construct (such as any of the anti-VISTA constructs described herein). In some embodiments, the cells are T cells (such as CD4 and / or CD8 T cells). In some embodiments, the cells are neutrophils. In some embodiments, the cells are dendritic cells (e.g., plasmacytoid dendritic cells). In some embodiments, the cells are macrophages. In some embodiments, the contact occurs in vitro.
[0252] In some embodiments, a method for genetically editing cells (e.g., immune cells) is provided, comprising introducing the cells: a) a donor template comprising a nucleic acid sequence encoding any of the anti-VISTA constructs described herein, and b) a DNA nuclease (e.g., a CRISPR-associated protein (Cas)) or a nucleotide sequence encoding a DNA nuclease. In some embodiments, the method further comprises administering genetically edited cells to an individual suffering from the disease or condition described herein.
[0253] In some embodiments, the individual is a mammal (such as a human).
[0254] In some embodiments, the individual's antinuclear antibody serum level is elevated (e.g., at least about 20%, 40%, 60%, 80%, 100%, 150%, 200%, 300%, 400%, or 500% higher than that of a healthy individual). In some embodiments, the individual's anti-dsDNA antibody serum level is elevated (e.g., at least about 20%, 40%, 60%, 80%, 100%, 150%, 200%, 300%, 400%, or 500% higher than that of a healthy individual). In some embodiments, the individual's IFNα serum level is elevated (e.g., at least about 20%, 40%, 60%, 80%, 100%, 150%, 200%, 300%, 400%, or 500% higher than that of a healthy individual). In some embodiments, the individual's urinary protein levels are elevated (e.g., at least about 20%, 40%, 60%, 80%, 100%, 150%, 200%, 300%, 400%, or 500% higher than those of a healthy individual). Dosage and method of administering the anti-VISTA construct.
[0255] The dosing regimen (such as specific dosage and frequency) of an anti-VISTA construct administered to an individual for the treatment of a disease or condition as described herein may vary depending on the specific anti-VISTA construct, the mode of administration, and the type of disease or condition being treated. In some embodiments, an effective amount of the anti-VISTA construct is an amount that effectively reduces at least one symptom of the disease or condition. In some embodiments, an effective amount of the anti-VISTA construct is an amount sufficient to prolong the overall survival of an individual. In some embodiments, an effective amount of the anti-VISTA construct is an amount sufficient to produce a clinical benefit greater than about 50%, 60%, 70%, 80%, or 90% in a population of individuals treated with the anti-VISTA construct.
[0256] In some embodiments, the effective amount of the anti-VISTA construct is an amount that slows or inhibits the progression of a disease or condition compared to an untreated individual (e.g., at least about 5%, 10%, 15%, 20%, 30%, 40%, 50%). In some embodiments, the disease or condition is an autoimmune disease. In some embodiments, the disease or condition is an infection.
[0257] In some embodiments, an effective amount of the anti-VISTA construct reduces the serum level of antinuclear antibodies by at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, or 70% compared to a reference individual (e.g., an individual with the same disease or condition but not treated with the anti-VISTA construct). In some embodiments, an effective amount of the anti-VISTA construct reduces the serum level of anti-dsDNA antibodies by at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, or 70% compared to a reference individual (e.g., an individual with the same disease or condition but not treated with the anti-VISTA construct). In some embodiments, an effective amount of the anti-VISTA construct reduces serum IFNα levels by at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, or 70% compared to a reference individual (e.g., an individual with the same disease or condition but not treated with the anti-VISTA construct). In some embodiments, an effective amount of the anti-VISTA construct reduces urinary protein levels by at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 70%, 80%, or 90% compared to a reference individual (e.g., an individual with the same disease or condition but not treated with the anti-VISTA construct).
[0258] In some embodiments, the effective amount of the anti-VISTA construct is an amount that reduces the side effects (autoimmune response) of the condition (e.g., transplantation) compared to an untreated individual (e.g., at least about 5%, 10%, 15%, 20%, 30%, 40%, or 50%).
[0259] In some embodiments of any of the above-mentioned samples, the effective amount of the anti-VISTA construct is in the range of about 0.001 μg / kg to about 100 mg / kg by total weight, for example, about 0.005 μg / kg to about 50 mg / kg, about 0.01 μg / kg to about 10 mg / kg or about 0.01 μg / kg to about 1 mg / kg.
[0260] In some embodiments of any of the above-mentioned embodiments, the effective amount of the anti-VISTA construct for human use is equivalent to a dose of 0.5 mg for mice.
[0261] In some embodiments of any of the above-described embodiments, the anti-VISTA structure is applied weekly. In some embodiments of any of the above-described embodiments, the anti-VISTA structure is applied every two weeks. In some embodiments, the anti-VISTA structure is applied weekly for at least about 2, about 4, about 6, about 8, about 10, about 12, about 14, about 16, about 18, or about 20 weeks.
[0262] The anti-VISTA construct can be administered to an individual (such as a human) via various routes, including, for example, intravenous, intraarterial, intraperitoneal, intrapulmonary, oral, inhalation, intravesical, intramuscular, intratracheal, subcutaneous, intraocular, intrathecal, transmucosal, and transdermal. In some embodiments, the anti-VISTA construct is included in a pharmaceutical composition when administered to an individual. In some embodiments, a continuously releasing formulation of the composition may be used. In some embodiments, the composition is administered intravenously. In some embodiments, the composition is administered intraperitoneally. In some embodiments, the composition is administered intravenously. In some embodiments, the composition is administered intraperitoneally. In some embodiments, the composition is administered intramuscularly. In some embodiments, the composition is administered subcutaneously. In some embodiments, the composition is administered intravenously. In some embodiments, the composition is administered orally. Combination therapy
[0263] This application also provides a method of administering an anti-VISTA construct to an individual to treat a disease or condition, wherein the method further includes administering a second agent or therapy. In some embodiments, the second agent or therapy is a standard or commonly used agent or therapy for treating a disease or condition.
[0264] In some embodiments, the anti-VISTA construct is administered simultaneously with a second agent or therapy. In some embodiments, the anti-VISTA construct is administered in parallel with a second agent or therapy. In some embodiments, the anti-VISTA construct is administered sequentially with a second agent or therapy. In some embodiments, the anti-VISTA construct is administered before a second agent or therapy. In some embodiments, the anti-VISTA construct is administered after a second agent or therapy. In some embodiments, the anti-VISTA construct and the second agent or therapy are administered in the same unit dosage form. In some embodiments, the anti-VISTA construct and the second agent or therapy are administered in different unit dosage forms. In some embodiments, the anti-VISTA construct and the second agent or therapy are administered in the same unit dosage form. In some embodiments, the anti-VISTA construct and the second agent or therapy are administered in different unit dosage forms. VI. Compositions, Kits, and Articles
[0265] This document also provides compositions (such as formulations) comprising: any of the anti-VISTA constructs or anti-VISTA antibody portions described herein, nucleic acid encoding the antibody portion, a vector comprising nucleic acid encoding the antibody portion, or a host cell comprising nucleic acid or a vector.
[0266] Suitable formulations of the anti-VISTA constructs described herein can be obtained by mixing an anti-VISTA construct or anti-VISTA antibody fraction of the desired purity with, where applicable, a pharmaceutically acceptable carrier, excipient or stabilizer (Remington's Pharmaceutical Sciences, 16th edition, Osol, A. ed. (1980)) into a lyophilized formulation or an aqueous solution. Acceptable carriers, excipients, or stabilizers are non-toxic to the recipient at the doses and concentrations used and include buffers such as phosphates, citrates, and other organic acids; antioxidants, including ascorbic acid and methionine; preservatives (such as octadecyl dimethylbenzyl ammonium chloride; hexahydroxyquaternary ammonium chloride; benzyl ammonium chloride, benzoyl ammonium chloride; phenol, butanol, or benzyl alcohol; alkyl esters of p-hydroxybenzoate, such as methylparaben or propylparaben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) peptides; proteins, Examples of suitable surfactants include serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamic acid, aspartic acid, histamine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates, including glucose, mannose, or dextrin; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose, or sorbitol; salt-forming ions such as sodium; metal complexes (e.g., Zn-protein complexes); and / or nonionic surfactants such as TWEEN™, PLURONICS™, or polyethylene glycol (PEG). Lyophilized formulations suitable for subcutaneous administration are described in WO97 / 04801. Such lyophilized formulations can be reconstituted to high protein concentrations with a suitable diluent, and the reconstituted formulations can be subcutaneously administered to individuals described herein for imaging, diagnosis, or treatment.
[0267] The preparation to be administered in vivo must be sterile. This can be easily achieved, for example, by filtration through a sterile filter membrane.
[0268] Kits containing either the anti-VISTA construct or the anti-VISTA antibody portion described herein are also provided. The kits may be used for any of the methods or treatments for modulating the cell compositions described herein.
[0269] In some embodiments, a kit is provided that includes an anti-VISTA structure specifically bonded to VISTA.
[0270] In some embodiments, the kit further includes a device capable of delivering the anti-VISTA construct into an individual. For applications such as non-enteral delivery, one type of device is a syringe for injecting the composition into the individual. Inhalation devices may also be used in certain applications.
[0271] In some embodiments, the kit further includes a therapeutic agent for treating diseases or conditions, such as infectious diseases, autoimmune diseases, or transplants.
[0272] The kit of this application is in suitable packaging. Suitable packaging includes, but is not limited to, vials, bottles, cans, flexible packaging (e.g., sealed Mylar or plastic bags) and the like. The kit may include other components such as cushioning agents and explanatory information, as appropriate.
[0273] Therefore, this application also provides an article of manufacture. The article of manufacture may include a container and a label or instruction leaflet on or attached to the container. Suitable containers include vials (such as sealed vials), bottles, jars, flexible packaging, and the like. Generally, the container contains the composition and may have a sterile dispensing port (e.g., the container may be an intravenous solution bag or a vial with a stopper that can be pierced by a hypodermic needle). The label or instruction leaflet indicates that the composition is intended for use on an individual to perform imaging, diagnosis, or treatment of a specific condition. The label or instruction leaflet will further include instructions on administering the composition to the individual and performing imaging on the individual. The label may indicate instructions on reconstitution and / or use. The container holding the composition may be a reusable vial that allows for repeated dispensing (e.g., 2 to 6 dispensings) of the reconstituted formulation. Instructions for manufacture refer to the information commonly included in the packaging of commercially available diagnostic products, containing information on indications, use, dosage, administration, contraindications, and / or warnings related to the use of such diagnostic products. Additionally, the product may further include a second container containing a pharmaceutically acceptable buffer solution, such as bactericidal water for injection (BWFI), phosphate-buffered saline, Ringer's solution, and dextran solution. It may further include other substances required from a commercial and user perspective, including other buffers, diluents, filters, needles, and syringes.
[0274] A kit or product may include a composition of multiple unit doses and instructions for use, packaged in a quantity sufficient for storage and use in a pharmacy (e.g., a hospital pharmacy and dispensing facility).
[0275] Those skilled in the art will recognize that various embodiments are possible within the scope and spirit of this invention. The invention will now be described in more detail with reference to the following non-limiting examples. The following examples further illustrate the invention, but should not be construed as limiting its scope in any way. Exemplary Embodiments
[0276] Example 1. An anti-VISTA construct comprising an antibody portion comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the antibody portion competes with an antibody or antibody fragment comprising a second heavy chain variable region (VH-2) and a second light chain variable region (VL-2) for the binding antigenic determinant of VISTA, wherein: a) the VH-2 comprises: HC-CDR1 comprising amino acid sequence SEQ ID NO: 1, HC-CDR2 comprising amino acid sequence SEQ ID NO: 2, and HC-CDR3 comprising amino acid sequence SEQ ID NO: 3, and the VL-2 comprises: LC-CDR1 comprising amino acid sequence SEQ ID NO: 4, LC-CDR2 comprising amino acid sequence SEQ ID NO: 5, and LC-CDR3 comprising amino acid sequence SEQ ID NO: 6; b) the VH-2 comprises: comprising amino acid sequence SEQ ID NO: c) The VH-2 comprises: HC-CDR1 containing the amino acid sequence SEQ ID NO: 10, HC-CDR2 containing the amino acid sequence SEQ ID NO: 10, and HC-CDR3 containing the amino acid sequence SEQ ID NO: 11, and the VL-2 comprises: LC-CDR1 containing the amino acid sequence SEQ ID NO: 12, LC-CDR2 containing the amino acid sequence SEQ ID NO: 13, and LC-CDR3 containing the amino acid sequence SEQ ID NO: 14; d) The VH-2 comprises: HC-CDR1 containing the amino acid sequence SEQ ID NO: 25, HC-CDR2 containing the amino acid sequence SEQ ID NO: 26, and HC-CDR3 containing the amino acid sequence SEQ ID NO: 27, and the VL-2 comprises: LC-CDR1 containing the amino acid sequence SEQ ID NO: 28, LC-CDR2 containing the amino acid sequence SEQ ID NO: 29, and LC-CDR3 containing the amino acid sequence SEQ ID NO: 30;Or e) The VH-2 comprises: HC-CDR1 containing the amino acid sequence SEQ ID NO: 33, HC-CDR2 containing the amino acid sequence SEQ ID NO: 34, and HC-CDR3 containing the amino acid sequence SEQ ID NO: 35, and the VL-2 comprises: LC-CDR1 containing the amino acid sequence SEQ ID NO: 36, LC-CDR2 containing the amino acid sequence SEQ ID NO: 37, and LC-CDR3 containing the amino acid sequence SEQ ID NO: 38.
[0277] Example 2. The anti-VISTA construct as in Example 1, wherein: a) the VH comprises: i) HC-CDR1 containing amino acid sequence SEQ ID NO: 1, ii) HC-CDR2 containing amino acid sequence SEQ ID NO: 2 and iii) HC-CDR3 containing amino acid sequence SEQ ID NO: 3, or variants thereof containing 5, 4, 3, 2 or 1 amino acid substitution in the HC-CDRs; and the VL comprises: i) LC-CDR1 containing amino acid sequence SEQ ID NO: 4, ii) LC-CDR2 containing amino acid sequence SEQ ID NO: 5 and iii) LC-CDR3 containing amino acid sequence SEQ ID NO: 6, or variants thereof containing 5, 4, 3, 2 or 1 amino acid substitution in the LC-CDRs; b) the VH comprises: i) HC-CDR1 containing amino acid sequence SEQ ID NO: 9, ii) HC-CDR2 ... 10) HC-CDR2 and iii) HC-CDR3 containing the amino acid sequence SEQ ID NO: 11, or variants thereof containing 5, 4, 3, 2 or 1 amino acid substitutions in such HC-CDRs; and the VL comprises: i) LC-CDR1 containing the amino acid sequence SEQ ID NO: 12, ii) LC-CDR2 containing the amino acid sequence SEQ ID NO: 13 and iii) LC-CDR3 containing the amino acid sequence SEQ ID NO: 14, or variants thereof containing 5, 4, 3, 2 or 1 amino acid substitutions in such LC-CDRs; c) the VH comprises: i) HC-CDR1 containing the amino acid sequence SEQ ID NO: 17, ii) HC-CDR2 containing the amino acid sequence SEQ ID NO: 18 and iii) HC-CDR3 containing the amino acid sequence SEQ ID NO: 19. 19. HC-CDR3, or a variant thereof containing 5, 4, 3, 2 or 1 amino acid substitution in such HC-CDR; and the VL contains: i) LC-CDR1 containing the amino acid sequence SEQ ID NO: 20, ii) LC-CDR2 containing the amino acid sequence SEQ ID NO: 21 and iii) LC-CDR3 containing the amino acid sequence SEQ ID NO: 22, or a variant thereof containing 5, 4, 3, 2 or 1 amino acid substitution in such LC-CDR; d) the VH contains: i) HC-CDR1 containing the amino acid sequence SEQ ID NO: 25, ii) HC-CDR2 containing the amino acid sequence SEQ ID NO: 26 and iii) HC-CDR3 containing the amino acid sequence SEQ ID NO: 27, or a variant thereof containing 5, 4, 3, 2 or 1 amino acid substitution in such HC-CDR;The VL comprises: i) LC-CDR1 containing the amino acid sequence SEQ ID NO: 28, ii) LC-CDR2 containing the amino acid sequence SEQ ID NO: 29, and iii) LC-CDR3 containing the amino acid sequence SEQ ID NO: 30, or variants thereof containing 5, 4, 3, 2, or 1 amino acid substitution in the LC-CDRs; e) the VH comprises: i) HC-CDR1 containing the amino acid sequence SEQ ID NO: 33, ii) HC-CDR2 containing the amino acid sequence SEQ ID NO: 34, and iii) HC-CDR3 containing the amino acid sequence SEQ ID NO: 35, or variants thereof containing 5, 4, 3, 2, or 1 amino acid substitution in the HC-CDRs; and the VL comprises: i) LC-CDR1 containing the amino acid sequence SEQ ID NO: 36, ii) LC-CDR2 containing the amino acid sequence SEQ ID NO: 37, ii) LC-CDR2 containing the amino acid sequence SEQ ID NO: 38, ii) LC-CDR3 containing the amino acid sequence SEQ ID NO: 39, ii) LC-CDR3 containing the amino acid sequence SEQ ID NO: 30, ii) LC-CDR3 containing the amino acid sequence SEQ ID NO: 39, ii) LC-CDR2 containing the amino acid sequence SEQ ID NO: 30, ii) LC-CDR3 containing the amino acid sequence SEQ ID NO: 39, ii) LC-CDR3 ... 37) LC-CDR2 and iii) LC-CDR3 containing the amino acid sequence SEQ ID NO: 38, or variants thereof containing 5, 4, 3, 2 or 1 amino acid substitutions in such LC-CDRs; f) The VH comprises: i) HC-CDR1 containing the amino acid sequence SEQ ID NO: 41, ii) HC-CDR2 containing the amino acid sequence SEQ ID NO: 42 or 51, and iii) HC-CDR3 containing the amino acid sequence SEQ ID NO: 11; and the VL comprises: i) LC-CDR1 containing the amino acid sequence SEQ ID NO: 46, ii) LC-CDR2 containing the amino acid sequence SEQ ID NO: 13, and iii) LC-CDR3 containing the amino acid sequence SEQ ID NO: 47; h) The VH comprises: i) HC-CDR1 containing the amino acid sequence SEQ ID NO: 43, ii) LC-CDR2 containing the amino acid sequence SEQ ID NO: 47, and iii) LC-CDR3 containing the amino acid sequence SEQ ID NO: 48. 44 or 52 of HC-CDR2 and iii) of HC-CDR3 containing the amino acid sequence SEQ ID NO: 45; and the VL contains: i) LC-CDR1 containing the amino acid sequence SEQ ID NO: 54, ii) LC-CDR2 containing the amino acid sequence SEQ ID NO: 55 and iii) LC-CDR3 containing the amino acid sequence SEQ ID NO: 56 or 57; or i) the VH contains: i) HC-CDR1 containing the amino acid sequence SEQ ID NO: 41 or 43, ii) HC-CDR2 containing any of the amino acid sequences SEQ ID NO: 58 and iii) HC-CDR3 containing the amino acid sequence SEQ ID NO: 11 or 45;Furthermore, the VL comprises: i) LC-CDR1 containing the amino acid sequence SEQ ID NO: 48, ii) LC-CDR2 containing the amino acid sequence SEQ ID NO: 49, and iii) LC-CDR3 containing the amino acid sequence SEQ ID NO: 50 or 53.
[0278] Example 3. The anti-VISTA structure as in Example 2, wherein the VH comprises: i) HC-CDR1 containing the amino acid sequence SEQ ID NO: 1, ii) HC-CDR2 containing the amino acid sequence SEQ ID NO: 2 and iii) HC-CDR3 containing the amino acid sequence SEQ ID NO: 3; and the VL comprises: i) LC-CDR1 containing the amino acid sequence SEQ ID NO: 4, ii) LC-CDR2 containing the amino acid sequence SEQ ID NO: 5 and iii) LC-CDR3 containing the amino acid sequence SEQ ID NO: 6.
[0279] Example 4. The anti-VISTA structure as in Example 2, wherein the VH comprises: i) HC-CDR1 containing the amino acid sequence SEQ ID NO: 9, ii) HC-CDR2 containing the amino acid sequence SEQ ID NO: 10 and iii) HC-CDR3 containing the amino acid sequence SEQ ID NO: 11; and the VL comprises: i) LC-CDR1 containing the amino acid sequence SEQ ID NO: 12, ii) LC-CDR2 containing the amino acid sequence SEQ ID NO: 13 and iii) LC-CDR3 containing the amino acid sequence SEQ ID NO: 14.
[0280] Example 5. The anti-VISTA structure as in Example 3, wherein the VH comprises: i) HC-CDR1 containing the amino acid sequence SEQ ID NO: 17, ii) HC-CDR2 containing the amino acid sequence SEQ ID NO: 18 and iii) HC-CDR3 containing the amino acid sequence SEQ ID NO: 19; and the VL comprises: i) LC-CDR1 containing the amino acid sequence SEQ ID NO: 20, ii) LC-CDR2 containing the amino acid sequence SEQ ID NO: 21 and iii) LC-CDR3 containing the amino acid sequence SEQ ID NO: 22.
[0281] Example 6. The anti-VISTA structure as in Example 3, wherein the VH comprises: i) HC-CDR1 containing the amino acid sequence SEQ ID NO: 25, ii) HC-CDR2 containing the amino acid sequence SEQ ID NO: 26 and iii) HC-CDR3 containing the amino acid sequence SEQ ID NO: 27; and the VL comprises: i) LC-CDR1 containing the amino acid sequence SEQ ID NO: 28, ii) LC-CDR2 containing the amino acid sequence SEQ ID NO: 29 and iii) LC-CDR3 containing the amino acid sequence SEQ ID NO: 30.
[0282] Example 7. An anti-VISTA construct comprising an antibody portion specifically binding to VISTA, the anti-VISTA construct comprising: a) HC-CDR1, HC-CDR2, and HC-CDR3, each comprising an amino acid sequence of CDR1, CDR2, and CDR3 within a VH chain region having the sequence described in SEQ ID NO: 7; and LC-CDR1, LC-CDR2, and LC-CDR3, each comprising an amino acid sequence of CDR1, CDR2, and CDR3 within a VL chain region having the sequence described in SEQ ID NO: 8; b) HC-CDR1, HC-CDR2, and HC-CDR3, each comprising an amino acid sequence of CDR1, CDR2, and CDR3 within a VH chain region having the sequence described in SEQ ID NO: 15; and LC-CDR1, LC-CDR2, and LC-CDR3, each comprising an amino acid sequence of CDR1, CDR2, and CDR3 within a VH chain region having the sequence described in SEQ ID NO: 15; and LC-CDR1, LC-CDR2, and LC-CDR3, each comprising an amino acid sequence of CDR1, CDR2, and CDR3 within a VH chain region having the sequence described in SEQ ID NO: 15; c) The amino acid sequences of CDR1, CDR2, and CDR3 within the VL region of the sequence described in SEQ ID NO: 23; and LC-CDR1, LC-CDR2, and LC-CDR3, each containing the amino acid sequences of CDR1, CDR2, and CDR3 within the VH region of the sequence described in SEQ ID NO: 24; d) The amino acid sequences of CDR1, CDR2, and CDR3 within the VH region of the sequence described in SEQ ID NO: 31; and LC-CDR1, LC-CDR2, and LC-CDR3, each containing the amino acid sequences of CDR1, CDR2, and CDR3 within the VL region of the sequence described in SEQ ID NO: 24. The amino acid sequences of CDR1, CDR2 and CDR3 within the VL chain region of the sequence described in SEQ ID NO: 32; or e) HC-CDR1, HC-CDR2 and HC-CDR3, each containing the amino acid sequences of CDR1, CDR2 and CDR3 within the VH chain region of the sequence described in SEQ ID NO: 39; and LC-CDR1, LC-CDR2 and LC-CDR3, each containing the amino acid sequences of CDR1, CDR2 and CDR3 within the VL chain region of the sequence described in SEQ ID NO: 40.
[0283] Example 8. An anti-VISTA construct as in any of Examples 1 to 7, wherein the VH contains any of the amino acid sequences SEQ ID NO: 7, 15, 23, 31 and 39, or contains a variant of an amino acid sequence having at least about 80% sequence identity; and / or wherein the VL contains any of the amino acid sequences SEQ ID NO: 8, 16, 24, 32 and 40, or contains a variant of an amino acid sequence having at least about 80% sequence identity.
[0284] Example 9. The anti-VISTA construct as in Example 8, wherein: a) the VH contains the amino acid sequence SEQ ID NO: 7, or contains a variant of the amino acid sequence having at least about 80% sequence identity; and the VL contains the amino acid sequence SEQ ID NO: 8, or contains a variant of the amino acid sequence having at least about 80% sequence identity; b) the VH contains the amino acid sequence SEQ ID NO: 15, or contains a variant of the amino acid sequence having at least about 80% sequence identity; and the VL contains the amino acid sequence SEQ ID NO: 16, or contains a variant of the amino acid sequence having at least about 80% sequence identity; c) the VH contains the amino acid sequence SEQ ID NO: 23, or contains a variant of the amino acid sequence having at least about 80% sequence identity; and the VL contains the amino acid sequence SEQ ID NO: 24, or contains a variant of the amino acid sequence having at least about 80% sequence identity. d) The VH contains the amino acid sequence SEQ ID NO: 31, or a variant of the amino acid sequence having at least about 80% sequence identity; and the VL contains the amino acid sequence SEQ ID NO: 32, or a variant of the amino acid sequence having at least about 80% sequence identity; or e) The VH contains the amino acid sequence SEQ ID NO: 39, or a variant of the amino acid sequence having at least about 80% sequence identity; and the VL contains the amino acid sequence SEQ ID NO: 40, or a variant of the amino acid sequence having at least about 80% sequence identity.
[0285] Example 10. An anti-VISTA construct as described in any of Examples 1 to 9, wherein the antibody portion is an antibody or its antigen-binding fragment selected from the group consisting of: full-length antibody, bispecific antibody, single-chain Fv (scFv) fragment, Fab fragment, Fab' fragment, F(ab')2, Fv fragment, disulfide bond stabilized Fv fragment (dsFv), (dsFv)2, Fv-Fc fusion, scFv-Fc fusion, scFv-Fv fusion, bifunctional antibody, trifunctional antibody, and tetrafunctional antibody.
[0286] Example 11. The anti-VISTA construct as in Example 10, wherein the antibody portion is a full-length antibody.
[0287] Example 12. An anti-VISTA construct as in any of Examples 1 to 11, wherein the antibody portion has an Fc fragment selected from the group consisting of: Fc fragments from IgG, IgA, IgD, IgE, IgM, and combinations thereof and hybrids thereof.
[0288] Example 13. The anti-VISTA construct as in Example 12, wherein the Fc fragment is selected from the group consisting of Fc fragments from IgG1, IgG2, IgG3, IgG4 and combinations thereof and hybrids thereof.
[0289] Example 14. The anti-VISTA structure as in Example 12 or Example 13, wherein the effect function of the Fc fragment is reduced compared to the corresponding wild-type Fc fragment.
[0290] Example 15. The VISTA-resistant structure as in any of Examples 12 to 14, wherein the half-life of the Fc fragment is longer than that of the corresponding wild-type Fc fragment.
[0291] Example 16. An anti-VISTA construct as in any of Examples 1 to 15, wherein the antibody in the anti-VISTA construct partially activates the downstream signal transduction pathway of VISTA.
[0292] Example 17. An anti-VISTA construct as in any of Examples 1 to 16, wherein the anti-VISTA construct is a VISTA-enhancing antibody.
[0293] Example 18. An anti-VISTA construct as in any of Examples 16, wherein the antibody portion of the anti-VISTA construct activates or enhances the downstream signaling pathways of VISTA by at least about 20%.
[0294] Example 19. An anti-VISTA structure as in any of Examples 1 to 18, wherein the VISTA is a human VISTA.
[0295] Example 20. A pharmaceutical composition comprising an anti-VISTA construct as in any of Examples 1 to 19 and a pharmaceutically acceptable carrier.
[0296] Example 21. An isolated nucleic acid encoding an anti-VISTA construct as in any of Examples 1 to 20.
[0297] Example 22. A vector comprising the isolated nucleic acid as in Example 21.
[0298] Example 23. An isolated host cell comprising the isolated nucleic acid as in Example 21 or the vector as in Example 22.
[0299] Example 24. An immune conjugate comprising an anti-VISTA construct as in any of Examples 1 to 19, the anti-VISTA construct being linked to a therapeutic agent or a marker.
[0300] Example 25. A method for generating an anti-VISTA construct, comprising: a) culturing the isolated host cell as in Example 23 under conditions that effectively express the anti-VISTA construct; and b) obtaining the expressed anti-VISTA construct from the host cell.
[0301] Example 26. A method of treating an individual’s disease or condition, comprising administering to the individual an effective amount of an anti-VISTA construct as in any of Examples 1 to 19 or a pharmaceutical composition as in Example 20.
[0302] Example 27. The method of Example 26, wherein the disease or condition is related to immune system dysfunction.
[0303] Example 28. The method of Example 26 or Example 27, wherein the disease or condition is an autoimmune disease, inflammation, infection, graft-versus-host disease (GvHD) or a graft-related condition.
[0304] Example 29. The method of Example 28, wherein the autoimmune disease is selected from cutaneous lupus, rheumatoid arthritis, psoriasis, autoimmune intestinal disease, systemic lupus erythematosus (SLE), and discoid lupus erythematosus (DLE).
[0305] Example 30. The method of any of Examples 26 to 29, wherein the anti-VISTA construct system is administered intravenously or subcutaneously to the individual.
[0306] Example 31. The method of any of the examples, wherein the anti-VISTA construct is administered at a dose of about 0.001 mg / kg to about 100 mg / kg.
[0307] Example 32. The method as in any of Examples 22 to 31, wherein the individual is a human.
[0308] Example 33. A kit comprising any of the VISTA-resistant structures as described in Examples 1 to 19. Example
[0309] The following examples are intended to illustrate this application only and should not be construed as limiting this application in any way. The following examples and detailed descriptions are provided in an illustrative rather than restrictive manner. Example 1. Materials
[0310] His-labeled extracellular domain proteins of human, mouse, and cynomolgus monkey VISTA cells were generated internally using a standard protocol. hVISTA-mFc was purchased from Adipogen (catalog number CHI-HF-211B7H5-C100). An Alexa Fluor 647-labeled anti-human VISTA antibody (BD Biosciences, catalog number 566670) and an APC-labeled anti-mouse VISTA antibody (Biolegend, catalog number 150205) were used to detect Jurkat cells expressing human and mouse VISTA.
[0311] Jurkat A6 parental cells were transduced with the full-length pLenti7.3 / TOPO-mouse VISTA or human VISTA sequence for binding analysis via flow cytometry. Jurkat-nfkb-GFP reporter cells were transduced via lentivirus carrying CMV-human VISTA transmembrane and CD3ζ CAR-EF1-puro for reporter activation analysis via flow cytometry. For each construct, VISTA-positive populations of Jurkat cells were sorted twice. Multiple cell lines were used for each construct. Example 2. Immunization
[0312] Three female VISTA knockout BALB / c mice were immunized four times according to the procedure outlined in Table I. Mice were immunized with both hVISTA (human VISTA-mFc) and mVISTA (mouse VISTA-his). The first three immunizations included subcutaneous and intraperitoneal injections. The final booster was administered only via intraperitoneal injection. Immune responses were analyzed by ELISA: serum samples collected on days 0, 42, and 74 were incubated with human VISTA ECD (2 µg / ml) or negative control antibodies adsorbed onto 96-well plates. Binding mouse IgG was detected using anti-mouse IgG horseradish peroxidase (Jackson ImmunoResearch, catalog number 615035214). The results are shown in Figures 1 and 2. Table 5. Immunization timeline. injection: 50ug hVISTA + 50ug mVISTA + CFA Day 0 50ug hVISTA + 50ug mVISTA + IFA Day 35 25ug hVISTA + 25ug mVISTA + IFA Day 67 50ug hVISTA + 50ug mVISTA + PBS Day 92 Bleeding: before bleeding Day 0 Test bleeding Day 42 Test bleeding Day 74 Spleen collection Cell fusion Day 97
[0313] As shown in Figures 1 and 2, hVISTA or mVISTA is used to generate antibodies that bind to each antigen. Example 3. Production of supernatant from fusion tumors.
[0314] Spleens were collected from mice. Fustomas were prepared following a well-known procedure. Fustomas were cultured in fustomas-SFM medium (Gibco) at 37°C for 7 to 10 days. Cells were aggregated by centrifugation, and the supernatant was analyzed as described in the examples below. Example 4. Primary screening (using ELISA in combination with human VISTA, mouse VISTA, and cynomolgus monkey VISTA).
[0315] 50 µl of fusion tumor supernatant was incubated together with human VISTA ECD (2 µg / mL), mouse VISTA ECD (2 µg / mL), cynomolgus monkey VISTA (2 µg / mL), or negative mouse IgG1 control plated on a 96-well ELISA plate. Mouse anti-VISTA antibodies were detected by anti-mouse IgG-HRP (Jackson ImmunoResearch, catalog number 615035214). The results are shown in Figure 3.
[0316] As shown in Figure 3, the supernatant of fusion tumors containing 9E9, 15D11, 16A1, 17E9, and 20E4 effectively bound to the extracellular domain of VISTA cells in humans, cynomolgus monkeys, and / or mice, and showed cross-species reactivity (especially between human and cynomolgus monkey VISTA proteins). Example 5. Secondary screening of antibodies derived from fusion tumors that bind to VISTA by FACS analysis.
[0317] Jurkat cells expressing human and mouse VISTA were cultured in RPMI 1640 containing 10% FBS. Cells were seeded at 1 × 10⁵ cells / well in 96-well plates. Cells were then incubated at 4°C for 30 min with anti-VISTA fusion tumor supernatant. 1E8 (Immunext, see WO2017 / 181139A2) was used as a reference antibody. After washing with FACS buffer, cells were incubated at 4°C for 30 min with anti-mouse IgG (H+L) (1 µg / ml) bound to Alexa Fluor 647 (Jackson ImmunoResearch, catalog number 61505214). After washing twice with FACS buffer, samples were flow-cytosed on a NovoCyte flow cytometer (Agilent). Data were analyzed using NovoExpress software.
[0318] Figures 4A and 4B show the effective binding of all tested anti-VISTA fusion tumors (9F9, 16A1, 17E9, and 20E4) to the Jurkat-hVISTA-expressing cell line and a certain binding affinity to the Jurkat-mVISTA-expressing cell line. Example 6. Reporter activation analysis of antibodies derived from fusion tumors.
[0319] Jurkat-nfkb-GFP / human VISTA-hCD3z cells were seeded at 1 × 10⁵ cells / well in 200 µl RPMI 1640 medium containing 10% FBS in 96-well plates. Fusoma supernatant was added to the medium at progressively increasing anti-VISTA concentrations (ELISA-based, 0.003, 0.01, 0.03, 0.1, 0.3, 1, 10, and 30 µg / ml). After 24 hours of incubation, GFP was measured by flow cytometry. The results are shown in Figures 5 through 7. To test the cell-activating effect of OKT3, OKT3 (3 ng / ml) was added to the cells in the presence of progressively increasing anti-VISTA concentrations of fusoma-derived antibody, and the cells were incubated for 24 hours. The results are shown in Figures 8A through 10.
[0320] Figures 5A-5B and 6A-6B show that, after co-culturing with various concentrations of 9F9 or 20E4 fusion tumor supernatant, Jurkat-NFKb-GFP / hVISTA-hCD3z cells exhibited activation of the downstream VISTA pathway in cells, as indicated by positive GFP staining. The degree of activation was concentration-dependent. 16A1, 17E9, and 1E8 also showed the ability to activate Jurkat-NFKb-GFP / hVISTA-hCD3z cells at certain concentrations. See Figure 7. Therefore, 9F9, 20E4, 1E8, 16A1, and 17E9 all exhibited activating effects on human VISTA, with 9F9 and 20E4 showing the greatest activating effect among these antibodies.
[0321] Figures 8A-8B, 9A-9B, and 10 show that OKT3 significantly increased the percentage of activated Jurkat-NFKb-GFP / hVISTA-hCD3z cells. The percentage of activated cells exceeded 60% for all tested antibodies except 15D11. For cells cultured with 20E4 and 17E9 or 16A1, activation exceeded 80% at certain concentrations. These results demonstrate the potent activating effect of these antibodies. Example 7. Sequence Analysis
[0322] Total RNA was isolated from fusion tumor cell line cultures. RNA was processed to remove aberrant transcripts and reverse transcribed using oligomeric (dT) primers. cDNA samples were amplified in individual PCRs using framework 1 and constant region primer pairs specific to heavy or light chains. Reaction products were separated on agarose gels, their size was assessed, and they were recovered. Amplicon were selected and colonized into the pUC19 vector (Clontech). Ten colonies were selected, and both plasso DNA and PCR products were Sanger sequenced.
[0323] Analyze the DNA sequence data of all constructs and determine the common sequence of the heavy and light chains. See Tables 3 and 4 below.
[0324] Table 3. VH CDR sequences and common sequences HC-CDR1 HC-CDR2 HC-CDR3 9F9 GYWMQ (SEQ ID NO:1) AIYPGDGDTRYSQKFKG (SEQ ID NO:2) RDYGAWFAY (SEQ ID NO:3) 20E4 SSWVE (SEQ ID NO:9) EIFPGSGSTHYNEKFKG (SEQ ID NO:10) RPPGWFFDV (SEQ ID NO:11) 16A1 SSWIE (SEQ ID NO:17) EIFPGSGSLNFNEKFKG (SEQ ID NO:18) RPPGWFFDV (SEQ ID NO:19) 17E9 SCWIE (SEQ ID NO:25) EILPGSDYTNYNEKFKD (SEQ ID NO:26) RPPGWYFDV (SEQ ID NO:27) 15D11 DTFIH (SEQ ID NO:33) RIDPANGNSKYDPKFQG (SEQ ID NO:34) WPSNWEAMDY (SEQ ID NO:35) Common sequence Based on 20E4 and 16A1 SSWX1E X1 = V or I (SEQ ID NO:41) EIFPGSGSX2X3X4NEKFKG X2 = T or L, X3 = H or N, X4 = Y or F (SEQ ID NO:42) EIFPGSGSX2X3X4NEKFKG X2X3X4=THY or LNF (SEQ ID NO:51) RPPGWFFDV (SEQ ID NO:11) Common sequence Based on 20E4 and 17E9 SX1WX2E X1 = S or C, X2 = V or I (SEQ ID NO:43) EIX3PGSX4X5TX6YNEKFKX7 X3 = F or L, X4 = G or D, X5 = Y or S, X6 = H or N. X7 = G or D (SEQ ID NO:44) EIX3PGSX4X5TX6YNEKFKX7 X3 = F or L, X4 / X5 = DY or GS, X6 = H or N. X7 = G or D (SEQ ID NO:52) RPPGWX8FDV X8 = F or Y (SEQ ID NO:45) The common sequence is based on 20E4, 16A1 and 17E9 SX1WX2E X1 = S or C, X2 = V or I (SEQ ID NO:43) EIX 3PGSX 4X5X6X7X8NEKFKX9 X3 = F or L, X4, X5, X6, X7, X8 = GSTHY, GSLNF, or DYTNY, X9 = F or L (SEQ ID NO:58) RPPGWX8FDV X8 = F or Y (SEQ ID NO:45)
[0325] Table 4. VL CDR sequences and common sequences LC-CDR1 LC-CDR2 LC-CDR3 9F9 KASQDINSYLS (SEQ ID NO:4) RANRLVD (SEQ ID NO:5) LQYDEFPYT (SEQ ID NO:6) 20E4 KASQDVSTDVA (SEQ ID NO:12) SASYRYT (SEQ ID NO:13) QQHYSTPWT (SEQ ID NO:14) 16A1 KASQDVTTDVA (SEQ ID NO:20) SASYRYT (SEQ ID NO:21) QQHYSSPWT (SEQ ID NO:22) 17E9 KASQDVSTDIA (SEQ ID NO:28) SASYRFT (SEQ ID NO:29) QHQYSTPWT (SEQ ID NO:30) 15D11 SASSSVSYMY (SEQ ID NO:36) DTSNLAS (SEQ ID NO:37) QQWISYPLT (SEQ ID NO:38) Common sequence Based on 20E4 and 16A1 KASQDVX1TDVA X1 = S or T (SEQ ID NO:46) SASYRYT (SEQ ID NO:13) QQHYSX2PWT X2 = S or T (SEQ ID NO:47) Common sequence Based on 20E4 and 17E9 KASQDVSTDX1A X1 = V or I (SEQ ID NO:54) SASYRX2T X2 = Y or F (SEQ ID NO:55) QX3X4YSTPWT X4 = Q or H, X5 = Q or H (SEQ ID NO:56) QX3X4YSTPWT X4X5=QH or HQ (SEQ ID NO:57) Common sequence Based on 20E4, 16A1 and 17E9 KASQDVX1TDX2A X1 = S or T, X2 = V or I (SEQ ID NO:48) SASYRX3T X3 = Y or F (SEQ ID NO:49) QX4X5YSX6PWT X4 = Q or H, X5 = Q or H, X6 = S or T (SEQ ID NO:50) QX4X5YSX6PWT X4X5=QH or HQ, X6=S or T (SEQ ID NO:53) Example 8. Expression of anti-VISTA antibody and purification of autofusion tumor cells
[0326] Fusion tumor cells were cultured at 37°C in SFM medium (Gibco) for 7 to 10 days. Cells were aggregated by centrifugation, and the supernatant was collected for antibody purification using protein G agarose (GE). Cells were dissociated from the column and buffer-exchanged to 1×PBS (pH 7.4) by permeation after centrifugation. The purity and size of the purified antibody were confirmed by SDS-PAGE gel electrophoresis. Antibody concentration was determined using an A280 spectrophotometer. The purified antibody was filtered through a 0.2 µm filter before storage. Example 9. Recombinant expression and purification of anti-VISTA antibody in Expi293 cells.
[0327] Anti-VISTA variable domains were selected from the mIgG1 constant domain and expressed in Expi293 cells. In short, mouse IgG1 variable domains were synthesized from the IDT gene using the human best codon. The gene fragment was then selected into the pcDNA3.4 vector, which contains the mouse antibody signal sequence and the mIgG1 Fc fragment. Antibodies were generated by transient transfection into Expi293 cells using the ExpiFectamine 293 transfection kit (Thermo Fisher Scientific). Five days post-transfection, the supernatant was collected from transfected cells and purified using protein G agarose (GE). The bound antibodies were lysed with 0.1 M glycine buffer (pH 2.7) and dialyzed overnight with 1×PBS (pH 7.4). The purified antibodies were analyzed on reducing and non-reducing SDS-PAGE to confirm purity and size. Recombinant protein concentration was determined spectrophotometer A280. Example 10. Binding of recombinant anti-VISTA antibody to human and mouse VISTA Jurkat cells expressed on the cell surface, as determined by fluorescence-activated cell sorting (FACS).
[0328] Human and mouse Jurkat cells were cultured in RPMI 1640 containing 10% FBS. Cells were seeded at 1 × 10⁵ cells / well in 96-well plates. Cells were then incubated at 4°C for 30 min with recombinant anti-VISTA antibody 9F9, 16A1, 17E9, 20E4, or V4 (Hummingbird) (10 µg / ml). After washing with FACS buffer, cells were incubated at 4°C for 30 min with anti-mouse IgG (H+L) bound to Alexa Fluor 647 (1 µg / ml) (Jackson ImmunoResearch, catalog number 615605214). The cells were washed twice with FACS buffer and the samples were flowed on a NovoCyte flow cytometer (Agilent). Data were analyzed using NovoExpress software. Results are shown in Figures 11A and 11B.
[0329] Figures 11A and 11B confirm that the recombinant mIgG1 anti-VISTA antibodies (9F9, 16A1, 17E9, and 20E4) all showed effective binding to the Jurkat-hVISTA-expressing cell line. Furthermore, 9F9 also showed effective binding to Jurkat-mVISTA, indicating cross-species reactivity. Example 11. Reporter activation analysis of recombinant anti-VISTA antibodies
[0330] Jurkat-nfkb-GFP / human VISTA-hCD3z cells were seeded at 1 × 10⁵ cells / well in 200 µl RPMI 1640 medium containing 10% FBS in 96-well plates. Recombinant anti-VISTA antibody was added to the medium at progressively increasing VISTA concentrations ((0.003, 0.01, 0.03, 0.1, 0.3, 1, 10, and 30 µg / ml) or (0.05, 0.5, 5, and 50 µg / ml)). After 24 hours of incubation, GFP was measured by flow cytometry. To test the cell-activating effect of OKT3, OKT3 (3 ng / ml) was added to the cells in the presence of progressively increasing anti-VISTA concentrations, and GFP was measured after 24 hours of incubation.
[0331] Figures 12 to 15 show the effective activation of Jurkat-NFKb-GFP / hVISTA-hCD3z expression cells induced by recombinant mIgG1 anti-VISTA antibodies (9F9, 16A1, 17E9, and 20E4), with 15%-50% of cells activated at a concentration of 5 µg / mL. Example 12. Antigenic determinant grouping analysis of anti-VISTA antibodies by Octet competition.
[0332] The anti-VISTA antibody antigenic determinant matrix was determined using Octet QKe (ForteBio). Human VISTA recombinant protein (Sino Biological Inc., catalog number 13485-H08H) was biotinylated using EZ-LINK NHS-PEG4 biotin (Thermo Fisher Scientific). The streptavidin biosensor tip (Fortebio) was used to capture the biotinylated VISTA protein (5 µg / ml for 300 seconds). The baseline measurement was stabilized in 1× kinetic buffer (Fortebio) for 60 seconds, followed by binding of the primary anti-VISTA antibody (10 µg / ml) to the captured protein for 300 seconds. Subsequently, a set of secondary anti-VISTA antibodies (10 µg / ml) was re-bound to the antigen and primary antibody complex for 300 seconds. The signals of each binding event were recorded and analyzed using ForteBio data analysis software HT 11.1.
[0333] Grouping analysis of antigenic determinants of major anti-VISTA antibodies. This Octet analysis shows three groups of binding antigenic determinants. Figure 16 shows that 16A1, 17E9, and 20E4 compete for the same antigenic determinant on VISTA, while 1E8, 9F9, and 15D11 bind to different antigenic determinants. The binding antigenic determinants of all these antibodies are different from those of the baseline control antibodies ovatilimab and IE8 (Immunext). Example 13. Cross-binding activity of anti-VISTA mAb against human, cynomolgus monkey, and mouse VISTA antigens determined by biofilm interferometry (BLI).
[0334] The cross-binding activity of the anti-VISTA antibody against human, cynomolgus monkey, and mouse VISTA antigens was determined using Octet QKe (ForteBio) with biofilm interferometry. Human recombinant VISTA protein (Sino Biological Inc., catalog 13482-H08H), mouse VISTA (Sino Biological Inc., catalog 51550-M08H), or cynomolgus monkey VISTA protein (internally prepared) was biotinylated using EZ-LINK NHS-PEG4 biotin (Thermo Fisher Scientific). A streptavidin biosensor (ForteBio) was used to load the biotinylated VISTA protein (5 µg / ml for 300 seconds). Baseline measurements were stabilized in 1× kinetic buffer (ForteBio) for 60 seconds, followed by binding of 5 µg / ml of anti-VISTA antibody to the captured protein for 300 seconds. The sensor was then dissociated in 1× kinetic buffer for 600 seconds. Data analysis was performed using the ForteBio HT 11.1 software.
[0335] Figures 17A to 17C show the effective binding of all tested antibodies to human, cynomolgus monkey, and mouse VISTA. In contrast, the baseline control antibody ovalizumab did not cross-react with mouse VISTA. Example 14. Human and cynomolgus monkey VISTA binding affinity of anti-VISTA antibodies determined by biofilm interferometry (BLI).
[0336] The binding affinity of anti-VISTA antibodies to humans and cynomolgus monkeys was determined using Octet QKe (ForteBio) with biofilm interferometry. Human recombinant VISTA protein (Sino Biological Inc., catalog number 13482-H08H) or cynomolgus monkey VISTA protein (internally prepared) was biotinylated using EZ-LINK NHS-PEG4 biotin (Thermo Fisher Scientific). A streptavidin biosensor (Fortebio) was used to load the biotinylated VISTA protein (at 5 µg / ml for 300 seconds). Baseline measurements were stabilized in 1× kinetic buffer (ForteBio) for 60 seconds, followed by association of serially diluted anti-VISTA antibodies (50, 25, 12.5, 6.25, and 3.125 µg / ml) with the captured protein for 300 seconds. The sensor was then dissociated in 1× kinetic buffer for 600 seconds. Data analysis was performed using the ForteBio HT 11.1 software.
[0337] Figures 18A to 18E show the binding affinity of all anti-VISTA antibodies to human and cynomolgus monkey VISTA. Example 15. Analysis of the ability of anti-VISTA antibodies to inhibit T cell proliferation.
[0338] The ability of anti-VISTA antibody to inhibit T cell proliferation was analyzed in an in vitro assay. Anti-CD3 (OKT3) and VISTA-Ig at a concentration ratio of 1:1 (2.5 µg / ml anti-CD3:2.5 µg / ml) were plated into 96 wells overnight at 37°C. Human PBMCs were purified from freshly collected skin-colored hemoglobin and labeled with CFSE (Invitrogen, catalog number C34554). Subsequently, the wells of the 96-well plate were washed three times with 1×PBS buffer, and 200,000 CFSE-labeled PBMCs were added to each well in the presence of anti-VISTA antibody (50 µg / ml) or mouse IgG control (50 µg / ml). After 5 days of treatment, cells were collected, labeled with an anti-human CD3 antibody conjugated to APC (Biolegend catalog number 300311), and flowed in a NovoCyte flow cytometer (Agilent). Data were analyzed using NovoExpress software. The results are shown in Figure 19.
[0339] The baseline control antibody 1E8 (Immunext) was used as a positive control, and mouse IgG isotypes were used as a negative control. As shown, approximately 50% to 70% of cells cultured with OKT3 alone, OKT3+VISTA-Ig, or OKT3+VISTA-Ig+mIgG proliferated, as indicated by CFSE staining. In contrast, the presence of anti-VISTA antibodies (1E8, 9F9, 15D11, 16A1, 17E9, and 20E4) significantly inhibited T cell proliferation. Among them, 9F9, 15D11, 16A1, and 20E4 showed better inhibitory effects than 1E8. Example 16. Animal Studies
[0340] Four-week-old female MRL-lpr mice were used in a lupus treatment model. From week 5 to week 12, mice in different groups were treated weekly with 200 µg mIgG1 (control) or anti-VISTA constructs (MH5A, 9F9, or 20E4). Most measurements were performed at week 12 or thereafter, with several measurements of serum antibody levels performed before week 12. A graphical overview of the protocol used in the lupus treatment model is shown in Figure 20. The following experiments A through F were designed to examine the efficacy of the anti-VISTA constructs tested in this study using key clinical indicators of lupus. A. Treatment of lymphadenopathy with anti-VISTA constructs
[0341] MRL-lpr mice exhibit extensive lymphadenopathy associated with abnormal T-cell proliferation caused by a spontaneous mutation in Faslpr. This autoimmune mouse model develops skin lesions and is commonly used as a model for lupus erythematosus. Lymph node enlargement can be felt with gentle pressure around the neck area and begins at 10 weeks of age. Lymph node enlargement can be an early sign of lupus, in which skin lesions develop as the animals age.
[0342] Lymph node size was examined in four groups of mice treated with mIgG, MH5A, 9F9, or 20E4 at 12, 14, and 15 weeks of age, respectively. The results are shown in Figure 21A, where the weekly data bars from left to right represent the mIgG treatment group, MH5A treatment group, 9F9 treatment group, and 20E4 treatment group. Lymph node size was categorized into five values: 0 (untouchable), 1 (pea-sized), 2 (pea-sized), 3 (peanut-sized), and 4 (walnut-sized). Figure 21A shows that compared to the control group (mIgG1 treatment), MH5A and 9F9 significantly reduced lymph node size in mice, while 20E4 slightly reduced lymph node size. Figure 21B shows an illustrative size of lymph nodes removed from the neck region of the mice used in the experiment. B. Anti-VISTA constructs reduce serum antinuclear immunoglobulin levels.
[0343] MRL-lpr mice exhibit systemic autoimmune symptoms, including the spontaneous production of autoantibodies against the cell nucleus (antinuclear antibodies, ANA). The ANA test has been used in humans to diagnose lupus; a positive test indicates that the immune system has initiated a misdirected attack on human tissues.
[0344] Serum ANA levels in mice treated with mIgG1, MH5A, 9F9, or 20E4 were measured at weeks 5, 6, 9, 12, and 15. The results are shown in Figure 22. The weekly data bars in Figure 22, from left to right, represent the mIgG treatment group, MH5A treatment group, 9F9 treatment group, and 20E4 treatment group. At week 15, MH5A and 9F9 significantly reduced serum ANA levels compared to mIgG1, while 20E4 slightly reduced serum ANA levels in mice. C. Anti-VISTA constructs reduce serum levels of anti-dsDNA immunoglobulin.
[0345] In clinical practice, high levels of anti-dsDNA antibodies in the blood are strongly associated with lupus, and these levels typically increase significantly during or just before the onset of the disease. Positive anti-dsDNA antibody tests that correlate with other lupus-related clinical signs and symptoms are used to diagnose lupus.
[0346] Serum levels of anti-dsDNA antibodies in mice treated with mIgG1, MH5A, 9F9, or 20E4 were measured at weeks 9, 12, and 15. The results are shown in Figure 23. At week 12, all tested anti-VISTA constructs (MH5A, 9F9, and 20E4) reduced serum levels of anti-dsDNA antibodies in mice, and the levels remained low for three weeks after week 15 treatment. D. Anti-VISTA constructs reduce serum IFNα levels.
[0347] Interferon-alpha (IFNα) is an important cytokine involved in the etiology and pathogenesis of lupus. IFNα is an important protein in immune regulation. IFNα is a pleiotropic cytokine that can affect multiple cell types involved in lupus. Increased serum IFNα levels and changes in the expression of several genes in the interferon pathway are associated with lupus risk, indicating the role of this pathway in etiology.
[0348] Serum IFNα levels in mice treated with mIgG1, MH5A, 9F9, or 20E4 were measured at weeks 12 and 15, respectively. Figure 24 clearly shows that, compared to mIgG1 (control), all three anti-VISTA constructs significantly reduced serum IFNα levels at week 12 and remained significantly lower at week 15. E. Anti-VISTA constructs reduced urinary protein content.
[0349] The MRL-lpr mice used in this study spontaneously developed lupus nephritis. The protein content in urine can reflect the pathogenesis of kidney disease. In clinical practice, in addition to blood tests, urine tests, including urine protein content, are used to diagnose and monitor the impact of lupus on the kidneys.
[0350] Urinary protein levels in mice treated with mIgG1, MH5A, 9F9, or 20E4 were measured at weeks 12 and 15. Six mice were in each group. Pie charts in Figures 25 and 26 show the distribution of mice in each treatment group under different urinary protein level categories. The percentage values below the charts show the percentage of mice in each treatment group with protein levels ≥100 mg / dL or ≥300 mg / dL. Compared to the mIgG group, fewer mice were classified into the 2+ (100–300 mg / dL protein) and 3+ (300–1000 mg / dL protein) groups in all anti-VISTA construct treatment groups at week 12. MH5A and 9F9 showed a long-term effect in maintaining the reduction in urinary protein levels at week 15. F. Anti-VISTA constructs reduce cutaneous lupus lesions.
[0351] The protective effect of the anti-VISTA construct against lupus lesions in mice was investigated at week 17. As shown in Figure 27, the skin lesions in mice treated with MH5A and 9F9 were reduced compared to those in mice treated with mIgG1. G. Conclusion
[0352] The therapeutic effects of MH5A, 9F9, and 20E4 on lupus, including systemic lupus erythematosus (SLE), were tested in MRL-lpr mice. Disease severity in each group after treatment was assessed using lymphadenopathy, serum autoantibody and intercytokine levels, urinary protein levels, and skin appearance. 9F9 and MH5A showed promising preclinical effects in the MRL-lpr mouse model, significantly reducing lymphadenopathy, serum antinuclear and anti-dsDNA autoantibody levels, serum IFNα levels, and urinary protein levels. Compared to mIgG1 (control), 20E4 also showed a protective effect by reducing serum anti-dsDNA and IFNα levels. Example 17. Efficacy study of anti-VISTA antibody in graft-versus-host disease (GvHD) mouse model.
[0353] The goal of this study is to evaluate the efficacy of anti-VISTA antibodies 9F9 and 20E4 in a mouse model of graft-versus-host disease (GvHD).
[0354] The efficacy of the study was assessed by measuring body weight and visually evaluating the peeling of mouse skin. Overall activity of the mice was assessed throughout the study. The extent of human CD45+ cell engraftment, which indicates the degree of GvHD development in the blood, was also measured. See, for example, Ali et al., PLoS One. 2012; 7(8): e44219.
[0355] NOD-scid IL2rg naked (NSG) mice were used in this study. On day 0, all mice were injected intravenously (IV) with 10 million human PBMCs and divided into three groups. Group 1 received mouse IgG isotype control (0.5 mg / mouse) on day 0. Groups 2 and 3 were treated intraperitoneally (ip) with 9F9 (0.5 mg / mouse) or 20E4 (0.5 mg / mouse), respectively. Body weight was collected weekly. A second dose of the test product was administered at week 2. Blood samples were obtained at weeks 2 and 5 for flow cytometry analysis. Mice were sacrificed on day 37.
[0356] The collected measurement results were analyzed using the Prism analysis software in GraphPad and used as raw data. P < 0.05 was considered statistically significant.
[0357] Graft-versus-host disease (GVHD) causes weight loss as animals become lethargic and reduces activity as the disease progresses. Figure 28 shows that treatment of mice with anti-VISTA antibodies 9F9 and 20E4 prevented weight loss during the study period. Weight changes were statistically different in the 9F9 and 20E4 treatment groups compared to the isotype control group. Reduced activity was observed in three-quarters of the isotype control mice. No changes in activity were observed in the groups treated with either 9F9 or 20E4 antibodies.
[0358] Mice with GvHD exhibit skin peeling as the disease progresses. On day 33, mice were photographed to capture the degree of skin peeling observed in different groups. Figure 30 shows skin peeling in mice injected with isotype control and mice treated with anti-VISTA antibody 9F9 or 20E4.
[0359] Serum was collected on days 14 and 37 post-PBMC transfer. Cells were collected and stained for human and mouse CD45 for flow cytometry analysis. Figure 29 shows the percentage of human CD45+ cells in different groups. Each symbol represents an individual mouse in the group. Compared to the control, mice treated with 9F9 or 20E4 antibodies showed a statistically significant reduction in human CD45+ cells. Sequence Listing SEQ ID NO. describe amino acid sequence 1. 9F9 HC-CDR1 (Kabat) GYWMQ 2. 9F9 HC-CDR2 (Kabat) AIYPGDGDTRYSQKFKG 3. 9F9 HC-CDR3 (Kabat) RDYGAWFAY 4. 9F9 LC-CDR1 (Kabat) KASQDINSYLS 5. 9F9 LC-CDR2 (Kabat) RANRLVD 6. 9F9 LC-CDR3 (Kabat) LQYDEFPYT 7. 9F9 VH amino acid sequence QVQFQQSGAELARPGASVKLSCKASGYTFTGYWMQWVKQRPGQGLEWIGAIYPGDGDTRYSQKFKGKVTLTADKSSSTAYMQLSSLASEDSAVYYCARRDYGAWFAYWGQGTLVTVSA 8. 9F9 VL amino acid sequence DIKVTQSPSSMYASLGERVTITCKASQDINSYLSWFQQKPGKSPKTLIYRANRLVDGVPSRFSGSGSGQDYSLTISSLDYEDMGIYYCLQYDEFPYTFGGGTKLEIK 9. 20E4 HC-CDR1 (Kabat) SSWVE 10. 20E4 HC-CDR2 (Kabat) EIFPGSGSTHYNEKFKG 11. 20E4 HC-CDR3 (Kabat) RPPGWFFDV 12. 20E4 LC-CDR1 (Kabat) KASQDVSTDVA 13. 20E4 LC-CDR2 (Kabat) SASYRYT 14. 20E4 LC-CDR3 (Kabat) QQHYSTPWT 15. 20E4 VH amino acid sequence QVQLQQSGAELMKPGASVKISCKATGYTFSSSWVEWVRQRPGHGLEWIGEIFPGSGSTHYNEKFKGKATFTADTSSNTAYLQLSSLTSDDSAVYYCARRPPGWFFDVWGAGTTVTVSS 16. 20E4 VL amino acid sequence DIVMTQSHKFMSTSVGDRVSITCKASQDVSTDVAWYQQKPGQSPKLLIYSASYRYTGVPDRFTGSGSGTDFTFTISSVQAEDLAVYYCQQHYSTPWTFGGGTKLEIK 17. 16A1 HC-CDR1 (Kabat) SSWIE 18. 16A1 HC-CDR2 (Kabat) EIFPGSGSLNFNEKFKG 19. 16A1 HC-CDR3 (Kabat) RPPGWFFDV 20. 16A1 LC-CDR1 (Kabat) KASQDVTTDVA 21. 16A1 LC-CDR2 (Kabat) SASYRYT 22. 16A1 LC-CDR3 (Kabat) QQHYSSPWT 23. 16A1 VH amino acid sequence QVQLQQSGAELMKPGASVKISCKATGYTFSSSWIEWVKQRPGHGLEWIGEIFPGSGSLNFNEKFKGKATFTADTSSNTAYLQLSSLTSDDSAVYYCARRPPGWFFDVWGAGTTVTVSS 24. 16A1 VL amino acid sequence DIVMTQSHKFMSTSVGDRVSITCKASQDVTTDVAWYQQKPGQSPKLLIYSASYRYTGVPDRFTGSGSGTDFTFTISSVQAEDLTVYYCQQHYSSPWTFGGGTKLEIK 25. 17E9 HC-CDR1 (Kabat) SCWIE 26. 17E9 HC-CDR2 (Kabat) EILPGSDYTNYNEKFKD 27. 17E9 HC-CDR3 (Kabat) RPPGWYFDV 28. 17E9 LC-CDR1 (Kabat) KASQDVSTDIA 29. 17E9 LC-CDR2 (Kabat) SASYRFT 30. 17E9 LC-CDR3 (Kabat) QHQYSTPWT 31. 17E9 VH amino acid sequence QVQLQQSGAELMKPGASVKISCTATGYTFSSCWIEWVKQRPGHGLEWLGEILPGSDYTNYNEKFKDKATFTADTSSDTAYMQLSSLTSEDSAVYYCARRPPGWYFDVWGAGTAVTVSS 32. 17E9 VL amino acid sequence DIVMTQSHKFMSTSVGDRVSITCKASQDVSTDIAWYQQKPGQSPKLLIYSASYRFTGVPDRFTGSGSGTDFTFTISSVQAEDLAVYYCQHQYSTPWTFGGGTKLDIK 33. 15D11 HC-CDR1 (Kabat) DTFIH 34. 15D11 HC-CDR2 (Kabat) RIDPANGNSKYDPKFQG 35. 15D11 HC-CDR3 (Kabat) WPSNWEAMDY 36. 15D11 LC-CDR1 (Kabat) SASSSVSYMY 37. 15D11 LC-CDR2 (Kabat) DTSNLAS 38. 15D11 LC-CDR3 (Kabat) QQWISYPLT 39. 15D11 VH amino acid sequence EVQLQQSGSELVKAGASVKLSCTASGFKIKDTFIHWVKQRPEQGLDWIGRIDPANGNSKYDPKFQGKATITADTSSNTAYLQLSSLTSEDTAVYYCARWPSNWEAMDYWGQGTSVTVSS 40. 15D11 VL amino acid sequence QIVLTQSPAIMSASPGEKVTMTCSASSSVSYMYWYQQKPGSSPRLLIYDTSNLASGVPFRFSGSGSGTSYSLTISRMEAEDAATYYCQQWISYPLTFGTGTKLELK 41. HC-CDR1 common sequence Based on 20E4 and 16A1 SSWX1E X1 = V or I 42. HC-CDR2 common sequence Based on 20E4 and 16A1 EIFPGSGSX2X3X4NEKFKG X2 = T or L, X3 = H or N, X4 = Y or F 43. HC-CDR1 common sequence Based on 20E4 and 17E9 SX1WX2E X1 = S or C, X2 = V or I 44. HC-CDR2 common sequence Based on 20E4 and 17E9 EIX3PGSX4X5TX6YNEKFKX7 X3 = F or L, X4 = G or D, X5 = Y or S, X6 = H or N. X7 = G or D 45. HC-CDR3 common sequence Based on 20E4 and 17E9 RPPGWX8FDV X8 = F or Y 46. LC-CDR1 common sequence Based on 20E4 and 16A1 KASQDVX1TDVA X1 = S or T 47. LC-CDR3 common sequence Based on 20E4 and 16A1 QQHYSX2PWT X2 = S or T 48. LC-CDR1 common sequence Based on 20E4, 16A1 and 17E9 KASQDVX1TDX2A X1 = S or T, X2 = V or I 49. LC-CDR2 common sequence Based on 20E4, 16A1 and 17E9 SASYRX3T X3 = Y or F 50. LC-CDR3 common sequence Based on 20E4, 16A1 and 17E9 QX4X5YSX6PWT X4 = Q or H, X5 = Q or H, X6 = S or T 51. HC-CDR2 common sequence Based on 20E4 and 16A1 EIFPGSGSX2X3X4NEKFKG X2X3X4=THY or LNF 52. HC-CDR2 common sequence Based on 20E4 and 17E9 EIX3PGSX4X5TX6YNEKFKX7 X3 = F or L, X4 / X5 = DY or GS, X6 = H or N. X7 = G or D 53. LC-CDR3 common sequence Based on 20E4, 16A1 and 17E9 QX4X5YSX6PWT X4X5=QH or HQ, X6=S or T 54. LC-CDR1 common sequence Based on 20E4 and 17E9 KASQDVSTDX1A X1 = V or I 55. LC-CDR2 common sequence Based on 20E4 and 17E9 SASYRX2T X2 = Y or F 56. LC-CDR3 common sequence Based on 20E4 and 17E9 QX3X4YSTPWT X4 = Q or H, X5 = Q or H 57. LC-CDR3 common sequence Based on 20E4 and 17E9 QX3X4YSTPWT X4X5=QH or HQ 58. LC-CDR2 Common sequence Based on 20E4, 16A1 and 17E9 EIX 3PGSX 4X5X6X7X8NEKFKX9 X3 = F or L, X4, X5, X6, X7, X8 = GSTHY, GSLNF or DYTNY, X9 = F or L (SEQ ID NO:58) 59. Human VISTA sequence MGVPTALEGSWRWGSLLFALFLAASLGPVAAFKVATPYSLYVCPEGQNVTLTCRLLGPVDKGHDVTFYKTWYRSSRGEVQTCSERRPIRNLTFQDLHLHHGGHQAANTSHDLAQRHGLESASDHHGNFSITMRNLTLLDSGLYCCLVVEIRHHH SEHRVHGAMELQVQTGKDAPSNCVVYPSSSQDSENITAAALATGACIVGILCLPLILLLVYKQRQAASNRRAQELVRMDSNIQGIENPGFEASPPAQGIPEAKVRHPLSYVAQRQPSESGRHLLSEPSSTPLSPPGPGDVFFPSLDPVPDSPNFEVI [Simplified Explanation of the Diagram]
[0021] Figure 1 shows the anti-human VISTA antibody titers in the serum of three mice that have been immunized with the VISTA gene knockout by ELISA.
[0022] Figure 2 shows the anti-mouse VISTA antibody titers in the serum of three mice that have been immunized with the VISTA gene knockout by ELISA.
[0023] Figure 3 illustrates the binding activity of various anti-VISTA antibodies against the extracellular domain of VISTA cells in humans, mice, and cynomolgus monkeys.
[0024] Figures 4A to 4B depict the binding activity of various anti-VISTA antibodies against cells expressing Jurkat-hVISTA and Jurkat-mVISTA using fluorescence activated cell sorting (FACS).
[0025] Figures 5A and 5B depict the activation of the VISTA downstream pathway by various concentrations of 9F9 in cells expressing Jurkat-NFKb-GFP / hVISTA-hCD3z.
[0026] Figures 6A and 6B depict the activation of the VISTA downstream pathway by various concentrations of 20E4 in cells expressing Jurkat-NFKb-GFP / hVISTA-hCD3z.
[0027] Figure 7 compares the ability of various concentrations of anti-VISTA antibodies to activate the downstream pathway of VISTA in cells expressing Jurkat-NFKb-GFP / hVISTA-hCD3z.
[0028] Figures 8A and 8B depict the activation of the VISTA downstream pathway by various concentrations of 9F9 in the presence of anti-CD3 antibody (OKT3) in cells expressing Jurkat-NFKb-GFP / hVISTA-hCD3z.
[0029] Figures 9A and 9B depict the activation of the downstream pathway of VISTA by various concentrations of 20E4 in the presence of OKT3 in cells expressing Jurkat-NFKb-GFP / hVISTA-hCD3z.
[0030] Figure 10 compares the ability of various concentrations of anti-VISTA antibodies to activate the downstream pathway of VISTA in cells expressing Jurkat-NFKb-GFP / hVISTA-hCD3z in the presence of OKT3.
[0031] Figures 11A to 11B depict various recombinant mIgG1 anti-VISTA antibodies (9F9, 16A1, 17E7, 20E4, V4) that specifically bind to cell lines expressing Jurkat-hVISTA and Jurkat-mVISTA using fluorescence activated cell sorting (FACS).
[0032] Figure 12 depicts activated recombinant mIgG1 anti-VISTA (9F9) in a cell line expressing Jurkat-NFKb-GFP / hVISTA-hCD3z using fluorescence activated cell sorting (FACS).
[0033] Figure 13 depicts activated recombinant mIgG1 anti-VISTA (17E9) in a cell line expressing Jurkat-NFKb-GFP / hVISTA-hCD3z using fluorescence activated cell sorting (FACS).
[0034] Figure 14 depicts activated recombinant mIgG1 anti-VISTA (16A1) in a cell line expressing Jurkat-NFKb-GFP / hVISTA-hCD3z using fluorescence activated cell sorting (FACS).
[0035] Figure 15 depicts activated recombinant mIgG1 anti-VISTA (20E4) in a cell line expressing Jurkat-NFKb-GFP / hVISTA-hCD3z using fluorescence activated cell sorting (FACS).
[0036] Figure 16 depicts the epitope binning analysis of anti-VISTA antibodies by Octet competition.
[0037] Figures 17A to 17C depict the cross-binding activity of anti-VISTA mAb against human, cynomolgus monkey and mouse VISTA antigens using biofilm interferometry (BLI).
[0038] Figures 18A to 18E depict the binding activity of various anti-VISTA mAb against VISTA in humans or cynomolgus monkeys.
[0039] Figure 19 illustrates the inhibitory effect of anti-VISTA mAb on T cell proliferation.
[0040] Figure 20 depicts an overview of the experimental protocol for the treatment model of lupus in mice.
[0041] Figure 21A depicts lymph node enlargement in mice treated with mIgG, MH5A, 9F9, and 20E4 at 12, 14, and 15 weeks of age, respectively. Figure 21B depicts lymph nodes removed from the neck region of one mouse in the 20E4 group at 19 weeks of age.
[0042] Figure 22 depicts the serum levels of antinuclear immunoglobulins in mice after treatment with mIgG, MH5A 9F9 and 20E4.
[0043] Figure 23 depicts the serum levels of anti-dsDNA immunoglobulins in mice after treatment with mIgG, MH5A, 9F9 and 20E4.
[0044] Figure 24 depicts the serum IFNα levels in mice after treatment with mIgG, MH5A, 9F9 and 20E4.
[0045] Figure 25 depicts the urinary protein content of 12-week-old mice after treatment with mIgG, MH5A, 9F9 and 20E4.
[0046] Figure 26 depicts the urinary protein content of 15-week-old mice after treatment with mIgG, MH5A, 9F9 and 20E4.
[0047] Figure 27 depicts the changes in skin lupus lesions in 17-week-old mice after treatment with mIgG, MH5A, 9F9 and 20E4.
[0048] Figure 28 depicts the weight changes of mice injected with isotype control and mice treated with anti-VISTA antibody 9F9 or 20E4.
[0049] Figure 29 depicts the human CD45+ cell content in the blood of mice injected with isotype control and mice treated with anti-VISTA antibody 9F9 or 20E4.
[0050] Figure 30 depicts skin peeling of mice injected with isotype control and mice treated with anti-VISTA antibody 9F9 or 20E4. [Sequence List]
[0360] <![CDATA[ <110> DYNAMICURE BIOTECHNOLOGY LLC (USA) <![CDATA[ <120> Anti-VISTA structures and their applications <![CDATA[ <130> 19385-20004.40]]> <![CDATA[ <140> TW111108076]]> <![CDATA[ <141> 2022-03-04 <![CDATA[ <150> US 63 / 157,182 <![CDATA[ <151> 2021-03-05 <![CDATA[ <160> 59]]> <![CDATA[ <170> FastSEQ for Windows Version 4.0]]> <![CDATA[ <210> 1]]> <![CDATA[ <211> 5]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <400> 1]]> Gly Tyr Trp Met Gln 1 5 <![CDATA[ <210> 2]]> <![CDATA[ <211> 17]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <400> 2]]> Ala Ile Tyr Pro Gly Asp Gly Asp Thr Arg Tyr Ser Gln Lys Phe Lys 1 5 10 15 Gly <![CDATA[ <210> 3]]> <![CDATA[ <211> 9]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <400> 3]]> Arg Asp Tyr Gly Ala Trp Phe Ala Tyr 1 5 <![CDATA[ <210> 4]]> <![CDATA[ <211> 11]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence<![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <400> 4]]> Lys Ala Ser Gln Asp Ile Asn Ser Tyr Leu Ser 1 5 10 <![CDATA[ <210> 5]]> <![CDATA[ <211> 7]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <400> 5]]> Arg Ala Asn Arg Leu Val Asp 1 5 <![CDATA[ <210> 6]]> <![CDATA[ <211> 9]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <400> 6]]> Leu Gln Tyr Asp Glu Phe Pro Tyr Thr 1 5 <![CDATA[ <210> 7]]> <![CDATA[ <211> 118]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <400> 7]]> Gln Val Gln Phe Gln Gln Ser Gly Ala Glu Leu Ala Arg Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 20 25 30 Trp Met Gln Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Ala Ile Tyr Pro Gly Asp Gly Asp Thr Arg Tyr Ser Gln Lys Phe 50 55 60 Lys Gly Lys Val Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80Met Gln Leu Ser Ser Leu Ala Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Arg Asp Tyr Gly Ala Trp Phe Ala Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ala 115 <![CDATA[ <210> 8]]> <![CDATA[ <211> 107]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <400> 8]]> Asp Ile Lys Val Thr Gln Ser Pro Ser Ser Met Tyr Ala Ser Leu Gly 1 5 10 15 Glu Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Ser Tyr 20 25 30 Leu Ser Trp Phe Gln Gln Lys Pro Gly Lys Ser Pro Lys Thr Leu Ile 35 40 45 Tyr Arg Ala Asn Arg Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Gln Asp Tyr Ser Leu Thr Ile Ser Ser Leu Asp Tyr 65 70 75 80 Glu Asp Met Gly Ile Tyr Tyr Cys Leu Gln Tyr Asp Glu Phe Pro Tyr 85 90 95 Thr Phe Gly Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <![CDATA[ <210> 9]]> <![CDATA[ <211> 5]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <400> 9]]> Ser Ser Trp Val Glu 1 5<![CDATA[ <210> 10]]> <![CDATA[ <211> 17]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <400> 10]]> Glu Ile Phe Pro Gly Ser Gly Ser Thr His Tyr Asn Glu Lys Phe Lys 1 5 10 15 Gly <![CDATA[ <210> 11]]> <![CDATA[ <211> 9]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <400> 11]]> Arg Pro Pro Gly Trp Phe Phe Asp Val 1 5 <![CDATA[ <210> 12]]> <![CDATA[ <211> 11]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <400> 12]]> Lys Ala Ser Gln Asp Val Ser Thr Asp Val Ala 1 5 10 <![CDATA[ <210> 13]]> <![CDATA[ <211> 7]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <400> 13]]> Ser Ala Ser Tyr Arg Tyr Thr 1 5 <![CDATA[ <210> 14]]> <![CDATA[ <211> 9]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <400> 14]]> Gln Gln His Tyr Ser Thr Pro Trp Thr 1 5<![CDATA[ <210> 15]]> <![CDATA[ <211> 118]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <400> 15]]> Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Met Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Ala Thr Gly Tyr Thr Phe Ser Ser Ser 20 25 30 Trp Val Glu Trp Val Arg Gln Arg Pro Gly His Gly Leu Glu Trp Ile 35 40 45 Gly Glu Ile Phe Pro Gly Ser Gly Ser Thr His Tyr Asn Glu Lys Phe 50 55 60 Lys Gly Lys Ala Thr Phe Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 65 70 75 80 Leu Gln Leu Ser Ser Leu Thr Ser Asp Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Arg Pro Pro Gly Trp Phe Phe Asp Val Trp Gly Ala Gly Thr 100 105 110 Thr Val Thr Val Ser Ser 115 <![CDATA[ <210> 16]]> <![CDATA[ <211> 107]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <400> 16]]> Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly 1 5 10 15 Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Thr Asp 20 25 30 ValAla Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Val Gln Ala 65 70 75 80 Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln His Tyr Ser Thr Pro Trp 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <![CDATA[ <210> 17]]> <![CDATA[ <211> 5]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <400> 17]]> Ser Ser Trp Ile Glu 1 5 <![CDATA[ <210> 18]]> <![CDATA[ <211> 17]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[<22]]> 3> Crafted Constructs]]>br / >br / > <![CDATA[ <400> 18]]>br / > <![CDATA[Glu Ile Phe Pro Gly Ser Gly Ser Leu Asn Phe Asn Glu Lys Phe Lys 1 5 10 15 Gly <![CDATA[ <210> 19]]> <![CDATA[ <211> 9]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <400> 19]]> Arg Pro Pro Gly Trp Phe Phe Asp Val 1 5 <![CDATA[ <210> 20]]> <![CDATA[ <211> 11]]><![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <400> 20]]> Lys Ala Ser Gln Asp Val Thr Thr Asp Val Ala 1 5 10 <![CDATA[ <210> 21]]> <![CDATA[ <211> 7]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <400> 21]]> Ser Ala Ser Tyr Arg Tyr Thr 1 5 <![CDATA[ <210> 22]]> <![CDATA[ <211> 9]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <400> 22]]> Gln Gln His Tyr Ser Ser Pro Trp Thr 1 5 <![CDATA[ <210> 23]]> <![CDATA[ <211> 118]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <400> 23]]> Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Met Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Ala Thr Gly Tyr Thr Phe Ser Ser Ser 20 25 30 Trp Ile Glu Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile 35 40 45 Gly Glu Ile Phe Pro Gly Ser Gly Ser Leu Asn Phe Asn Glu Lys Phe 50 55 60 Lys Gly Lys Ala Thr PheThr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 65 70 75 80 Leu Gln Leu Ser Ser Leu Thr Ser Asp Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Arg Pro Pro Gly Trp Phe Phe Asp Val Trp Gly Ala Gly Thr 100 105 110 Thr Val Thr Val Ser Ser 115 <![CDATA[<210> 24]]> <![CDATA[<211> 107]]> <![CDATA[<212> PRT]]> <![CDATA[<213> Artificial Sequence]]> <![CDATA[<220> ]]> <![CDATA[<223> Synthetic Construct]]> <![CDATA[<400> 24]]> Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly 1 5 10 15 Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Thr Thr Asp 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Val Gln Ala 65 70 75 80 Glu Asp Leu Thr Val Tyr Tyr Cys Gln Gln His Tyr Ser Ser Pro Trp 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <![CDATA[<210> 25]]> <![CDATA[<211> 5]]> <![CDATA[<212> PRT]]> <![CDATA[<213> Artificial Sequence]]> <![CDATA[<220> ]]> <![CDATA[<223>Synthetic Constructs <![CDATA[ <400> 25]]> Ser Cys Trp Ile Glu 1 5 <![CDATA[ <210> 26]]> <![CDATA[ <211> 17]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <400> 26]]> Glu Ile Leu Pro Gly Ser Asp Tyr Thr Asn Tyr Asn Glu Lys Phe Lys 1 5 10 15 Asp <![CDATA[ <210> 27]]> <![CDATA[ <211> 9]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <400> 27]]> Arg Pro Pro Gly Trp Tyr Phe Asp Val 1 5 <![CDATA[ <210> 28]]> <![CDATA[ <211> 11]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <400> 28]]> Lys Ala Ser Gln Asp Val Ser Thr Asp Ile Ala 1 5 10 <![CDATA[ <210> 29]]> <![CDATA[ <211> 7]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <400> 29]]> Ser Ala Ser Tyr Arg Phe Thr 1 5 <![CDATA[ <210> 30]]> <![CDATA[ <211> 9]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <400>30]]> Gln His Gln Tyr Ser Thr Pro Trp Thr 1 5 <![CDATA[ <210> 31]]> <![CDATA[ <211> 118]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <400> 31]]> Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Met Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Ser Cys Thr Ala Thr Gly Tyr Thr Phe Ser Ser Cys 20 25 30 Trp Ile Glu Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Leu 35 40 45 Gly Glu Ile Leu Pro Gly Ser Asp Tyr Thr Asn Tyr Asn Glu Lys Phe 50 55 60 Lys Asp Lys Ala Thr Phe Thr Ala Asp Thr Ser Ser Asp Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Arg Pro Pro Gly Trp Tyr Phe Asp Val Trp Gly Ala Gly Thr 100 105 110 Ala Val Thr Val Ser Ser 115 <![CDATA[ <210> 32]]> <![CDATA[ <211> 107]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <400> 32]]> Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly 1 5 10 15 Asp Arg Val Ser Ile Thr CysLys Ala Ser Gln Asp Val Ser Thr Asp 20 25 30 Ile Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Tyr Arg Phe Thr Gly Val Pro Asp Arg Phe Thr Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Val Ser Ser Gln Ala 65 70 75 80 Glu Asp Leu Ala Val Tyr Tyr Cys Gln His Gln Tyr Ser Thr Pro Trp 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Asp Ile Lys 100 105 <![CDATA[ <210> 33]]> <![CDATA[ <211> 5]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <400> 33]]> Asp Thr Phe Ile His 1 5 <![CDATA[ <210> 34]]> <![CDATA[ <211> 17]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <400> 34]]> Arg Ile Asp Pro Ala Asn Gly Asn Ser Lys Tyr Asp Pro Lys Phe Gln 1 5 10 15 Gly <![CDATA[ <210> 35]]> <![CDATA[ <211> 10]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <400> 35]]> Trp Pro Ser Asn Trp Glu Ala Met Asp Tyr 1 5 10<![CDATA[ <210> 36]]> <![CDATA[ <211> 10]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <400> 36]]> Ser Ala Ser Ser Ser Ser Val Ser Tyr Met Tyr 1 5 10 <![CDATA[ <210> 37]]> <![CDATA[ <211> 7]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <400> 37]]> Asp Thr Ser Asn Leu Ala Ser 1 5 <![CDATA[ <210> 38]]> <![CDATA[ <211> 9]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <400> 38]]> Gln Gln Trp Ile Ser Tyr Pro Leu Thr 1 5 <![CDATA[ <210> 39]]> <![CDATA[ <211> 119]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <400> 39]]> Glu Val Gln Leu Gln Gln Ser Gly Ser Glu Leu Val Lys Ala Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Lys Ile Lys Asp Thr 20 25 30 Phe Ile His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Asp Trp Ile 35 40 45 Gly Arg Ile Asp Pro Ala Asn Gly Asn Ser Lys Tyr Asp ProLys Phe 50 55 60 Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 65 70 75 80 Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Trp Pro Ser Asn Trp Glu Ala Met Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Ser Val Thr Val Ser Ser 115 <![CDATA[<210> 40]]> <![CDATA[<211> 106]]> <![CDATA[<212> PRT]]> <![CDATA[<213> Artificial Sequence]]> <![CDATA[<220> ]]> <![CDATA[<223> Synthetic Construct]]> <![CDATA[<400> 40]]> Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 1 5 10 15 Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met 20 25 30 Tyr Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Arg Leu Leu Ile Tyr 35 40 45 Asp Thr Ser Asn Leu Ala Ser Gly Val Pro Phe Arg Phe Ser Gly Ser 50 55 60 Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Met Glu Ala Glu 65 70 75 80 Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ile Ser Tyr Pro Leu Thr 85 90 95 Phe Gly Thr Gly Thr Lys Leu Glu Leu Lys 100 105 <![CDATA[<210> 41]]> <![CDATA[<211> 5]]> <![CDATA[<212> PRT]]> <![CDATA[<213>Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <220> ]]> <![CDATA[ <221> VARIANT <![CDATA[ <222> 4]]> <![CDATA[ <223> Xaa = V or I]]> <![CDATA[ <400> 41]]> Ser Ser Trp Xaa Glu 1 5 <![CDATA[ <210> 42]]> <![CDATA[ <211> 17]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <220> ]]> <![CDATA[ <221> VARIANT <![CDATA[ <222> 9]]> <![CDATA[ <223> Xaa = T or L]]> <![CDATA[ <220> ]]> <![CDATA[ <221> VARIANT <![CDATA[ <222> 10]]> <![CDATA[ <223> Xaa = H or N]]> <![CDATA[ <220> ]]> <![CDATA[ <221> VARIANT <![CDATA[ <222> 11]]> <![CDATA[ <223> Xaa = Y or F]]> <![CDATA[ <400> 42]]> Glu Ile Phe Pro Gly Ser Gly Ser Xaa Xaa Xaa Asn Glu Lys Phe Lys 1 5 10 15 Gly <![CDATA[ <210> 43]]> <![CDATA[ <211> 5]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <220> ]]> <![CDATA[ <221> VARIANT <![CDATA[ <222> 2]]> <![CDATA[ <223> Xaa = S or C]]> <![CDATA[ <220> ]]> <![CDATA[ <221> VARIANT <![CDATA[ <222> 4]]><![CDATA[ <223> Xaa = V or I]]> <![CDATA[ <400> 43]]> Ser Xaa Trp Xaa Glu 1 5 <![CDATA[ <210> 44]]> <![CDATA[ <211> 17]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <220> ]]> <![CDATA[ <221> VARIANT <![CDATA[ <222> 3]]> <![CDATA[ <223> Xaa = F or L]]> <![CDATA[ <220> ]]> <![CDATA[ <221> VARIANT <![CDATA[ <222> 7]]> <![CDATA[ <223> Xaa = G or D]]> <![CDATA[ <220> ]]> <![CDATA[ <221> VARIANT <![CDATA[ <222> 8]]> <![CDATA[ <223> Xaa = Y or S]]> <![CDATA[ <220> ]]> <![CDATA[ <221> VARIANT <![CDATA[ <222> 10]]> <![CDATA[ <223> Xaa = H or N]]> <![CDATA[ <220> ]]> <![CDATA[ <221> VARIANT <![CDATA[ <222> 17]]> <![CDATA[ <223> Xaa = G or D]]> <![CDATA[ <400> 44]]> Glu Ile Xaa Pro Gly Ser Xaa Xaa Thr Xaa Tyr Asn Glu Lys Phe Lys 1 5 10 15 Xaa <![CDATA[ <210> 45]]> <![CDATA[ <211> 9]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <220> ]]> <![CDATA[ <221> VARIANT <![CDATA[ <222> 6]]> <![CDATA[ <223> Xaa = F or Y]] ><![CDATA[ <400> 45]]> Arg Pro Pro Gly Trp Xaa Phe Asp Val 1 5 <![CDATA[ <210> 46]]> <![CDATA[ <211> 11]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Combined structure <![CDATA[ <220> ]]> <![CDATA[ <221> VARIANT <![CDATA[ <222> 7]]> <![CDATA[ <223> Xaa = S or T]]> <![CDATA[ <400> 46]]> Lys Ala Ser Gln Asp Val Xaa Thr Asp Val Ala 1 5 10 <![CDATA[ <210> 47]]> <![CDATA[ <211> 9]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <220> ]]> <![CDATA[ <221> VARIANT <![CDATA[ <222> 6]]> <![CDATA[ <223> Xaa = S or T]]> <![CDATA[ <400> 47]]> Gln Gln His Tyr Ser Xaa Pro Trp Thr 1 5 <![CDATA[ <210> 48]]> <![CDATA[ <211> 11]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <220> ]]> <![CDATA[ <221> VARIANT <![CDATA[ <222> 7]]> <![CDATA[ <223> Xaa = S or T]]> <![CDATA[ <220> ]]> <![CDATA[ <221> VARIANT <![CDATA[ <222> 10]]> <![CDATA[ <223> Xaa = V or I]]> <![CDATA[ <400> 48]]> Lys Ala Ser Gln AspVal Xaa Thr Asp Xaa Ala 1 5 10 <![CDATA[ <210> 49]]> <![CDATA[ <211> 7]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <220> ]]> <![CDATA[ <221> VARIANT <![CDATA[ <222> 6]]> <![CDATA[ <223> Xaa = Y or F]]> <![CDATA[ <400> 49]]> Ser Ala Ser Tyr Arg Xaa Thr 1 5 <![CDATA[ <210> 50]]> <![CDATA[ <211> 9]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <220> ]]> <![CDATA[ <221> VARIANT <![CDATA[ <222> 2, 3]]> <![CDATA[ <223> Xaa = Q or H]]> <![CDATA[ <220> ]]> <![CDATA[ <221> VARIANT <![CDATA[ <222> 6]]> <![CDATA[ <223> Xaa = S or T]]> <![CDATA[ <400> 50]]> Gln Xaa Xaa Tyr Ser Xaa Pro Trp Thr 1 5 <![CDATA[ <210> 51]]> <![CDATA[ <211> 17]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <220> ]]> <![CDATA[ <221> VARIANT <![CDATA[ <222> (9)..(11)]]> <![CDATA[ <223> Xaa = THY or LNF]]> <![CDATA[ <400> 51]]> Glu Ile Phe Pro Gly Ser Gly Ser Xaa Xaa Xaa Asn Glu LysPhe Lys 1 5 10 15 Gly <![CDATA[ <210> 52]]> <![CDATA[ <211> 17]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <220> ]]> <![CDATA[ <221> VARIANT <![CDATA[ <222> 3]]> <![CDATA[ <223> Xaa = F or L]]> <![CDATA[ <220> ]]> <![CDATA[ <221> VARIANT <![CDATA[ <222> (7)..(8)]]> <![CDATA[ <223> Xaa = DY or GS]]> <![CDATA[ <220> ]]> <![CDATA[ <221> VARIANT <![CDATA[ <222> 10]]> <![CDATA[ <223> Xaa = H or N]]> <![CDATA[ <220> ]]> <![CDATA[ <221> VARIANT <![CDATA[ <222> 17]]> <![CDATA[ <223> Xaa = G or D]]> <![CDATA[ <400> 52]]> Glu Ile Xaa Pro Gly Ser Xaa Xaa Thr Xaa Tyr Asn Glu Lys Phe Lys 1 5 10 15 Xaa <![CDATA[ <210> 53]]> <![CDATA[ <211> 9]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <220> ]]> <![CDATA[ <221> VARIANT <![CDATA[ <222> (2)..(3)]]> <![CDATA[ <223> Xaa = QH or HQ]]> <![CDATA[ <220> ]]> <![CDATA[ <221> VARIANT <![CDATA[ <222> 6]]> <![CDATA[ <223> Xaa = S or T]]> <![CDATA[ <400> 53]]> Gln Xaa Xaa TyrSer Xaa Pro Trp Thr 1 5 <![CDATA[ <210> 54]]> <![CDATA[ <211> 11]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <220> ]]> <![CDATA[ <221> VARIANT <![CDATA[ <222> 10]]> <![CDATA[ <223> Xaa = V or I]]> <![CDATA[ <400> 54]]> Lys Ala Ser Gln Asp Val Ser Thr Asp Xaa Ala 1 5 10 <![CDATA[ <210> 55]]> <![CDATA[ <211> 7]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <220> ]]> <![CDATA[ <221> VARIANT <![CDATA[ <222> 6]]> <![CDATA[ <223> Xaa = Y or F]]> <![CDATA[ <400> 55]]> Ser Ala Ser Tyr Arg Xaa Thr 1 5 <![CDATA[ <210> 56]]> <![CDATA[ <211> 9]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <220> ]]> <![CDATA[ <221> VARIANT <![CDATA[ <222> 2, 3]]> <![CDATA[ <223> Xaa = Q or H]]> <![CDATA[ <400> 56]]> Gln Xaa Xaa Tyr Ser Thr Pro Trp Thr 1 5 <![CDATA[ <210> 57]]> <![CDATA[ <211> 9]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]><![CDATA[ <223> Synthetic Constructs <![CDATA[ <220> ]]> <![CDATA[ <221> VARIANT <![CDATA[ <222> (2)..(3)]]> <![CDATA[ <223> Xaa = QH or HQ]]> <![CDATA[ <400> 57]]> Gln Xaa Xaa Tyr Ser Thr Pro Trp Thr 1 5 <![CDATA[ <210> 58]]> <![CDATA[ <211> 17]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Artificial sequence <![CDATA[ <220> ]]> <![CDATA[ <223> Synthetic Constructs <![CDATA[ <220> ]]> <![CDATA[ <221> VARIANT <![CDATA[ <222> 3]]> <![CDATA[ <223> Xaa = F or L]]> <![CDATA[ <220> ]]> <![CDATA[ <221> VARIANT <![CDATA[ <222> (7)..(11)]]> <![CDATA[ <223> Xaa = GSTHY, GSLNF or DYTNY]]> <![CDATA[ <220> ]]> <![CDATA[ <221> VARIANT <![CDATA[ <222> 17]]> <![CDATA[ <223> Xaa = F or L]]> <![CDATA[ <400> 58]]> Glu Ile Xaa Pro Gly Ser Xaa Xaa Xaa Xaa Xaa Asn Glu Lys Phe Lys 1 5 10 15 Xaa <![CDATA[ <210> 59]]> <![CDATA[ <211> 311]]> <![CDATA[ <212> PRT]]> <![CDATA[ <213> Homo sapiens <![CDATA[ <400> 59]]> Met Gly Val Pro Thr Ala Leu Glu Ala Gly Ser Trp Arg Trp Gly Ser 1 5 10 15 Leu Leu Phe Ala Leu Phe Leu Ala Ala Ser Leu Gly Pro Val Ala Ala 20 25 30 Phe Lys Val Ala Thr ProTyr Ser Leu Tyr Val Cys Pro Glu Gly Gln 35 40 45 Asn Val Thr Leu Thr Cys Arg Leu Leu Gly Pro Val Asp Lys Gly His 50 55 60 Asp Val Thr Phe Tyr Lys Thr Trp Tyr Arg Ser Ser Arg Gly Glu Val 65 70 75 80 Gln Thr Cys Ser Glu Arg Arg Pro Ile Arg Asn Leu Thr Phe Gln Asp 85 90 95 Leu His Leu His His Gly Gly His Gln Ala Ala Asn Thr Ser His Asp 100 105 110 Leu Ala Gln Arg His Gly Leu Glu Ser Ala Ser Asp His His Gly Asn 115 120 125 Phe Ser Ile Thr Met Arg Asn Leu Thr Leu Leu Asp Ser Gly Leu Tyr 130 135 140 Cys Cys Leu Val Val Glu Ile Arg His His His Ser Glu His Arg Val 145 150 155 160 His Gly Ala Met Glu Leu Gln Val Gln Thr Gly Lys Asp Ala Pro Ser 165 170 175 Asn Cys Val Val Tyr Pro Ser Ser Ser Gln Asp Ser Glu Asn Ile Thr 180 185 190 Ala Ala Ala Leu Ala Thr Gly Ala Cys Ile Val Gly Ile Leu Cys Leu 195 200 205 Pro Leu Ile Leu Leu Leu Val Tyr Lys Gln Arg Gln Ala Ala Ser Asn 210 215 220 Arg Arg Ala Gln Glu Leu Val Arg Met Asp Ser Asn Ile Gln Gly Ile 225 230 235 240 Glu Asn Pro Gly Phe Glu Ala Ser ProPro Ala Gln Gly Ile Pro Glu 245 250 255 Ala Lys Val Arg His Pro Leu Ser Tyr Val Ala Gln Arg Gln Pro Ser 260 265 270 Glu Ser Gly Arg His Leu Leu Ser Glu Pro Ser Thr Pro Leu Ser Pro 275 280 285 Pro Gly Pro Gly Asp Val Phe Phe Pro Ser Leu Asp Pro Val Pro Asp 290 295 300 Ser Pro Asn Phe Glu Val Ile 305 310
Claims
1. An anti-VISTA construct comprising an antibody portion comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises: HC-CDR1 comprising the amino acid sequence SEQ ID NO: 9, HC-CDR2 comprising the amino acid sequence SEQ ID NO: 10, and HC-CDR3 comprising the amino acid sequence SEQ ID NO: 11, and the VL comprises: LC-CDR1 comprising the amino acid sequence SEQ ID NO: 12, LC-CDR2 comprising the amino acid sequence SEQ ID NO: 13, and LC-CDR3 comprising the amino acid sequence SEQ ID NO:
14.
2. An anti-VISTA construct comprising an antibody moiety specifically binding to VISTA, the anti-VISTA construct comprising HC-CDR1, HC-CDR2, and HC-CDR3, each comprising an amino acid sequence of CDR1, CDR2, and CDR3 within a heavy chain variable region (VH) having the sequence described in SEQ ID NO: 15; and LC-CDR1, LC-CDR2, and LC-CDR3, each comprising an amino acid sequence of CDR1, CDR2, and CDR3 within a light chain variable region (VL) having the sequence described in SEQ ID NO:
16.
3. The anti-VISTA construct of claim 1, wherein the VH contains an amino acid sequence SEQ ID NO: 15, or contains a variant of an amino acid sequence having at least about 80% sequence identity; and the VL contains an amino acid sequence SEQ ID NO: 16, or contains a variant of an amino acid sequence having at least about 80% sequence identity.
4. The anti-VISTA construct as claimed in claim 3, wherein the VH contains the amino acid sequence SEQ ID NO: 15, and the VL contains the amino acid sequence SEQ ID NO:
16.
5. An anti-VISTA construct as requested in any of items 1 to 4, wherein the antibody portion is an antibody or its antigen-binding fragment selected from the group consisting of: full-length antibody, bispecific antibody, single-chain Fv (scFv) fragment, Fab fragment, Fab' fragment, F(ab')2, Fv fragment, disulfide bond-stabilized Fv fragment (dsFv), (dsFv)2, Fv-Fc fusion, scFv-Fc fusion, scFv-Fv fusion, bifunctional antibody (diabody), trifunctional antibody (tribody), and tetrafunctional antibody (tetrabody).
6. The anti-VISTA construct as described in claim 5, wherein the antibody portion is a full-length antibody.
7. An anti-VISTA construct as claimed in any of claims 1 to 4, wherein the antibody portion has an Fc fragment selected from the group consisting of: Fc fragments derived from IgG, IgA, IgD, IgE, IgM, and combinations thereof and hybrids thereof.
8. As in Request 7, the VISTA-resistant structure, wherein: (a) The Fc fragment is selected from the group consisting of Fc fragments derived from IgG1, IgG2, IgG3, IgG4, and combinations thereof and hybrids thereof; (b) The Fc fragment has a reduced effector function compared to the corresponding wild-type Fc fragment; and / or (c) The Fc fragment has an extended half-life compared to the corresponding wild-type Fc fragment.
9. An anti-VISTA construct as claimed in any of claims 1 to 4, wherein the antibody portion of the anti-VISTA construct partially activates the downstream signal transduction pathway of VISTA.
10. The anti-VISTA construct of claim 9, wherein the antibody portion of the anti-VISTA construct activates or enhances the downstream signaling pathways of VISTA by at least about 20%.
11. An anti-VISTA construct as claimed in any of claims 1 to 4, wherein the anti-VISTA construct is a VISTA activating antibody.
12. A VISTA-resistant structure as described in any of claims 1 to 4, wherein the VISTA is a human VISTA.
13. A pharmaceutical composition comprising an anti-VISTA construct as claimed in any one of claims 1 to 12 and a pharmaceutically acceptable carrier.
14. An isolated nucleic acid encoding an anti-VISTA construct as described in any one of claims 1 to 12.
15. A vector comprising the isolated nucleic acid as claimed in claim 14.
16. An isolated host cell comprising the isolated nucleic acid as claimed in claim 14, or the vector as claimed in claim 15.
17. An immune conjugate comprising an anti-VISTA construct as claimed in any one of claims 1 to 12, the anti-VISTA construct being linked to a therapeutic agent or a marker.
18. A method for generating an anti-VISTA construct, comprising: a) culturing the isolated host cell of claim 16 under conditions that effectively express the anti-VISTA construct; and b) obtaining the expressed anti-VISTA construct from the host cell.
19. Use of an anti-VISTA construct as claimed in any one of claims 1 to 12 or a pharmaceutical composition as claimed in claim 13, for the preparation of a medicine for treating an individual’s disease or condition related to immune system dysregulation or inflammation.
20. For the purposes of claim 19, wherein the disease or condition is an autoimmune disease, infection, graft-versus-host disease (GvHD), or a graft-related condition.
21. As claimed in claim 20, wherein the autoimmune disease is selected from the group consisting of: cutaneous lupus, rheumatoid arthritis, psoriasis, autoimmune intestinal disease, systemic lupus erythematosus (SLE) and discoid lupus erythematosus (DLE).
22. The use of any of claims 19 to 21, wherein the anti-VISTA construct system is administered intravenously or subcutaneously to the individual; and / or wherein the anti-VISTA construct system is administered at a dose of 0.001 mg / kg to 100 mg / kg.
23. The use of any of the claims 19 to 21, wherein the individual is a human being.
24. A suite comprising a VISTA-resistant structure as claimed in any one of claims 1 to 12.
Citation Information
Patent Citations
Anti-human vista antibodies and use thereof
WO2017181139A2
